0001493152-21-029537.txt : 20211122 0001493152-21-029537.hdr.sgml : 20211122 20211122150605 ACCESSION NUMBER: 0001493152-21-029537 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211122 DATE AS OF CHANGE: 20211122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adhera Therapeutics, Inc. CENTRAL INDEX KEY: 0000737207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 112658569 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-13789 FILM NUMBER: 211431986 BUSINESS ADDRESS: STREET 1: P.O. BOX 2161 CITY: WAKE FOREST STATE: NC ZIP: 27588 BUSINESS PHONE: 919-578-5901 MAIL ADDRESS: STREET 1: P.O. BOX 2161 CITY: WAKE FOREST STATE: NC ZIP: 27588 FORMER COMPANY: FORMER CONFORMED NAME: Marina Biotech, Inc. DATE OF NAME CHANGE: 20100722 FORMER COMPANY: FORMER CONFORMED NAME: MDRNA, Inc. DATE OF NAME CHANGE: 20080610 FORMER COMPANY: FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm
0000737207 false 12/31 Q3 52500 34000 three 209 253 247 3 3 3 3 0000737207 2021-01-01 2021-09-30 0000737207 2021-11-22 0000737207 2021-09-30 0000737207 2020-12-31 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesCConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesDConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesDConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesEConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesFConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesGConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesGConvertiablePreferredStockMember 2020-12-31 0000737207 2021-07-01 2021-09-30 0000737207 2020-07-01 2020-09-30 0000737207 2020-01-01 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2019-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2019-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2019-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2019-12-31 0000737207 us-gaap:CommonStockMember 2019-12-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000737207 us-gaap:RetainedEarningsMember 2019-12-31 0000737207 2019-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000737207 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000737207 2020-01-01 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-03-31 0000737207 us-gaap:CommonStockMember 2020-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000737207 us-gaap:RetainedEarningsMember 2020-03-31 0000737207 2020-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000737207 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000737207 2020-04-01 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-06-30 0000737207 us-gaap:CommonStockMember 2020-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000737207 us-gaap:RetainedEarningsMember 2020-06-30 0000737207 2020-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000737207 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-09-30 0000737207 us-gaap:CommonStockMember 2020-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000737207 us-gaap:RetainedEarningsMember 2020-09-30 0000737207 2020-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2020-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2020-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2020-12-31 0000737207 us-gaap:CommonStockMember 2020-12-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000737207 us-gaap:RetainedEarningsMember 2020-12-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000737207 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000737207 2021-01-01 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-03-31 0000737207 us-gaap:CommonStockMember 2021-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000737207 us-gaap:RetainedEarningsMember 2021-03-31 0000737207 2021-03-31 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000737207 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000737207 2021-04-01 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-06-30 0000737207 us-gaap:CommonStockMember 2021-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000737207 us-gaap:RetainedEarningsMember 2021-06-30 0000737207 2021-06-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000737207 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesEPreferredStockMember 2021-09-30 0000737207 us-gaap:PreferredStockMember us-gaap:SeriesFPreferredStockMember 2021-09-30 0000737207 us-gaap:CommonStockMember 2021-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000737207 us-gaap:RetainedEarningsMember 2021-09-30 0000737207 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000737207 srt:MinimumMember 2021-01-01 2021-09-30 0000737207 srt:MaximumMember 2021-01-01 2021-09-30 0000737207 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000737207 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000737207 atrx:WarrantsMember 2020-12-31 0000737207 atrx:ConvertibleNotesMember 2020-12-31 0000737207 atrx:WarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-01-01 2021-09-30 0000737207 atrx:WarrantsMember 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-09-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-09-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-09-30 0000737207 atrx:StockOptionsOutstandingMember 2021-01-01 2021-09-30 0000737207 atrx:StockOptionsOutstandingMember 2020-01-01 2020-09-30 0000737207 atrx:WarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:WarrantsMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2020-01-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2019-12-31 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-01-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2019-12-28 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-07-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-01-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-07-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-09-30 0000737207 atrx:FourConvertibleNotesMember 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember 2020-02-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember 2020-05-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember 2020-05-04 2020-05-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:WarrantMember 2020-02-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2020-02-04 2020-02-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2020-02-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2020-02-04 2020-02-05 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2020-06-14 2020-06-15 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-03-18 2021-03-19 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-07-27 2021-07-29 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-08-15 2021-08-16 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-09-12 2021-09-13 0000737207 us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:HoldersMember atrx:ConvertibleNoteMember 2021-09-30 0000737207 atrx:SecuritiesPurchaseAgreementMember atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember atrx:ConvertibleNoteMember 2020-06-26 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-09-24 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-09-23 2020-09-24 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-06-25 2020-06-26 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-06-26 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-08-04 2020-08-05 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-10-30 0000737207 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-04-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:WarrantMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-01-01 2021-09-30 0000737207 atrx:ConversionFeatureMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember atrx:InvestorAndLenderMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-30 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-03-18 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-07-27 2021-07-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-30 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-04-10 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-04-10 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-10-11 2021-10-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-10-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-08-10 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember atrx:RegistrationRightsAgreementMember 2021-08-10 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-08-10 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:CommonStockMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-01-01 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember atrx:RegistrationRightsAgreementMember 2021-08-15 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-08-15 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:CommonStockMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:ConvertibleDebtMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-01 2021-09-30 0000737207 us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0000737207 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2021-09-30 0000737207 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2021-09-30 0000737207 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2021-09-30 0000737207 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2021-09-30 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-09-30 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-01-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2021-07-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2021-01-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2020-07-01 2020-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2020-01-01 2020-09-30 0000737207 atrx:NovosomVerwaltungsGmbHMember us-gaap:IntellectualPropertyMember 2018-05-01 2018-05-31 0000737207 atrx:NovosomVerwaltungsGmbHMember us-gaap:IntellectualPropertyMember 2019-12-22 2019-12-23 0000737207 atrx:NovosomVerwaltungsGmbHMember us-gaap:IntellectualPropertyMember atrx:UponExecutionOfAgreementMember 2020-09-30 0000737207 atrx:NovosomVerwaltungsGmbHMember us-gaap:IntellectualPropertyMember atrx:AchievementOfPerformanceObligationMember 2020-09-30 0000737207 atrx:NovosomAgreementMember 2020-07-01 2020-09-30 0000737207 atrx:NovosomAgreementMember 2020-01-01 2020-09-30 0000737207 us-gaap:AccruedLiabilitiesMember atrx:LicenseOfDiLAAssetsMember 2018-03-15 2018-03-16 0000737207 us-gaap:SeriesBPreferredStockMember 2021-09-30 0000737207 atrx:SeriesAJuniorParticipatingPreferredStockMember 2021-09-30 0000737207 atrx:SeriesAPreferredStockAndSeriesBPreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2014-03-31 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2015-08-31 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2018-04-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2018-07-31 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2019-12-31 0000737207 us-gaap:SeriesCPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2020-12-31 0000737207 us-gaap:SeriesDPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiblePreferredStockAndWarrantsMember 2021-09-30 0000737207 atrx:SeriesEConvertiblePreferredStockAndWarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:SeriesEWarrantsMember srt:MaximumMember 2021-03-19 0000737207 atrx:SeriesEWarrantsMember srt:MinimumMember 2021-03-19 0000737207 atrx:SeriesEWarrantsMember 2021-03-18 2021-03-19 0000737207 us-gaap:SeriesEPreferredStockMember 2021-03-18 2021-03-19 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 us-gaap:SeriesEPreferredStockMember srt:MinimumMember 2021-03-19 0000737207 us-gaap:SeriesEPreferredStockMember srt:MaximumMember 2021-03-19 0000737207 atrx:SeriesEPreferredMember 2021-06-07 2021-06-08 0000737207 atrx:SeriesEPreferredMember 2021-06-08 0000737207 us-gaap:WarrantMember 2021-06-07 2021-06-08 0000737207 atrx:SeriesEPreferredMember 2021-07-27 2021-07-30 0000737207 us-gaap:CommonStockMember 2021-07-27 2021-07-30 0000737207 atrx:SeriesEWarrantsMember 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-12-31 0000737207 atrx:SeriesFConvertiblePreferredStockAndWarrantsMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockAndWarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2019-10-28 2019-10-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2019-10-30 0000737207 atrx:SeriesFWarrantsMember srt:MaximumMember 2021-03-19 0000737207 atrx:SeriesFWarrantsMember srt:MinimumMember 2021-03-19 0000737207 atrx:SeriesFWarrantsMember 2021-03-18 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember 2021-03-18 2021-03-19 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember srt:MinimumMember 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember srt:MaximumMember 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2021-01-01 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2020-01-01 2020-12-31 0000737207 atrx:SeriesGConvertiblePreferredSharesMember 2021-09-30 0000737207 atrx:SeriesGConvertiblePreferredSharesMember 2021-01-01 2021-09-30 0000737207 atrx:TermLoanMember 2021-03-18 2021-03-19 0000737207 atrx:TermLoanMember 2021-03-19 0000737207 atrx:ConvertibleNoteInvestorMember 2021-08-10 2021-08-11 0000737207 atrx:ConvertibleNoteInvestorMember 2021-08-15 2021-08-18 0000737207 atrx:BankingAgreementMember 2021-09-21 2021-09-22 0000737207 atrx:FebruaryTwoThousandTwentyConvertibleNoteMember 2021-07-01 2021-09-30 0000737207 atrx:FebruaryTwoThousandTwentyConvertibleNoteMember 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-09-30 0000737207 atrx:OtherMember 2021-09-30 0000737207 us-gaap:WarrantMember 2021-09-30 0000737207 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000737207 atrx:RangeOneMember 2021-01-01 2021-09-30 0000737207 atrx:RangeOneMember 2021-09-30 0000737207 atrx:RangeTwoMember 2021-01-01 2021-09-30 0000737207 atrx:RangeTwoMember 2021-09-30 0000737207 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000737207 atrx:LicensingAgreementMLR1019Member 2021-07-27 2021-07-28 0000737207 atrx:LicensingAgreementMLR1019Member 2021-07-28 0000737207 atrx:LicensingAgreementMLR1023Member 2021-08-21 2021-08-24 0000737207 atrx:LicensingAgreementMLR1019Member srt:MinimumMember 2021-07-28 0000737207 atrx:LicensingAgreementMLR1019Member srt:MaximumMember 2021-07-28 0000737207 us-gaap:SubsequentEventMember atrx:JanuaryConvertibleNoteMember 2021-10-03 2021-10-04 0000737207 atrx:SecuredPromissoryNoteMember 2021-07-30 0000737207 us-gaap:SubsequentEventMember 2021-10-03 2021-10-04 0000737207 us-gaap:SubsequentEventMember us-gaap:SeriesEPreferredStockMember 2021-10-03 2021-10-04 0000737207 us-gaap:SubsequentEventMember 2021-10-14 2021-10-15 0000737207 us-gaap:SubsequentEventMember us-gaap:SeriesFPreferredStockMember 2021-10-14 2021-10-15 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:InstitutionalInvestorMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember atrx:SecuritiesPurchaseAgreementMember 2021-10-06 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:BuyerMember 2021-10-06 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-06 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-05 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-03 2021-10-05 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember atrx:InstitutionalInvestorMember 2021-10-13 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember atrx:SecuritiesPurchaseAgreementMember 2021-10-11 2021-10-13 0000737207 us-gaap:SubsequentEventMember atrx:BuyerMember 2021-10-11 2021-10-13 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-11 2021-10-13 0000737207 us-gaap:SubsequentEventMember atrx:ConvertibleRedeemableNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-10-13 0000737207 us-gaap:SubsequentEventMember 2021-10-25 2021-10-27 0000737207 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2021-11-02 2021-11-04 0000737207 us-gaap:SubsequentEventMember us-gaap:WarrantMember 2021-11-04 0000737207 atrx:LicensingAgreementMLR1023Member us-gaap:SubsequentEventMember 2021-11-15 2021-11-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure atrx:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2021

or

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________.

 

Commission File Number: 000-13789

 

ADHERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   11-2658569

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

 

8000 Innovation Parkway

Baton Rouge, LA

   70820
(Address of principal executive offices)   (Zip Code)

 

(919) 518-3748

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

  

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☐ Smaller reporting company ☒
       
    Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to13(a) of the Exchange Act: ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

 

As of November 22, 2021, there were 15,575,294 shares of the registrant’s common stock outstanding.

 

 

 

 

 

 

ADHERA THERAPEUTICS, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021

 

TABLE OF CONTENTS

 

    Page
     
PART I - FINANCIAL INFORMATION  
     
ITEM 1 Financial Statements (unaudited)  
     
  Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020 3
     
  Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021, and 2020 (unaudited) 4
     
  Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2021, and 2020 (unaudited) 5
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 (unaudited) 6
     
  Notes to Unaudited Condensed Consolidated Financial Statements 7
     
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 25
     
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 30
     
ITEM 4. Controls and Procedures 30
     
PART II - OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 31
     
ITEM 1A. Risk Factors 31
     
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 31
     
ITEM 3. Defaults on Senior Securities 32
     
ITEM 4. Mine Safety Disclosures 32
     
ITEM 5. Other Information 32
     
ITEM 6. Exhibits 32
     
SIGNATURES 33

 

 2 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share amounts)

 

   September 30, 2021   December 31, 2020 
   (Unaudited)     
ASSETS          
Current assets          
Cash  $151   $1 
Total current assets   151    1 
Total assets  $151   $1 
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
           
Current liabilities          
Accounts payable  $2,287   $2,257 
Due to related party   4    4 
Accrued expenses   2,874    2,112 
Accrued dividends   5,211    4,083 
Term loan   5,677    5,677 
Convertible notes payable, net   862    641 
Derivative liability   3,475    — 
Total current liabilities   20,390    14,774 
Total liabilities   20,390    14,774 
Commitments and contingencies (Note 7)   -       
Stockholders’ deficit          
Preferred stock, $0.01 par value; 100,000 shares authorized Series C convertible preferred stock, $0.01 par value; 1,200 shares designated; 100 shares issued and outstanding as of September 30, 2021, and December 31, 2020. ($510,000 liquidation preference)   —    — 
Series D convertible preferred stock, $0.01 par value; 220 shares designated; 40 shares issued and outstanding as of September 30, 2021, and December 31, 2020. ($12,000 liquidation preference)   —    — 
Series E convertible preferred stock, $0.01 par value; 3,500 shares designated; 3,400 and 3,458 shares issued and outstanding as of September 30, 2021, and December 31, 2020. ($17,000,000 liquidation preference)   —    — 
Series F convertible preferred stock, $0.01 par value; 2,200 shares designated; 361 shares issued and outstanding as of September 30, 2021, and December 31, 2020. ($1,805,000 liquidation preference)   —    — 
Series G convertible preferred stock, $0.01 par value, 6,000 shares designated; zero shares outstanding as of September 30, 2021, and December 31, 2020.   —    — 
Common stock, $0.006 par value; 180,000,000 shares authorized, 14,485,438 and 11,112,709 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively   87    67 
Additional paid-in capital   30,647    29,772 
Accumulated deficit   (50,973)   (44,612)
Total stockholders’ deficit   (20,239)   (14,773)
Total liabilities and stockholders’ deficit  $151   $1 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 3 

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except for share and per share amounts)

 

                 
   For the Three-Months ended   For the Nine-Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
                 
Operating expenses                    
Sales and marketing  $-   $20   $17   $818 
General and administrative   232    174    454    1,055 
Total operating expenses   231    194    471    1,873 
Loss from operations   (231)   (194)   (471)   (1,873)
Other income (expense)                    
Interest expense   (261)   (255)   (749)   (1,082)
Other Income   -    5    -    45 
Loss on extinguishment of debt   

(177

)   -    

(177

)   - 
Derivative expense   (2,968)   -    (3,055)   - 
Amortization of debt discount   (101)   (95)   (230)   (373)
Total other income (expense)   (3,507)   (345)   (4,211)   (1,410)
Net loss   (3,739)   (539)   (4,682)   (3,283)
Dividends   (406)   (388)   (1,679)   (1,153)
Net Loss Applicable to Common Stockholders  $(4,145)  $(927)  $(6,361)  $(4,436)
Net loss per share – Common Stockholders - basic and diluted  $(0.32)  $(0.09)  $(0.54)  $(0.41)
Weighted average shares outstanding - basic and diluted   12,986,391    10,869,530    11,742,315    10,869,530 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 4 

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except for share amounts)

(Unaudited)

 

                                                     
   Series C Preferred Stock   Series D Preferred Stock   Series E Preferred Stock   Series F Preferred Stock   Common Stock   Additional Paid-in   Accumulated     
   Number   Par Value   Number   Par Value   Number   Par Value   Number   Par Value   Number   Par Value   Capital   Deficit   Total 
Balance, December 31, 2019   100    -    40    -    3,478    -    361    -    10,869,530    65    29,375    (39,327)   (9,887)
Accrued dividend   -    -    -    -    -    -    -    -    -    -    -    (383)   (383)
Issuance of warrants with notes payable   -    -    -    -    -    -    -    -    -    -    239    -    239 
Share based compensation   -    -    -    -    -    -    -    -    -    -    36    -    36 
Net loss   -    -    -    -    -    -    -    -    -    -    -    (1,838)   (1,838)
Balance, March 31, 2020   100    -    40    -    3,478    -    361   $-    10,869,530    65   $29,650   $(41,548)  $(11,833)
Accrued dividend   -    -    -    -    -    -    -    -    -    -    -    (382)   (382)
Benefical conversion feature - convertible notes   -    -    -    -    -    -    -    -    -    -    50    -    50 
Share based compensation   -    -    -    -    -    -    -    -    -    -    (26)   -    (26)
Net loss   -    -    -    -    -    -    -    -    -    -    -    (906)   (906)
Balance, June 30, 2020   100    -    40    -    3,478    -    361   $-    10,869,530    65   $29,674   $(42,836)  $(13,097)
Accrued dividend   -    -    -    -    -    -    -    -    -    -    -    (388)   (388)
Share based compensation   -    -    -    -    -    -    -    -    -    -    (2)   -    (2)
Net loss   -    -    -    -    -    -    -    -    -    -    -    (539)   (539)
Balance, September 30, 2020   100    -    40    -    3,478    -    361   $-    10,869,530    65   $29,672   $(43,763)  $(14,026)

 

   Series C Preferred Stock   Series D Preferred Stock   Series E Preferred Stock   Series F Preferred Stock   Common Stock   Additional Paid-in   Accumulated     
   Number   Par Value   Number   Par Value   Number   Par Value   Number   Par Value   Number   Par Value   Capital   Deficit   Total 
Balance, December 31, 2020   100   $-    40   $-    3,458   $-    361   $-    11,112,709   $67   $29,772   $(44,612)  $(14,773)
Accrued and deemed dividend   -    -    -    -    -    -    -    -    -    -    505    (882)   (377)
Issuance of common stock for convertible note conversion   -    -    -    -    -    -    -    -    518,000    3    23    -    26 
Issuance of warrants with convertible notes   -    -    -    -    -    -    -    -    -    -    28    -    28 
Net loss   -    -    -    -    -    -    -    -    -    -    -    (428)   (428)
Balance, March 31, 2021   100   $-    40   $-    3,458   $-    361   $-    11,630,709   $70   $30,328   $(45,922)  $(15,524)
Accrued and deemed dividend   -    -    -    -    -    -    -    -    -    -    11    (392)   (381)
Issuance of warrants with convertible notes   -    -    -    -    -    -    -    -    -    -    69    -    69 
Issuance of common stock for cashless exercise of warrants   -    -    -    -    -    -    -    -    53,571    -    -    -    - 
Issuance of common stock for Series E conversion   -    -    -    -    (8)   -    -    -    101,010    1    9    -    10 
Net loss   -    -    -    -    -    -    -    -    -    -    -    (514)   (514)
Balance, June 30, 2021   100   $-    40   $-    3,450   $-    361   $-    11,785,290   $71   $30,417   $(46,828)  $(16,340)
Accrued dividend   -    -    -    -    -    -    -    -    -    -    25    (406)   (381)
Issuance of warrants and common stock with convertible notes -   -    -    -    -    -    -    -    500,148    3    154              157 
Issuance of common stock for convertible note and interest conversions                                           1,700,000    10    75         85 
Reclassification of derivative   -                                                 

(21

)        

(21

)
Issuance of common stock for Series E conversion   -    -    -    -    (50)   -    -    -    500,000    3    (3)   -    - 
Net loss   -    -    -    -    -    -    -    -    -    -    -    (3,739)   (3,739)
Balance, September 30, 2021   100   $-    40   $-    3,400   $-    361   $-    14,485,438   $87   $30,647   $(50,973)  $(20,239)

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 5 

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

 

         
   For the Nine Months ended September 30, 
   2021   2020 
         
Cash Flows Used in Operating Activities:          
Net loss  $(4,682)  $(3,283)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share based compensation   -    8 
Loss on debt extinguishment   

177

    

-

 
Amortization of debt discount   230    765 
Derivative expense   3,055    - 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   -    316 
Accounts payable   30    850 
Accrued interest   749    689 
Accrued expenses   72    157 
           
Net Cash Used in Operating Activities   (369)   (498)
           
Cash Flows Provided By Financing Activities:          
Proceeds from notes payable, net or original issue discounts   591    553 
Notes payable issuance costs   (72)   (105)
Net Cash Provided by Financing Activities   519    448 
Net (decrease) in cash   150    (50)
Cash – Beginning of Period   1    50 
Cash - End of Period  $151   $- 
           
Supplementary Cash Flow Information:          
           
Non-cash Investing and Financing Activities:          
Dividends  $1,679   $1,153 
Conversion of Series E to common stock   4    - 
Beneficial conversion feature on issuance notes payable   -    50 
Cashlesss exercise of Series E warrants   4    - 
Issuance of common stock for conversion of convertible debt   111    - 
Debt discounts for issuance costs, warrants and derivatives   473    239 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 6 

 

 

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021

(Unaudited)

 

Note 1 – Nature of Operations, Basis of Presentation and Significant Accounting Policies

 

Business Overview

 

Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company.

 

Previously, the Company was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. On January 4, 2021, the licensor terminated the licensing agreement for the product candidate.

 

On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. In October 2021, the company commenced the manufacturing of drug product for use in the development of MLR-1019.

 

On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.

 

On October 20, 2021 the Company as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Melior’s Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.

 

To the extent that resources have been available, the Company has continued to work with its advisors to restructure our company and to identify potential strategic transactions, including the Melior transactions described above. There can be no assurance that the Company will be successful in raising sufficient capital to meet its obligations under the Melior license agreements. If the Company does not raise substantial additional capital to develop and commercialize repay its indebtedness which is in default or restructure the indebtedness, it is likely that the Company will discontinue all operations and seek bankruptcy protection.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the Nine months ended September 30, 2021, are not necessarily indicative of the results for the year ending December 31, 2021 or for any future period.

 

 7 

 

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.

 

Going Concern and Management’s Liquidity Plans

 

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2021, the Company had cash and cash equivalents of approximately $151,000 and has negative working capital of approximately $20.2 million.

 

The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $4.7 million for the nine months ended September 30, 2021. The Company had an accumulated deficit of approximately $51.0 million as of September 30, 2021.

 

In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to us or at all. General market conditions, as well as market conditions for companies in our financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

 

Summary of Significant Accounting Policies

 

Reclassification

 

Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.

 

 8 

 

 

Fair Value of Financial Instruments

 

The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

As of September 30, 2021, the Company measured conversion features on outstanding convertible notes as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $3.5 million. The value of the derivative liability as of September 30, 2021 was determined by using the binomial lattice model using the following inputs: 0.09% risk free rate, volatility of 404% and time to maturity of 0 - .18 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2021, and there were no liabilities or assets measured at fair value on a reoccurring or non-recurring basis as of December 31, 2020.

 

(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at September 30, 2021 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liability  $-   $-   $3,475   $3,475 
Total  $-   $-   $3,475   $3,475 

 

A roll forward of the level 3 valuation financial instruments is as follows:

 

                
  

Nine months Ended

September 30, 2021		 
(In thousands)  Warrants   Notes   Total 
Balance at December 31, 2020  $—   $—   $— 
Initial valuation of derivative liabilities included in debt discount   —    223    223 
Initial valuation of derivative liabilities included in derivative expense   —    619    619 
Reclassification of derivative liabilities to gain on debt extinguishment   —    (92)   (92)
Reclass from Additional paid-in capital   46    244   290
Change in fair value included in derivative expense   361    2,074    2,435 
Balance at September 30, 2021  $407   $3,068   $3,475 

 

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.

 

Convertible Debt and Warrant Accounting

 

Debt with warrants

 

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

Convertible debt – derivative treatment

 

When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet that requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.

 

 9 

 

 

Convertible debt – beneficial conversion feature

 

Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) on January 1, 2021, if the conversion feature was not treated as a derivative, the Company assessed whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.

 

Recently Issued Accounting Pronouncements

 

Recently Adopted

 

In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.

 

Not Yet Adopted

 

In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic:

 

1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument.
   
2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows:
       
  a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider:
       
    i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments.
       
    ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50.
       
  b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged.
       
3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows:
       
  a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs.
     
  b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest.
       
  c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation.

 

An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction.

 

The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

Net Loss per Common Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.

 

 10 

 

 

The following table presents the computation of net loss per share (in thousands, except share and per share data):

 

   2021   2020   2021   2020 
  

Three Months Ended

September 30,

   Nine Months Ended

September 30,

 
   2021   2020   2021   2020 
Numerator                
Net loss  $(3,739)  $(539)  $(4,682)  $(3,283)
Dividends   (406)   (388)   (1,679)   (1,153)
Net Loss allocable to common stockholders  $(4,145)  $(927)  $(6,361)  $(4,436)
Denominator                    
Weighted average common shares outstanding used to compute net loss per share, basic and diluted   12,986,391    10,869,530    11,742,315    10,869,530 
Net loss per share of common stock, basic and diluted                    
Net loss per share  $(0.32)  $(0.09)  $(0.54)  $(0.41)

 

Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:

 

   2021   2020 
Convertible Notes   24,332,784    23,690,018 
Stock options outstanding   387,550    1,216,350 
Warrants   61,306,350    69,047,000 
Series C Preferred Stock   66,667    66,667 
Series D Preferred Stock   50,000    50,000 
Series E Preferred Stock   43,514,922    41,597,256 
Series F Preferred Stock   4,519,872    4,230,973 
Total   134,178,046    139,898,264 

 

Note 2 – Notes Payable

 

2019 Term Loan

 

During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $5.7 million. The Company paid $707,000 in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the straight-line method.

 

The Notes accrue interest at a rate of 12% per annum. Interest is payable quarterly with the first interest payment to be made on December 28, 2019, and each subsequent payment every three months thereafter.

 

The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, matured on June 28, 2020. The Notes are secured by a first lien and security interest on all the assets of the Company and certain of its wholly owned subsidiaries.

 

 11 

 

 

On December 28, 2019, the Company defaulted on the initial interest payment on the loan and the interest rate per annum increased to the default rate of 15%. On June 28, 2020, the Company defaulted on the maturity date principal payment.

 

The Company recognized approximately $215,000 and $986,000 in interest expense related to Notes for the three and nine months ended September 30, 2020, including $0 and $347,000 related to the amortization of debt issuance costs. The Company recognized approximately $215,000 and $637,000 in interest expense related to the Notes for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discount and issuance costs for this term loan were fully amortized.

 

As of September 30, 2021, the Company had approximately $1.8 million of accrued interest on the Notes included in accrued expenses and remains in default on the repayment of approximately $5.7 in principal and interest on the Notes.

 

CONVERTIBLE PROMISSORY NOTES

 

The following table summarizes the Company’s outstanding convertible notes as of September 30, 2021, and December 31, 2020:

 

(in thousands)  September 30, 2021   December 31, 2020 
Convertible Notes  $1,296   $720 
Unamortized discounts   (434)   (79)
Convertible Notes Payable  $862   $641 

 

Five convertible notes with outstanding principal of approximately $788,000 were in default as of the issuance date of this report.

 

Secured Convertible Promissory Note – February 2020

 

On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes (the “Convertible Notes”), with a principal of $550,500 issued at a 10% original issue discount, for a total purchase price of $499,950, and (ii) warrants to purchase up to such number of shares of the common stock of the Company as is equal to the product obtained by multiplying 1.75 by the quotient obtained by dividing (A) the principal amount of the Notes by (B) the then applicable conversion price of the Notes.

 

The maturity date was August 5, 2020. Interest shall accrue to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10% per annum, calculated on the basis of a 360-day year and accrues daily.

 

On or after May 5, 2020, until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $0.50 per share of Common Stock and (ii) 70% of the volume weighted average price of the Common Stock on the trading market on which the Common Stock is then listed or quoted for trading for the prior ten (10) trading days (as adjusted for stock splits, stock combinations and similar events); provided, that if the Notes are not prepaid on or before May 5, 2020, then the conversion price shall be the lower of (x) 60% of the conversion price as calculated above or (y) $0.05 (as adjusted for stock splits, stock combinations and similar events). The conversion price of the Convertible Notes shall also be adjusted as a result of subsequent equity sales by the Company, with customary exceptions.

 

The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5-year term.

 

The Company recorded a discount related to the Warrants of approximately $322,000, which includes an allocation of OID and issue costs of $30,000 and $53,000 based on the relative fair value of the instruments as determined by using the Monte-Carlo simulation model. The Company also recorded the remaining debt discount related to the convertible debt OID of approximately $21,000 and debt issuance costs of $38,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. Total discounts recorded were $380,593.

 

On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18%.

 

 12 

 

  

The Company recognized $31,000 and $86,000 in interest expense related to the notes for the three and nine months ended September 30, 2020, respectively including $7,000 and $38,000 related to the amortization of debt issuance costs. The Company amortized $67,000 and $343,000 of debt discount for the three and nine months ended September 30, 2020, respectively. The Company recognized approximately $25,000 and $75,000 in interest expense related to the notes for the three and Nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discounts for this Convertible Note were fully amortized.

 

On March 19, 2021, the holder of the Convertible Note converted $25,900 of interest into 518,000 shares of common stock.

 

On July 29, 2021, the holder of the Convertible Note converted $27,500 of interest into 550,000 shares of common stock.

 

On August 16, 2021, the holder of the Convertible Note converted $25,000 of principal and interest into 500,000 shares of common stock.

 

On September 13, 2021, the holder of the Convertible Note converted $32,500 of principal and interest into 650,000 shares of common stock.

 

The total note principal and interest converted during the nine months ended September 30, 2021 was $110,900 and 2,218,000 common shares issued were valued at fair value based on the quoted trading prices on the conversion dates aggregating $379,422 resulting on a loss on debt extinguishment of $268,522. In addition, derivative fair value of $91,890 relating to the portion of the Note converted was settled resulting in gain on extinguishment of $91,890. The net loss on extinguishment was $176,632. The total shares issued upon conversion during the nine months ended September 30, 2021, was $2,218,000.

 

During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $2.0 million as a derivative liability on the accompanying balance sheet.

 

As of September 30, 2021, the Company had accrued interest on the Convertible Note of approximately $90,000.

 

As of September 30, 2021, the Company remains in default on the repayment of remaining principal of $499,615 and accrued interest on the Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due 140% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. The 40% premium will be recorded once a demand occurs.

 

Secured Convertible Promissory Note – June 2020

 

On June 26, 2020, the Company issued to an existing investor in the Company a 10% original issue discount Senior Secured Convertible Promissory Note with a principal of $58,055, for a purchase price of $52,500, net of the original issue discount of $5,555. The Convertible Note matured on December 26, 2020. Interest accrues on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10% per annum, calculated on the basis of a 360-day year. The Company incurred approximately $14,000 in debt issuance costs.

 

The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.02 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 65% of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered. The conversion price shall also be adjusted for subsequent equity sales by the Company. Because the share price on the commitment date was in excess of the conversion price, the Company recorded a beneficial conversion feature of $50,000 related to this note that was credited to additional paid in capital and reduced the carrying amount. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $203,000. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method.

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $5.7 million agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019 that such holders entered into with the Company and its subsidiaries to the security interest granted to the holder of the Note.

 

For the three and nine months ended September 30, 2020, the Company recognized approximately $9,000 and $10,000 in interest expense including $7,000 and $8,000 related to the amortization of debt issuance costs, respectively. For the three and nine months ended September 30, 2020, the Company recognized $28,000 and $30,000 related to the amortization of debt discount.

 

On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18%.

 

For the three and nine months ended September 30, 2021, the Company recognized approximately $3,000 and $8,000 in interest expense related to the note, respectively. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized.

 

As of September 30, 2021, the Company remains in default on the repayment of principal of $58,055 and approximately $13,000 in accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 140% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 40% premium will be recorded once a demand occurs.

 

 13 

 

 

Secured Convertible Promissory Note – October 2020

 

On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10% original issue discount senior secured convertible promissory note with a principal of $111,111, for a purchase price of $100,000. The note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of then conversion price. The conversion price of the notes is subject to anti-dilution price protection and on March 19, 2021, the conversion price of the notes was adjusted to $0.05 per share. as a result of subsequent equity sales by the Company.

 

The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company.

 

The Company recorded approximately $9,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method.

 

The interest rate on the note was 10% per annum, calculated on the basis of a 360-day year. On April 30, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to 18%.

 

Additionally, the Company issued the noteholder 1,587,301 warrants to purchase the Company’s common stock at $0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $0.05 and the Company issued an additional 634,919 warrants to the note holder. The Company recorded approximately $57,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of 0.92 years in calculating the fair value of the warrants.

 

The Company recorded a discount related to the warrants of approximately $66,000, including a discount of $6,000 and issuance costs of $5,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The Company recorded a beneficial conversion feature of $45,000 related to the note that was credited to additional paid in capital and reduced the carrying amount. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $69,000. The Company also recorded a debt discount related to the convertible debt of approximately $5,000 and debt issuance cost of $4,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.

 

For the three and nine months ended September 30, 2021, the Company recognized approximately $5,000 and $15,600 in interest expense including $0 and $2,600 related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $0 and $79,000 and related to the amortization of debt discount. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized. No interest expense or debt discount was recognized for the same period of 2020.

 

During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $76,000 as a derivative liability on the accompanying balance sheet.

 

As of September 30, 2021, the Company has outstanding principal of $111,111 and accrued interest on the note of approximately $13,000.

 

As of September 30, 2021, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 25% premium will be recorded once a demand occurs

 

 14 

 

 

Secured Convertible Promissory Note – January 2021

 

On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal of $52,778, for a purchase price of $47,500, net of original issue discount of $5,278. The Note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price of the notes is subject to anti-dilution price protection and will be adjusted upon subsequent equity sales by the Company.

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

Additionally, the Company issued to the investor 753,968 warrants to purchase the Company’s common stock at an exercise price of $0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $0.05 and the Company issued an additional 301,592 warrants to the note holder. The Company recorded approximately $27,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of 0.97 years in calculating the fair value of the warrants.

 

The Company recorded approximately $2,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method.

 

The interest rate on the note was 10% per annum, calculated on the basis of a 360-day year. On July 31, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to the default rate of 18% per annum.

 

The Company recorded a discount related to the warrants of approximately $32,000, which includes an allocated original issue discount, of $3,000 and allocated issuance costs of $1,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.45%, volatility of 240.83%, and an expected term of one year in calculating the fair value of the warrants.

 

The Company also recorded a debt discount related to the convertible debt of approximately $2,000 remaining original issue discount and remaining debt issuance cost of $1,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.

 

Total discounts recorded including the original issue discount wer approximately $35,000.

 

For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $2,900 and $5,700 in interest expense including approximately $100 and $700 related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $5,600 and $34,000 related to the amortization of debt discount. No interest expense or debt discount was recognized for the same period of 2020.

 

As of September 30, 2021, the Company has outstanding principal of $52,778 on the note, has recorded approximately $5,000 of accrued interest. As of September 30, 2021, the debt discount and issuance costs on the note were fully amortized.

 

As of September 30, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 25% premium will be recorded once a demand occurs

 

 15 

 

 

Secured Convertible Promissory Note – April 2021

 

On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $66,667, for a purchase price of $60,000 net of an original discount of $6,667. Additionally, the Company issued to the investor 800,000 five-year warrants to purchase the Company’s common stock at an exercise price of $0.095 per share. The warrants have full ratchet protection.

 

The note matured on October 12, 2021, Interest accrues on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on-the-basis of a 360-day year.

 

The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $0.075 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price shall also be adjusted upon subsequent equity sales by the Company. The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

The Company recorded a discount related to the warrants of approximately $34,000, which includes approximately $3,700 of OID discount allocated under the relative fair value method, and a remaining discount related to the OID of $3,000 based on the relative fair value of the instruments. The fair value of the warrants on which the relative fair value is based was determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.89%, volatility of 240.64%, and an expected term of one year in calculating the fair value of the warrants.

 

On June 25, 2021, the exercise price of the warrants was adjusted to $0.075 and the Company issued an additional 88,893 warrants to the note holder. The Company recorded approximately $11,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.92%, volatility of 247.52%, and expected term of 0.96 years in calculating the fair value of the warrants.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $19,000 and $35,000, respectively related to the amortization of debt discount. For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $1,700 and $3,200 in interest expense, respectively. No interest expense or debt discount was recognized for the same period of 2020.

 

As of September 30, 2021, the Company has recorded $66,667 of principal and approximately $2,400 of unamortized debt discount and $3,200 of accrued interest for the note on the accompanying balance sheet.

 

On October 12, 2021, the Company defaulted on the note and the interest rate on the note reset to 18% per annum. Upon default, and upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this note. The 25% premium will be recorded once a demand occurs

 

Secured Convertible Promissory Note – June 2021

 

On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $66,500, for a purchase price of $63,000, net of an original issue discount of $3,500. Additionally, the Company issued to the investor 800,000 three-year warrants to purchase the Company’s common stock at an exercise price of $0.095 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain $76,000 which is a full ratchet price protection provision

 

The note matures on June 25, 2022, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on the basis of a 365-day year.

 

The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $0.075 (as adjusted for stock splits, stock combinations and similar events); provided, however that in the event, the Company’s Common Stock trades below $0.08 per share for more than three (3) consecutive trading days, the Holder of this Note is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 65% of the lowest trading price of the Common Stock for the twenty prior trading days including the day upon which a Notice of Conversion is received. The conversion discount, look back period and other terms of the Note will be adjusted on a ratchet basis if the Company offers a more favorable conversion discount, prepayment rate, interest rate, (whether through a straight discount or in combination with an original issue discount), look back period or other more favorable term to another party for any financings while this Note is in effect

 

 16 

 

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

The Company incurred approximately $9,300 in debt issuance costs.

 

The company also issued 47,547 shares of common stock as a commission fee to the investment banker. The fair value of the common stock which was approximately $5,040 was recorded as debt issuance expense.

 

Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $102,823 with $87,039 charged to derivative expense and $15,784 recorded as a debt discount.

 

Total discounts recorded were $66,500. The Company recorded an original issue discount of $3,500, a discount of $9,300 for issuance costs, a discount related to the warrants of approximately $37,916 and a discount related to the derivative of $15,784 based on the relative fair value of the instruments. The warrant fair value on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.48%, volatility of 302.11%, and an expected term of 0.60 years in calculating the fair value of the warrants.

 

On August 11, 2021, the exercise price of the warrants was adjusted to $0.075 and the Company issued an additional 213,333 warrants to the note holder. The Company recorded approximately $25,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.81, volatility of 209%, and expected term of 0.57 years in calculating the fair value of the warrants.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $13,000 and $18,000 to the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $4,000 in interest expense. No interest expense or debt discount was recognized for the same period of 2020.

 

At September 30, 2021, the Company has recorded $66,500 of outstanding principal and approximately $4,000 of accrued interest and $49,000 of unamortized discount and issuance expenses.

 

Convertible Promissory Note – August 11, 2021

 

On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $220,500 and warrants to purchase 800,000 shares of the common stock of the Company for which the Company received consideration of $210,000 net of an original issued discount of $10,500. In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 100,000 common shares as a commitment fee.

 

The note matures one year from issuance and provides for an interest rate of 10% per annum, payable at maturity, and is convertible into common stock of the Company at a price of $0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date.

 

In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.

 

 17 

 

 

The Warrants are initially exercisable for a period of three years at a price of $0.095 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant.

 

The Company incurred approximately $30,000 in debt issuance costs.

 

The Company also issued 140,000 shares of common stock to the investment banker as a commission on the note.

 

Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $340,893 with $234,388 charged to derivative expense and $106,505 recorded as a debt discount.

 

The Company recorded a total debt discount of $220,500 including an original issue discount of $10,500, a discount related to the warrants of approximately $56,454 a discount related to issuance costs of $30,000 and a discount related to the issuance of common stock of approximately $17,041, and a $106,505 discount related to the initial derivative value of the embedded conversion feature on the note all based on the relative fair value of the instruments,

 

The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81%, volatility of 253%, and an expected term of one year in calculating the fair value of the warrants. The discounts are being amortized over the term of the convertible note.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $30,810 for the amortization of the debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $3,000 in interest expense.

 

At September 30, 2021, the Company has remaining $220,500 of outstanding principal and approximately $3,000 of accrued interest and $190,000 of unamortized discount.

 

Convertible Promissory Note – August 17, 2021

 

On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $220,500 and warrants to purchase 800,000 shares of the common stock of the Company for which the Company received consideration of $210,000 net of original discount of $10,500. In addition, the Company entered into a Registration Rights Agreement with the Buyer and issued the Buyer 100,000 common shares as a commitment fee.

 

The note matures one year from issuance and provides for an interest rate of 10% per annum, payable at maturity, and is convertible into common stock of the Company at a price of $0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. The embedded conversion option will be treated as a bifurcated derivative liability.

 

In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.

 

 18 

 

 

The Warrants are initially exercisable for a period of three years at a price of $0.095 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant

 

The Company incurred approximately $30,000 in debt issuance costs. The Company also issued 112,601 shares of common stock to the investment banker as a commission on the note.

 

Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $398,404 with $297,833 charged to derivative expense and $100,571 recorded as a debt discount.

 

The Company recorded a total debt discount of $220,500 including an original issue discount of $10,500, a discount related to the warrants of approximately $62,220 a discount related to issuance costs of $30,000 a discount related to the issuance of common stock of approximately $17,209, and a $100,571 discount related to the initial derivative value of the embedded conversion feature on the Note all based on the relative fair value of the instruments.

 

The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77%, volatility of 254%, and an expected term of one year in calculating the fair value of the warrants. The discounts are being amortized over the life of the convertible note.

 

At September 30, 2021, the Company has recorded $220,500 of outstanding principal and approximately $3,000 of accrued interest and $193,000 of unamortized discount and issuance expenses.

 

Derivative Liabilities Pursuant to Convertible Notes and Warrants

 

In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion option to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. In accordance with ASC 815-40 –Derivatives and Hedging – Contracts in an Entity’s Own Stock, the embedded conversion option contained in the Notes and Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion options was determined using the Binomial Lattice valuation model. At the end of each period and on note conversion date or repayment, the Company revalues the derivative liabilities resulting from the embedded option.

 

During the nine months ended September 30, 2021, in connection with the issuance of the Notes and Warrants, on the initial measurement dates, the fair values of the embedded conversion options of $842,120 was recorded as derivative liabilities of which $222,860 was allocated as a debt discount and $619,260 as derivative expense.

 

At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with these revaluations, the Company recorded a loss from the change in the derivative liabilities fair value of approximately $3.1 million for the nine months ended September 30, 2021.

 

During the nine months ended September 30, 2021, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2021, using the Binomial Lattice valuation model with the following assumptions:

 

Dividend rate   —%
Term (in years)   0.01 to 1 year 
Volatility   247% to 412%
Risk-free interest rate   0.07% to 0.87%

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $27,000 for the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $3,000 in interest expense.

 

Note 3 - Licensing Agreements

 

Les Laboratories Servier

 

As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions).

 

On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®.

 

No royalties were paid for the three or nine-month periods ended September 30, 2020, or 2021.

 

Novosom Agreements

 

In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 51,988 shares of our common stock, with a fair value of $75,000, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017. On December 23, 2019, Novosom repurchased the acquired intellectual property for $45,000 of which $20,000 was payable upon execution of the agreement and $25,000 was to be paid upon the Company’s achievement of certain performance obligations by September 30, 2020.

 

The Company recognized $5,000 and $45,000 as other income from the agreement for the three and nine-month periods ended September 30, 2020, respectively.

 

 19 

 

 

License of DiLA2 Assets

 

On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $200,000 and future additional consideration for sales and development milestones. The upfront fee was contingent upon the Company obtaining a third-party consent to the agreement within ninety days of execution. As of September 30, 2021, and December 31, 2020, the Company had not obtained consent for the sublicense and has classified the upfront payment it had previously recorded as an accrued liability on its balance sheet.

 

Note 4 - Related Party Transactions

 

Due to Related Party

 

The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.

 

The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018.

 

An unpaid balance for previous years services performed under the agreement of approximately $4,000 is included in due to related party in the accompanying consolidated balance sheets at September 30, 2021, and December 31, 2020.

 

Note 5 - Stockholders’ Equity

 

Preferred Stock

 

Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock.

 

Series C Preferred

 

Each share of Series C Preferred has a stated value of $5,000 per share, has a $5,100 liquidation preference per share, has voting rights of 666.67 votes per share, and is convertible into shares of common stock at a conversion price of $7.50 per share.

 

As of September 30, 2021, and December 31, 2020, 100 shares of Series C Preferred stock were outstanding.

 

Series D Preferred

 

Each share of Series D Preferred has a stated value of $5,000 per share, has a liquidation preference of $300 per share, has voting rights of 1,250 votes per share and is convertible into shares of common stock at a conversion price of $4.00 per share. The Series D Preferred has a 5% stated dividend rate when, and if declared by the Board of Directors, is not redeemable and has voting rights on an as-converted basis.

 

 20 

 

 

As of September 30, 2021, and December 31, 2020, 40 shares of Series D Preferred were outstanding.

 

Series E Convertible Preferred Stock and Warrants

 

The Series E Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series E Preferred stock is convertible into shares of common stock at $0.50. Anti-dilution price protection on Series E Preferred stock expired on February 10, 2020. Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.

 

On March 19, 2021, the exercise price of the Series E warrants was adjusted from $0.50 to $0.05 per share upon the conversion of $25,900 debt for 518,000 shares common stock. The Company recorded approximately $390,000 as a deemed dividend based upon the change in fair value of the Series E Preferred stock warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of .41 to .43 years in calculating the fair value of the warrants.

 

As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders.

 

On June 8, 2021, an investor converted 8 shares of Series E Preferred and accrued dividends of approximately $10,000 into 101,010 shares of common stock. In addition, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants.

 

On July 30, 2021, and investor converted 50 shares of Series E Preferred stock with a state value of $250,000 into 500,000 shares of common stock.

 

As of September 30, 2021, the Company had a total of 30,405,600 warrants issued with Series E Preferred stock outstanding. The warrants expire in 2023.

 

The Company had accrued dividends on the Series E Preferred stock of approximately $4,756,000 and $3.7 million, as of September 30, 2021, and December 31, 2020, respectively.

 

At September 30, 2021 and December 31, 2020, there were 3,400 and 3,458 Series E shares outstanding, respectively.

 

Series F Convertible Preferred Shares and Warrants

 

The Series F Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series F Preferred stock is convertible into shares of common stock at $0.50. Anti-dilution price protection on Series F Preferred stock expired on February 10, 2020. The Series F Preferred stock includes a mandatory conversion feature on November 9, 2021, which is the three-year anniversary of the closing of the issuance. Warrants issued with Series F Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.

 

On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $100,000 by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.

 

On March 19, 2021, the exercise price of the Series F warrants was adjusted from $0.50 to $0.05 upon the conversion of $25,900 of debt for 518,000 shares of common stock. The Company recorded approximately $31,000 as a deemed dividend based upon the change in fair value of the Series F Preferred stock using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and an expected term of .46 to .53 years in calculating the fair value of the warrants.

 

As of September 30, 2021, the Company had a total of 3,088,500 Series F Preferred stock warrants outstanding. The warrants expire in 2023.

 

The Company had accrued dividends on the Series F Preferred stock of approximately $455,000 and $347,000, as of September 30, 2021, and December 31, 2020, respectively.

 

At September 30, 2021 and December 31, 2020, there were 361 Series F Preferred shares outstanding.

 

 21 

 

 

Series G Convertible Preferred Shares

 

The Series G Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series G Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series G Preferred stock is convertible into shares of common stock at $0.50.

 

As of September 30, 2021, no Series G Preferred Stock has been issued by the Company.

 

Common Stock

 

On March 19, 2021, the Company issued 518,000 unregistered shares of common stock to the holder of the January 2020 convertible note for conversion of $25,900 in accrued interest.

 

On June 8, 2021, an investor converted 8 shares of Series E Preferred and accrued dividends of approximately $10,000 into 101,010 shares of common stock. In addition, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants.

 

On July 30, 2021, and investor converted 50 shares of Series E Preferred stock with a stated value of $250,000 into 500,000 shares of common stock.

 

On August 11, 2021, the Company issued 100,000 shares of common stock to a convertible note investor as a commitment fee which was valued at it relative fair value of $56,464.

 

On August 18, 2021, the Company issued 100,000 shares of common stock to a convertible note investor as a commitment fee which was valued at its relative fair value of $62,220.

 

On September 22, 2021, the Company issued 300,148 shares of common stock to an investment banker for commissions due under a banking agreement. The shares were recorded at their relative fair value of approximately $39,290.

 

During the three-month period ending September 30, 2021 the company issued 1.7 million common shares upon the conversion of $50,855 principal and $34,155 accrued interest on the February 2020 convertible note.

 

The common shares issued upon conversions of convertible notes for the nine months ended September 30,2021 were valued at fair value based on the quoted trading prices on the conversion dates aggregating $379,422 resulting in a loss on debt extinguishment of $268,522.

 

Warrants

 

As of September 30, 2021, there were 61,306,350 warrants outstanding, with a weighted average exercise price of $0.07 per share, and annual expirations as follows:

 

Warrant Summary:                    
   Shares   2023   2024   2025   2026 
Series E Preferred    30,405,600    30,405,600                
Series F Preferred   3,088,500    3,088,500                
Convertible Notes   27,463,517         1,013,333    22,905,731    3,544,453 
Other   348,733    10,080    335,452    3,201      
Total Warrants   61,306,350    33,504,180    1,348,785    22,908,932    3,544,453 

 

The above includes 60,957,617 price adjustable warrants.

 

A total of 343,750 warrants expired during the period. There were 75,000 Series E warrants exercised as of September 30, 2021 on a cashless basis.

 

Note 6 - Stock Incentive Plans

 

Stock Options

 

The following table summarizes stock option activity for the Nine months ended September 30, 2021.

 

   Options Outstanding 
   Shares  

Weighted

Average

Exercise Price

 
Outstanding, December 31, 2020   391,350   $0.58 
Options granted   —    — 
Options expired / forfeited   (3,800)   2.60 
Outstanding, September 30, 2021   387,550    0.99 
Exercisable, September 30, 2021   387,550   $0.99 

 

 22 

 

 

The following table summarizes additional information on stock options outstanding as of September 30, 2021.

 

      Options Outstanding    Options Exercisable 
 Range of Exercise Prices     Number Outstanding    Weighted- Average Remaining Contractual Life (Years)    Weighted Average Exercise Price    Number Exercisable    Weighted Average Exercise Price 
$0.98 - $1.00      383,500    1.57   $0.98    383,500   $0.98 
$1.70    4,050    .27   $1.70    4,050   $1.70 
                           
 Totals    387,550    1.56   $0.99    387,550   $0.99 

 

During the nine months ended September 30, 2021, the Company granted no stock options.

 

Total expense related to stock options was approximately $8,000 for the nine months ended September 30, 2020, respectively. No stock-based compensation expense was recognized for the nine-month period ended September 30, 2021.

 

As of September 30, 2021, the Company had no unrecognized compensation expense related to unvested stock options.

 

As of September 30, 2021, the intrinsic value of stock options outstanding was zero.

 

Note 7 - Commitments and Contingencies

 

Litigation

 

Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors.

 

Leases

 

The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs.

 

Share Repurchase Agreement

 

On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $100,000 by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.

 

Licensing Agreement– MLR 1019

 

On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $21,750,000 upon meeting certain performance milestones, as well as a royalty of 5% of gross sales.

 

The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to get its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to affect an Uplisting Event, the Company will have the option to purchase the all rights held by MP on the MLR-1019 licensed products in consideration for 10% of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5% royalty of future gross product sales.

 

As of September 30, 2021, no performance milestones had been met.

 

Licensing Agreement – MLR 1023

 

On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.

 

Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $21,750,000 upon meeting certain performance milestones, as well as a tiered royalty of 8-12% of gross sales.

 

If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.

 

Note 8 - Subsequent Events

 

Except for the events discussed below, there were no subsequent events that required recognition or disclosure.

 

Issuance of Common Stock

 

On October 4, 2021, the Company issued 525,000 shares of common stock upon the conversion of $26,250 of principal and interest on the January 2020 convertible note.

 

Secured Note Default

 

On July 30, 2021, the Company defaulted under the Secured Convertible Promissory Note from January 2021 and the interest rate on the note reset to 18%.

 

 23 

 

 

Issuance of Common Stock

 

On October 4, 2021, the Company issued 255,540 shares of common stock upon the conversion of 20 shares Series E Preferred stock and accrued dividends.

 

Issuance of Common Stock

 

On October 15, 2021, the Company issued 37,043 shares of common stock upon the conversion of 3 shares of Series F Preferred stock and accrued dividends.

 

Issuance of a Convertible Note

 

On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received consideration of $110,000. In addition, the Company issued 59,523 shares of common stock as a commitment fee to the Buyer.

 

The Note is due October 5, 2022. The Note provides for guaranteed interest at the rate of 10% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $0.075 per share, subject to certain adjustments.

 

The Warrants are exercisable for three-years from October 5, 2021, at an exercise price of $0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $45,238.05. The company will record a debt discount related to the relative fair value of the warrants.

 

Issuance of a Convertible Note

 

On October 13, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received consideration of $110,000. In addition, the Company issued 59,523 shares of common stock as a commitment fee to the Buyer.

 

The Note is due October 7, 2022. The Note provides for guaranteed interest at the rate of 10% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $0.075 per share, subject to certain adjustments.

 

The Warrants are exercisable for three-years from October 7, 2021, at an exercise price of $0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $45,238.05. The company will record a debt discount related to the relative fair value of the warrants.

 

Extension of Notes Maturity Date

 

On October 27, 2021, the Company and the institutional investor who holds two convertible promissory notes agreed to extend the maturity date of each of the Notes by six months. The $220,500 Note issued in August 2021 had its maturity date extended to February 17, 2023, and the $66,500 Note issued in June 2021 had its maturity date extended to December 25, 2022.

 

Issuance of Common Stock

 

On November 4, 2021, the Company issued 153,227 shares of common stock upon a cashless exercise of 250,000 warrants issued with the April 2021 Convertible Note.

 

Licensing Agreement MLR-1023 Amendment

 

On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.

 

 24 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect management’s current views with respect to future events and financial performance including meeting our obligations under the Melior license agreement and our liquidity. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10-K, for the year ended December 31, 2020, as filed with the Securities and Exchange Commission (“SEC”) on April 7, 2021. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

 

Forward-looking statements are inherently subject to risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not even anticipate. Although we believe that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, we can give no assurance that such expectations will be achieved. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform them to actual results, new information, future events or otherwise, except as otherwise required by securities and other applicable laws.

 

The following factors, among others, could cause our or our industry’s future results to differ materially from historical results or those anticipated:

 

● our ability to obtain additional funding for our company, whether pursuant to a capital raising transaction arising from the sale of our securities, a strategic transaction or otherwise;
   
● our ability to satisfy our disclosure obligations under the Securities Exchange Act of 1934, as amended, and to maintain the registration of our common stock thereunder; and
   
● our ability to attract and retain qualified officers, directors, employees and consultants as necessary.

 

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

 

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. We are under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.

 

As used in this quarterly report and unless otherwise indicated, the terms “we,” “us,” “our” or the “Company” refer to Adhera Therapeutics, Inc., a Delaware corporation. and its wholly-owned subsidiaries, MDRNA Research, Inc., Cequent Pharmaceuticals, Inc., Atossa Healthcare, Inc., and IthenaPharma, Inc. Unless otherwise specified, all amounts are expressed in United States dollars. Our common stock is currently listed on the OTC Pink Market, under the symbol “ATRX.”

 

 25 

 

 

Corporate Overview

 

Nature of Business

 

We are an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company.

 

On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales.

 

On August 24, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.

 

On October 20, 2021, we as licensee expanded the an exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.

 

To the extent that resources have been available, we have continued to work with its advisors to restructure our company and to identify potential strategic transactions, including the Melior transaction described above to enhance the value of the company. Because of our substantial unpaid debt, if we do not raise substantial additional capital in the immediate future, it is likely that the company will discontinue all operations and seek bankruptcy protection.

 

 26 

 

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2021 to the Three Months Ended September 30, 2020

 

Operating Expenses

 

Our operating expenses for the three months ended September 30, 2021, and 2020 are summarized as follows:

 

   Three Months Ended 
   September 30,
2021		   September 30,
2020		   Increase/
(Decrease)		 
(in thousands)            
Sales and marketing  $-   $20   $(20)
General and administrative expenses   232    174    58 
Total operating expenses  $232   $194   $38 

 

Sales and Marketing

 

For the three months ended September 30, 2021, sales and marketing expense decreased by approximately $20,000 as compared to the three months ended September 30, 2020. Sales and marketing expenses for the three months ended September 30, 2020, and September 30, 2021 were primarily related to storage and other related costs incurred for Prestalia® inventory.

 

General and Administrative

 

General and administrative expense increased by approximately $58,000 for the three months ended September 30, 2021, as compared to the three months ended September 30, 2020. The increase was primarily due to an increase in public company fees including legal expenses and fees paid for investor relation services.

 

Other Expense

 

   Three Months Ended 
  

September 30,

2021

  

September 30,

2020

  

Increase/

(Decrease)

 
(in thousands)            
Interest expense  $(261)  $(255)  $6 
Other income   -    5    5 
Loss on extinguishment of debt   

(177

)   

-

    

177

 
Derivative expense   (2,968)   -    2,968 
Amortization of debt discount   (101)   (95)   6
Total other expense, net  $(3,507)  $(345)  $3,162

 

Interest expense for the three months ended September 30, 2021 increased by $6,000 compared to the three months ended September 30, 2020 primarily due to an increase in interest as a result of an increase in our outstanding convertible notes. Other income for the three months ended September 30, 2020, was a result of fees received from release of certain intellectual property rights in 2019 from a third-party vendor and fees received from the cancellation of a contractual obligation with a third-party vendor. The increase of $2,968 for derivative expense was due to conversion features and warrants on convertible notes that were classified as a derivative on our balance sheet as of September 30, 2021. The loss on extinguishment of debt was due to the conversion of principal and interest on our outstanding convertible notes.

 

Comparison of the Nine Months Ended September 30, 2021, to the Nine Months Ended September 30, 2020

 

Operating Expenses

 

Our operating expenses for the Nine months ended September 30, 2021, and 2020 are summarized as follows:

 

   Nine Months Ended 
  

September 30,

2021

  

September 30,

2020

  

Increase/

(Decrease)

 
(in thousands)            
Sales and marketing  $17   $818   $(801)
General and administrative expenses   454    1,055    (601)
Total operating expenses  $471   $1,873   $(1,402)

 

 27 

 

 

Sales and Marketing

 

For the three months ended September 30, 2021, sales and marketing expense decreased by approximately $801,000 as compared to the nine months ended September 30, 2020. Sales and marketing expenses for the nine months ended September 30, 2020 were primarily related to regulatory costs incurred for maintaining the Prestalia® NDA including approximately $679,000 of PFUFA fees. No such costs were incurred for the same period of 2021.

 

General and Administrative

 

General and administrative expense decreased by approximately $601,000 for the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The decrease was primarily due to a reduction in personnel related expenses and public company fees including legal expenses and insurance for the nine months ended September 30, 2021 as compared to the same period of 2020.

 

Other Expense

 

   Nine Months Ended 
  

September 30,

2021

  

September 30,

2020

  

Increase/

(Decrease)

 
(in thousands)            
Interest expense  $(749)  $(1,082)  $(333)
Other income   -    45    45 
Derivative expense   (3,055)       3,055 

Loss on extinguishment of debt

   

(177

)   -    177 
Amortization of debt discount   (230)   (373)   (143)
Total other expense, net  $(4,211)  $(1,410)  $

2,801

 

Interest expense for the nine months ended September 30, 2021, decreased by $333,000 compared to the nine months ended September 30, 2020 primarily due to a decrease in the amortization of debt issuance costs for our term notes. The amortization of debt discount decreased by $143,000 primarily due to the maturity of our outstanding convertible notes. Other income for the nine months ended September 30, 2020, was a result of fees received from release of certain intellectual property rights in 2019 from a third-party vendor and fees received from the cancellation of a contractual obligation with a third-party vendor. The increase in derivative expense was due to conversion features on a convertible notes that were classified as a derivative on our balance sheet as of September 30, 2021. The loss on extinguishment of debt was due to the conversion of principal and interest on our outstanding convertible notes.

 

Liquidity & Capital Resources

 

Working Capital

 

(in thousands) 

September 30, 2021

  

December 31, 2020

 
Current assets  $151   $1 
Current liabilities   (20,390)   (14,774)
Working capital deficit  $(20,239)  $(14,773)

 

Negative working capital as of September 30, 2021, was approximately $20.2 million as compared to negative working capital of approximately $14.8 million as of December 31, 2020. The decrease in working capital is primarily related to an increase in current liabilities of approximately $3.5 million including approximately $1.1 million in accrued dividends, $762,000 of accrued expenses and $3.5 million for a derivative liability related to our convertible notes.

 

 28 

 

 

Cash Flows and Liquidity

 

Net cash used in Operating Activities

 

Net cash used in operating activities was approximately $369,000 during the nine months ended September 30, 2021. This was primarily due to our net operating loss of approximately $4.6 million, partially offset by to our derivative expense of approximately $3.1 million, non-cash interest expense related to term loans of $749,000, non-cash amortization of debt discount of $230,000 and other changes in operating assets and liabilities including an increase in accounts payable and accrued expenses of approximately $102,000.

 

Net cash used in operating activities was approximately $0.5 million during the nine months ended September 30, 2020. This was primarily due to our net loss of approximately $3.3 million, partially offset by non-cash interest expense related to our term loans of approximately $1.5 million and other changes in operating assets and liabilities including an increase in accounts payable and accrued expenses of approximately $1.0 million.

 

Net cash used in Investing Activities

 

There was no cash used in or provided by investing activities for the nine months ended September 30, 2021, or September 30, 2020.

 

Net cash provided by Financing Activities

 

Net cash provided by financing activities for the nine months ended September 30, 2021, and 2020 was approximately $519,000 and $448,000, respectively from the issuance of convertible notes to certain accredited investors, net of issuance costs

 

We will need to raise immediate additional operating capital to maintain our operations and to realize our business plan. Without additional sources of cash and/or the deferral, reduction, or elimination of significant planned expenditures, we will not have the cash resources to continue as a going concern thereafter.

 

Future Financing

 

We do not have sufficient funds to meet our working capital needs for the next 12 months. We will require immediate additional funds to continue our business. Historically, we have raised additional capital to supplement our commercialization, clinical development and operational expenses. We will need to raise additional funds required through equity financing, debt financing, strategic alliances or other sources, which may result in further dilution in the equity ownership of our shares. There can be no assurance that additional financing will be available when needed or, if available, that it can be obtained on commercially reasonable terms. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on our ability to achieve our intended business objectives. These factors raise substantial doubt about our ability to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2021, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

 

Critical Accounting Policies and Estimates

 

Our significant accounting policies are more fully described in the notes to our financial statements included herein for the period ended September 30, 2021, and in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

 29 

 

 

New and Recently Adopted Accounting Pronouncements

 

Any new and recently adopted accounting pronouncements are more fully described in Note 1 to our financial statements included herein for the period ended September 30, 2021.

 

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4 CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

 

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that, our disclosure controls and procedures were not effective due to the material weakness(es) in internal control over financial reporting described below.

 

Material Weakness in Internal Control over Financial Reporting

 

Management assessed the effectiveness of our internal control over financial reporting as of September 30, 2021, based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that our internal control over financial reporting as of September 30, 2021, was not effective.

 

A material weakness, as defined in the standards established by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:

 

● Inadequate segregation of duties consistent with control objectives;
   
● Lack of qualified accounting personnel to prepare and report financial information in accordance with GAAP; and
   
● Lack of documentation on policies and procedures that are critical to the accomplishment of financial reporting objectives.

 

 30 

 

 

Management’s Plan to Remediate the Material Weakness

 

Providing funds are available, management plans to implement measures designed to ensure that control deficiencies, contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions planned include:

 

● Identifying gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company including the need for outsourced expertise; and
   
● Continuing to develop policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

 

We will continue to reassess our plans to remedy our internal control deficiencies in light of our personnel structure and our financial condition. We hope that such measures will lead to an improvement in the timely preparation of financial reports and strengthen our segregation of duties at our company. We are committed to developing a strong internal control environment, and we believe that the remediation efforts that we will implement will result in significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow. However, our significant working capital deficiency may delay remediation.

 

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2021, that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

General

 

Currently, there is no material litigation pending against our company. From time to time, we may become a party to litigation and subject to claims incident to the ordinary course of our business.

 

ITEM 1A. RISK FACTORS

 

An investment in our common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Annual Report”), as filed with the SEC on April 7, 2021, in addition to other information contained in those documents and reports that we have filed with the SEC pursuant to the Securities Act and the Exchange Act since the date of the filing of the Annual Report, including, without limitation, this Quarterly Report on Form 10-Q, in evaluating our company and its business before purchasing shares of our common stock. Our business, operating results and financial condition could be adversely affected due to any of those risks.

 

The information presented below updates, and should be read in conjunction with, the risk factors and information disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

If we are unable to successfully commercialize MLR-1019 or any of our other product candidates and are unable to make milestone payments, our result of operations would be adversely affected.

 

We recently entered into an exclusive license agreement with Melior Pharmaceuticals II, LLC to develop and commercialize MLR-1019 as a new class of therapeutics for Parkinson’s Disease. Upon MLR-1019 meeting certain milestones, the Company is required to make payments which aggregate approximately $21.75 million. We currently do not have enough capital to meet any milestone and cannot assure you will be successful in raising the $250,000 we need to attempt to meet the first milestone. If any milestone is met, we can provide you with no assurance that we will be able to raise capital in order to fund that milestone. If the drug candidate fails to meet any of the milestones and therefore is unable to be commercialized, we will receive no benefits from this license. In any such event, our results of operations will suffer and we may need to cease operations. Additionally, MLR–1019 may be classified as a controlled substance in the United States which may have an adverse effect on our future revenues if we are able to commercialize it in the United States.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

 31 

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION

 

None.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
4.1   Form of Convertible Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on January 31, 2021 (filed as Exhibit 4.1 to our Current Report on Form 8-K dated February 9, 2021, and incorporated herein by reference).
     
4.2   Form of Common Stock Purchase Warrants issued by Adhera Therapeutics, Inc. to select accredited investors on January 31, 2021 (filed as Exhibit 4.2 to our Current Report on Form 8-K dated February 9, 2021, and incorporated herein by reference)
     
4.3   Form of Convertible Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on April 12, 2021 (filed as Exhibit 4.1 to our Current Report on Form 8-K dated April 23, 2021, and incorporated herein by reference).
     
4.4   Form of Common Stock Purchase Warrants issued by Adhera Therapeutics, Inc. to select accredited investors on April 12, 2021 (filed as Exhibit 4.2 to our Current Report on Form 8-K dated April 23, 2021, and incorporated herein by reference)
     
4.5   Form of Convertible Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on June 25, 2021. (filed as Exhibit 4.5 to our Current Report on Form 10-Q dated August 23, 2021, and incorporated herein by reference)
     
4.6   Form of Common Stock Purchase Warrants issued by Adhera Therapeutics, Inc. to select accredited investors on June 25, 2021. (filed as Exhibit 4.6 to our Current Report on Form 10-Q dated August 23 ,2021, and incorporated herein by reference)
     
4.7   Form of Convertible Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on August 12, 2021 (filed as Exhibit 4.1 to our Current Report on Form 8-K dated August 18, 2021, and incorporated herein by reference).
     
4.8   Form of Common Stock Purchase Warrants issued by Adhera Therapeutics, Inc. to select accredited investors on August 12, 2021 (filed as Exhibit 4.2 to our Current Report on Form 8-K dated August 18 , 2021, and incorporated herein by reference)
     
4.9   Form of Convertible Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on August 18, 2021 (filed as Exhibit 4.1 to our Current Report on Form 8-K dated August 24, 2021, and incorporated herein by reference).
     
4.10   Form of Common Stock Purchase Warrants issued by Adhera Therapeutics, Inc. to select accredited investors on August 18, 2021 (filed as Exhibit 4.2 to our Current Report on Form 8-K dated August 24, 2021, and incorporated herein by reference)
     
10.1   Form of Securities Purchase Agreement issued by Adhera Therapeutics, Inc. to select accredited investors on August 18, 2021 (filed as Exhibit 10.1 to our Current Report on Form 8-K dated August 24, 2021, and incorporated herein by reference)
     
31.1   Certification of Principal Executive and Principal Financial Officer pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)
     
32.1   Certification of Principal Executive and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
     
101INS   Inline XBRL Instance Document (1)
     
101SCH   Inline XBRL Taxonomy Extension Schema Document (1)
     
101CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)
     
101DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document (1)
     
101LAB   Inline XBRL Taxonomy Extension Label Linkbase Document (1)
     
101PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
(1)   Filed herewith.
     
(2)   Furnished herewith.

 

 32 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  ADHERA THERAPEUTICS, INC.
     
Date: November 22, 2021 By: /s/ Andrew Kucharchuk
   

Andrew Kucharchuk

CEO (Principal Executive Officer and Principal Financial Officer)

 

 33 

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Andrew Kucharchuk, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Adhera Therapeutics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

By: /s/ Andrew Kucharchuk  
  Andrew Kucharchuk  
  CEO  
  (Principal Executive Officer and Principal Financial Officer)  
     
Date: November 22, 2021  

 

 

 

 EX-32.1 3 ex32-1.htm

 

Exhibit 32.1

 

ADHERA THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with this Quarterly Report on Form 10-Q of Adhera Therapeutics, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

By: /s/ Andrew Kucharchuk  
  Andrew Kucharchuk  
  CEO  
  (Principal Executive Officer and Principal Financial Officer)  
     
Date: November 22, 2021  

 

 

 

 EX-101.SCH 4 atrx-20210930.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock Incentive Plans link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Schedule of Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Schedule of Roll Forward of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Licensing Agreements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Incentive Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 atrx-20210930_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 atrx-20210930_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 atrx-20210930_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series G Convertible Preferred Stock [Member] Series G Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Series C Preferred Stock [Member] Series D Preferred Stock [Member] Series E Preferred Stock [Member] Series F Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Debt Instrument [Axis] Warrants [Member] Convertible Notes [Member] Antidilutive Securities [Axis] Convertible Notes Payable [Member] Stock Options Outstanding [Member] Title of Individual [Axis] Accredited Investors [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Term Loan Subscription Agreements [Member] Short-term Debt, Type [Axis] Four Convertible Notes [Member] Securities Purchase Agreement [Member] Warrant [Member] Convertible Debt [Member] Convertible Note [Member] Holders [Member] Senior Secured Convertible Promissory Note [Member] Secured Convertible Promissory Note [Member] Senior Secured Convertible Promissory Note One [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Valuation Approach and Technique [Axis] Valuation Technique, Option Pricing Model [Member] Conversion Feature [Member] Senior Secured Convertible Promissory Note Two [Member] Related Party [Axis] Investor and lender [Member] Senior Secured Convertible Promissory Note Three [Member] Senior Secured Convertible Promissory Note Four [Member] Secured Convertible Promissory Note One [Member] Registration Rights Agreement [Member] Secured Convertible Promissory Note Two [Member] Measurement Input, Expected Dividend Rate [Member] Measurement Input, Expected Term [Member] Les Laboratories Servier License Agreement [Member] Series [Axis] Novosom Verwaltungs GmbH [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Property [Member] Scenario [Axis] Upon Execution of Agreement [Member] Achievement of Performance Obligation [Member] Novosom Agreement [Member] Balance Sheet Location [Axis] Accrued Liabilities [Member] License Of DiLA Assets [Member] Series B Preferred Stock [Member] Series A Junior Participating Preferred Stock [Member] Series A Preferred Stock and Series B Preferred Stock [Member] Series E Convertible Preferred Stock and Warrants [Member] Series E Warrants [Member] Series E Preferred [Member] Series F Convertible Preferred Stock and Warrants [Member] Series F Warrants [Member] Class of Warrant or Right [Axis] Series G Convertible Preferred Shares [Member] 2020 Term Loan [Member] Convertible Note Investor [Member] Banking Agreement [Member] February 2020 Convertible Note [Member] Other [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Award Type [Axis] Share-based Payment Arrangement, Option [Member] Licensing Agreement M L R 1019 [Member] Licensing Agreement M L R 1023 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] January Convertible Note [Member] Secured Promissory Note [Member] Convertible Redeemable Note [Member] Institutional Investor [Member] Buyer [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current assets Cash Total current assets Total assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable Due to related party Accrued expenses Accrued dividends Term loan Convertible notes payable, net Derivative liability Total current liabilities Total liabilities Commitments and contingencies (Note 7) Stockholders’ deficit Preferred stock value Common stock, $0.006 par value; 180,000,000 shares authorized, 14,485,438 and 11,112,709 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively Additional paid-in capital Accumulated deficit Total stockholders’ deficit Total liabilities and stockholders’ deficit Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Preferred stock, liquidation preference value Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Outstanding Income Statement [Abstract] Operating expenses Sales and marketing General and administrative Total operating expenses Loss from operations Other income (expense) Interest expense Other Income Loss on extinguishment of debt Derivative expense Amortization of debt discount Total other income (expense) Net loss Dividends Net Loss Applicable to Common Stockholders Net loss per share – Common Stockholders - basic and diluted Weighted average shares outstanding - basic and diluted Beginning balance, value Balance, shares Accrued and deemed dividend Issuance of common stock for convertible note conversion Issuance of common stock for convertible note conversion, shares Issuance of warrants and common stock with convertible notes - Issuance of common stock for cashless exercise of warrants Issuance of common stock for cashless exercise of warrants, shares Issuance of common stock for Series E conversion Issuance of common stock for Series E conversion, shares Accrued dividend Issuance of warrants and common stock with convertible notes, shares Benefical conversion feature - convertible notes Issuance of common stock for convertible note and interest conversions Issuance of common stock for convertible note and interest conversions, shares Reclassification of derivative Issuance of warrants with notes payable Share based compensation Net loss Ending balance, value Balance, shares Statement of Cash Flows [Abstract] Cash Flows Used in Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Share based compensation Loss on debt extinguishment Amortization of debt discount Derivative expense Changes in operating assets and liabilities: Prepaid expenses and other assets Accounts payable Accrued interest Accrued expenses Net Cash Used in Operating Activities Cash Flows Provided By Financing Activities: Proceeds from notes payable, net or original issue discounts Notes payable issuance costs Net Cash Provided by Financing Activities Net (decrease) in cash Cash – Beginning of Period Cash - End of Period Supplementary Cash Flow Information: Non-cash Investing and Financing Activities: Dividends Conversion of Series E to common stock Beneficial conversion feature on issuance notes payable Cashlesss exercise of Series E warrants Issuance of common stock for conversion of convertible debt Debt discounts for issuance costs, warrants and derivatives Accounting Policies [Abstract] Nature of Operations, Basis of Presentation and Significant Accounting Policies Debt Disclosure [Abstract] Notes Payable Licensing Agreements Licensing Agreements Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stockholders’ Equity Share-based Payment Arrangement [Abstract] Stock Incentive Plans Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Reclassification Use of Estimates Fair Value of Financial Instruments Convertible Debt and Warrant Accounting Recently Issued Accounting Pronouncements Net Loss per Common Share Schedule of Fair Value Measurements Schedule of Roll Forward of Level 3 Financial Instruments Schedule of Earnings Per Share, Basic and Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Convertible Promissory Notes Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Share-based Payment Arrangement, Option, Activity Schedule of Share-based Payment Arrangement, Option, Exercise Price Range Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Derivative liability Total Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Balance at December 31, 2020 Initial valuation of derivative liabilities included in debt discount Initial valuation of derivative liabilities included in derivative expense Reclassification of derivative liabilities to gain on debt extinguishment Reclass from Additional paid-in capital Change in fair value included in derivative expense Balance at September 30, 2021 Dividends Net Loss allocable to common stockholders Weighted average common shares outstanding used to compute net loss per share, basic and diluted Net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Cash and Cash Equivalents, at Carrying Value Working capital Net loss Accumulated deficit Long-term Debt, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Fair Value, Net Asset (Liability) Convertible Notes Unamortized discounts Convertible Notes Payable Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Derivative Liability, Measurement Input Long-term Debt, Term Principal amount Debt issuance costs, net Debt instrument, interest rate Debt maturity date Debt instrument, effective percentage Interest expense Amortization of debt issuance costs Accured interest Repayments of Debt Convertible notes payable, current Debt instrument, convertible, conversion price Weighted average price of common stock Debt conversion rate Conversion price adjusted for stock splits, stock combinations and similar events (in dollars per share) Warrant term Debt discount to be amortized Debt default interest rate Debt conversion amount Debt Conversion, Converted Instrument, Shares Issued Debt principal and interest Loss on extinguishment of debt Derivative liability Gain on extinguishment of debt Net loss on extinguishment Conversion of convertible debt Debt instrument, convertible, beneficial conversion feature Convertible note, premimum description Intrinsic value of the beneficial conversion feature Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Unamortized debt issuance expense Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of warrant or right, exercise price of warrants or rights Deemed dividend Fair value of warrants measurement inputs Debt Instrument, Convertible, Conversion Ratio Warrants issued Amotized interest expense Debt Instrument, Unamortized Discount, Current Notes payable Class of Warrant or Right, Expense or Revenue Recognized Secured Debt Warrants and Rights Outstanding Stock Issued During Period, Shares, New Issues Derivative liabilities Derivative expense Debt discount Debt term [custom:InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount] [custom:InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense] Payments for royalties Common stock issued Fair value of common stock issued Proceeds form sale of intangible asset Payables on intellectual property Other income Upfront payment agreement for license agreement Due to Related Parties Schedule of Stock by Class [Table] Class of Stock [Line Items] Warrant shares Expiring in 2023 Expiring in 2024 Expiring in 2025 Expiring in 2026 Preferred Stock, Shares Authorized Preferred stock designated, shares Stated value per share Preferred stock liquidation preference per share Preferred Stock, Voting Rights Common stock at a conversion price, per share Preferred stock stated dividend rate Anti-dilution price protection, expiration date Warrant exercise price per share Number of shares converted, value Number of shares converted Deemed dividend Accrued dividends Number of shares in accrued dividends Number of shares issued Common stock for a cashless exercise Warrants outstanding Dividends, Preferred Stock Warrants term description Number of shares repurchased Warrants to purchase shares of common stock Stock repurchase Value of warrants held Value of converted shares Number of shares issued upon conversion Accrued dividends Interest payable Fair value Stock Issued During Period, Shares, Conversion of Convertible Securities [custom:LossOnExtinguishmentOfDebt] Adjustable warrants, shares Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations [custom:NumberOfWarrantsExercised] Options Outstanding Beginning Options outstanding, weighted average exercise price, beginning Options granted Options granted, weighted average exercise price Options expired / forfeited Options expired/forfeited, weighted average exercise price Options Outstanding Ending Options outstanding, weighted average exercise price, ending Options Exercisable Exercisable, weighted average exercise price Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of exercise prices, lower Range of exercise prices, upper Numbers outstanding Weighted- Average Remaining Contractual Life (Years) Weighted average exercise price Number exercisable Weighted average exercise price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Payment Arrangement, Expense Loss Contingencies [Table] Loss Contingencies [Line Items] Debt instrument cash payment Gross sales percentage License agreement commitments description Subsequent Event [Table] Subsequent Event [Line Items] Debt conversion converted instrument amount Debt instrument effective percentage Debt Instrument, Face Amount Warrants and Rights Outstanding, Term Class of Warrant or Right, Outstanding Proceeds from Convertible Debt Number of share issued Maturity date Debt Instrument, Convertible, Conversion Price Class of Warrant or Right, Exercise Price of Warrants or Rights Aggregate exercise price of warrants Debt Instrument, Interest Rate, Stated Percentage Maturity date description Number of stock issued conversion Number of warrant issued Series C Convertible Preferred Stock [Member] Series C Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Series F Convertible Preferred Stock [Member] Series G Convertible Preferred Stock [Member] Stock issued during period value accrued dividend. Fair value of derivative liability. Issuance of warrants with convertible notes. Issuance of common stock for cashless exercise of warrants. Issuance of common stock for series E conversion. Series G Convertible Preferred Stock [Member] Working capital. Retained earnings accumulated deficit. Accredited Investors [Member] Term Loan Subscription Agreements [Member] Extension period for term of loan. Four Convertible Notes [Member] Securities Purchase Agreement [Member] Weighted average price of common stock. Conversion price adjusted for stock splits, stock combinations and similar events. Accrued and deemed dividends. Conversion of stock. Beneficial conversion feature on notes payable. Accrued interest. Cashless exercise of warrants. Issuance of warrants with convertible notes. Holders [Member] Senior Secured Convertible Promissory Note [Member] Intrinsic value of the beneficial conversion feature. Debt default interest rate. Secured Convertible Promissory Note [Member] Senior Secured Convertible Promissory Note One [Member] Deemed dividend. Investor and lender [Member] Senior Secured Convertible Promissory Note Two [Member] Number of warrants issued during the period. Senior Secured Convertible Promissory Note Three [Member] Secured Promissory Note [Member] Senior Secured Convertible Promissory Note Four [Member] Secured Convertible Promissory Note One [Member] Registration Rights Agreement [Member] Secured Convertible Promissory Note Two [Member] Les Laboratories Servier License Agreement [Member] Novosom Verwaltungs GmbH [Member] Payables on intellectual property. Upon Execution of Agreement [Member] Achievement of Performance Obligation [Member] Novosom Agreement [Member] Upfront payment agreement for license agreement. License Of DiLA Assets [Member] Licensing Agreement [Text Block] Range One [Member] Range Two [Member] Value of warrants held. January Convertible Note [Member] Represents class of warrant or right expiring in year two. Class of warrant or Right expiring in three year. Convertible Redeemable Note [Member] Class of warrant or Right expiring in four year. Class of warrant or Right expiring in five year. Accredited Institutional Investor [Member] Convertible Notes [Member] Other [Member] Institutional Investor [Member] Preferred Stock Designated, Shares. Series A Junior Participating Preferred Stock [Member] Preferred stock liquidation preference per share. Common stock at a conversion price, per share. Series E Convertible Preferred Stock and Warrants [Member] Antidilution price protection expiration date. Series E Warrants [Member] Series E Preferred [Member] Common stock for cashless exercise, shares. Series F Convertible Preferred Stock and Warrants [Member] Warrants term description. Series F Warrants [Member] Series G Convertible Preferred Shares [Member] 2020 Term Loan [Member] Convertible Note Investor [Member] Aggregate exercise price of warrants. Banking Agreement [Member] February 2020 Convertible Note [Member] Adjustable warrants, shares. Amotized interest expense. Number of warrants exercised. Change in fair value of derivative liability. Convertible Note [Member] Series A Preferred Stock and Series B Preferred Stock [Member] Derivative expense. Buyer [Member] Additional debt discount. Loss on extinguishment of debt. Reclassification of derivative. Issuance of common stock for convertible note and interest conversions. Issuance of common stock for convertible note and interest conversions, shares. Gain on extinguishment of debt. Schedule of Roll Forward of Level 3 Financial Instruments [Table Text Block] Initial valuation of derivative liabilities included in debt discount. Initial valuation of derivative liabilities included in derivative expense. Reclassification of derivative liabilities to gain on debt extinguishment. Reclassification of derivative from equity. Change in fair value included in derivative expense. Reclass from APIC. Series C Convertible Preferred Stock [Member] [Default Label] Series D Convertible Preferred Stock [Member] [Default Label] Series E Convertible Preferred Stock [Member] [Default Label] Series F Convertible Preferred Stock [Member] [Default Label] Series G Convertible Preferred Stock [Member] [Default Label] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other DerivativeExpense Amortization of Debt Issuance Costs and Discounts Nonoperating Income (Expense) Preferred Stock Dividends, Income Statement Impact Shares, Outstanding Dividends [Default Label] Share-based Payment Arrangement, Noncash Expense Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents ConversionOfSeriesEToCommonStock BeneficialConversionFeatureOnNotesPayable CashlessExerciseOfWarrants DebtDiscountsForIssuanceCostsWarrantsAndDerivatives LicensingAgreementTextBlock Derivative Liability, Fair Value, Gross Liability Derivative Assets (Liabilities), at Fair Value, Net Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Retained earnings accumulated deficit Derivative, Gain (Loss) on Derivative, Net Dividends, Preferred Stock, Stock Accrued Investment Income Receivable Dividends, Preferred Stock, Cash Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price EX-101.PRE 8 atrx-20210930_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000737207 2021-01-01 2021-09-30 0000737207 2021-11-22 0000737207 2021-09-30 0000737207 2020-12-31 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesCConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesDConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesDConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesEConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesFConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiablePreferredStockMember 2020-12-31 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2021-09-30 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2020-12-31 0000737207 atrx:SeriesGConvertiablePreferredStockMember 2021-09-30 0000737207 atrx:SeriesGConvertiablePreferredStockMember 2020-12-31 0000737207 2021-07-01 2021-09-30 0000737207 2020-07-01 2020-09-30 0000737207 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0000737207 us-gaap:CommonStockMember 2019-12-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000737207 us-gaap:RetainedEarningsMember 2019-12-31 0000737207 2019-12-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000737207 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000737207 2020-01-01 2020-03-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0000737207 us-gaap:CommonStockMember 2020-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000737207 us-gaap:RetainedEarningsMember 2020-03-31 0000737207 2020-03-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000737207 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000737207 2020-04-01 2020-06-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0000737207 us-gaap:CommonStockMember 2020-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000737207 us-gaap:RetainedEarningsMember 2020-06-30 0000737207 2020-06-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000737207 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0000737207 us-gaap:CommonStockMember 2020-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000737207 us-gaap:RetainedEarningsMember 2020-09-30 0000737207 2020-09-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000737207 us-gaap:CommonStockMember 2020-12-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000737207 us-gaap:RetainedEarningsMember 2020-12-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000737207 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000737207 2021-01-01 2021-03-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000737207 us-gaap:CommonStockMember 2021-03-31 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000737207 us-gaap:RetainedEarningsMember 2021-03-31 0000737207 2021-03-31 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000737207 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000737207 2021-04-01 2021-06-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000737207 us-gaap:CommonStockMember 2021-06-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000737207 us-gaap:RetainedEarningsMember 2021-06-30 0000737207 2021-06-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000737207 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000737207 us-gaap:CommonStockMember 2021-09-30 0000737207 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000737207 us-gaap:RetainedEarningsMember 2021-09-30 0000737207 us-gaap:FairValueInputsLevel3Member 2021-09-30 0000737207 srt:MinimumMember 2021-01-01 2021-09-30 0000737207 srt:MaximumMember 2021-01-01 2021-09-30 0000737207 us-gaap:FairValueInputsLevel1Member 2021-09-30 0000737207 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000737207 atrx:WarrantsMember 2020-12-31 0000737207 atrx:ConvertibleNotesMember 2020-12-31 0000737207 atrx:WarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-01-01 2021-09-30 0000737207 atrx:WarrantsMember 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-09-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2021-01-01 2021-09-30 0000737207 us-gaap:ConvertibleNotesPayableMember 2020-01-01 2020-09-30 0000737207 atrx:StockOptionsOutstandingMember 2021-01-01 2021-09-30 0000737207 atrx:StockOptionsOutstandingMember 2020-01-01 2020-09-30 0000737207 atrx:WarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:WarrantsMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2020-01-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2019-12-31 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-01-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2019-12-28 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-07-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-01-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-07-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2021-09-30 0000737207 atrx:FourConvertibleNotesMember 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:SecuritiesPurchaseAgreementMember 2020-02-05 0000737207 atrx:AccreditedInvestorsMember atrx:SecuritiesPurchaseAgreementMember 2020-05-05 0000737207 atrx:AccreditedInvestorsMember atrx:SecuritiesPurchaseAgreementMember 2020-05-04 2020-05-05 0000737207 atrx:AccreditedInvestorsMember us-gaap:WarrantMember atrx:SecuritiesPurchaseAgreementMember 2020-02-05 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember atrx:SecuritiesPurchaseAgreementMember 2020-02-04 2020-02-05 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember atrx:SecuritiesPurchaseAgreementMember 2020-02-05 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2020-02-04 2020-02-05 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2020-06-14 2020-06-15 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2020-07-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2020-01-01 2020-09-30 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2021-07-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember us-gaap:ConvertibleDebtMember atrx:SecuritiesPurchaseAgreementMember 2021-01-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-03-18 2021-03-19 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-07-27 2021-07-29 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-08-15 2021-08-16 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-09-12 2021-09-13 0000737207 us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-09-30 0000737207 atrx:HoldersMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-09-30 0000737207 atrx:AccreditedInvestorsMember atrx:ConvertibleNoteMember atrx:SecuritiesPurchaseAgreementMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember atrx:ConvertibleNoteMember 2020-06-26 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-09-24 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-09-23 2020-09-24 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-06-25 2020-06-26 0000737207 atrx:AccreditedInvestorsMember atrx:TermLoanSubscriptionAgreementsMember 2020-06-26 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-07-01 2020-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2020-08-04 2020-08-05 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteMember us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-10-30 0000737207 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-04-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:WarrantMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ValuationTechniqueOptionPricingModelMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2020-10-29 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2020-10-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-01-01 2021-09-30 0000737207 atrx:ConversionFeatureMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteOneMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember atrx:InvestorAndLenderMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-30 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-03-18 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember 2021-03-19 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-07-27 2021-07-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-30 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-01-31 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteTwoMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-04-10 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-04-10 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:WarrantMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-10-11 2021-10-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteThreeMember 2021-10-12 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-06-23 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-06-25 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:WarrantMember 2021-08-10 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-07-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-01-01 2021-09-30 0000737207 atrx:SeniorSecuredConvertiblePromissoryNoteFourMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember atrx:RegistrationRightsAgreementMember 2021-08-10 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-08-10 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:CommonStockMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:ConvertibleDebtMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-11 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-01-01 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteOneMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember atrx:RegistrationRightsAgreementMember 2021-08-15 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-08-15 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:CommonStockMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:ConvertibleDebtMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-08-17 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember us-gaap:WarrantMember 2021-01-01 2021-09-30 0000737207 us-gaap:MeasurementInputExpectedDividendRateMember 2021-09-30 0000737207 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2021-09-30 0000737207 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2021-09-30 0000737207 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0000737207 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2021-09-30 0000737207 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000737207 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-09-30 0000737207 atrx:SecuredConvertiblePromissoryNoteTwoMember 2021-01-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2021-07-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2021-01-01 2021-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2020-07-01 2020-09-30 0000737207 atrx:LesLaboratoriesServierLicenseAgreementMember 2020-01-01 2020-09-30 0000737207 us-gaap:IntellectualPropertyMember atrx:NovosomVerwaltungsGmbHMember 2018-05-01 2018-05-31 0000737207 us-gaap:IntellectualPropertyMember atrx:NovosomVerwaltungsGmbHMember 2019-12-22 2019-12-23 0000737207 atrx:UponExecutionOfAgreementMember us-gaap:IntellectualPropertyMember atrx:NovosomVerwaltungsGmbHMember 2020-09-30 0000737207 atrx:AchievementOfPerformanceObligationMember us-gaap:IntellectualPropertyMember atrx:NovosomVerwaltungsGmbHMember 2020-09-30 0000737207 atrx:NovosomAgreementMember 2020-07-01 2020-09-30 0000737207 atrx:NovosomAgreementMember 2020-01-01 2020-09-30 0000737207 us-gaap:AccruedLiabilitiesMember atrx:LicenseOfDiLAAssetsMember 2018-03-15 2018-03-16 0000737207 us-gaap:SeriesBPreferredStockMember 2021-09-30 0000737207 atrx:SeriesAJuniorParticipatingPreferredStockMember 2021-09-30 0000737207 atrx:SeriesAPreferredStockAndSeriesBPreferredStockMember 2021-09-30 0000737207 atrx:SeriesCConvertiblePreferredStockMember 2014-03-31 0000737207 atrx:SeriesDConvertiblePreferredStockMember 2015-08-31 0000737207 atrx:SeriesEConvertiblePreferredStockMember 2018-04-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2018-07-31 0000737207 atrx:SeriesGConvertiblePreferredStockMember 2019-12-31 0000737207 us-gaap:SeriesCPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesCPreferredStockMember 2020-12-31 0000737207 us-gaap:SeriesDPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesDPreferredStockMember 2020-12-31 0000737207 atrx:SeriesEConvertiblePreferredStockAndWarrantsMember 2021-09-30 0000737207 atrx:SeriesEConvertiblePreferredStockAndWarrantsMember 2021-01-01 2021-09-30 0000737207 srt:MaximumMember atrx:SeriesEWarrantsMember 2021-03-19 0000737207 srt:MinimumMember atrx:SeriesEWarrantsMember 2021-03-19 0000737207 atrx:SeriesEWarrantsMember 2021-03-18 2021-03-19 0000737207 us-gaap:SeriesEPreferredStockMember 2021-03-18 2021-03-19 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 srt:MinimumMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 srt:MaximumMember us-gaap:SeriesEPreferredStockMember 2021-03-19 0000737207 atrx:SeriesEPreferredMember 2021-06-07 2021-06-08 0000737207 atrx:SeriesEPreferredMember 2021-06-08 0000737207 us-gaap:WarrantMember 2021-06-07 2021-06-08 0000737207 atrx:SeriesEPreferredMember 2021-07-27 2021-07-30 0000737207 us-gaap:CommonStockMember 2021-07-27 2021-07-30 0000737207 atrx:SeriesEWarrantsMember 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-01-01 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-12-31 0000737207 atrx:SeriesFConvertiblePreferredStockAndWarrantsMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockAndWarrantsMember 2021-01-01 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2019-10-28 2019-10-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2019-10-30 0000737207 srt:MaximumMember atrx:SeriesFWarrantsMember 2021-03-19 0000737207 srt:MinimumMember atrx:SeriesFWarrantsMember 2021-03-19 0000737207 atrx:SeriesFWarrantsMember 2021-03-18 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember 2021-03-18 2021-03-19 0000737207 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 srt:MinimumMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 srt:MaximumMember us-gaap:SeriesFPreferredStockMember 2021-03-19 0000737207 us-gaap:SeriesFPreferredStockMember 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2021-01-01 2021-09-30 0000737207 atrx:SeriesFConvertiblePreferredStockMember 2020-01-01 2020-12-31 0000737207 atrx:SeriesGConvertiblePreferredSharesMember 2021-09-30 0000737207 atrx:SeriesGConvertiblePreferredSharesMember 2021-01-01 2021-09-30 0000737207 atrx:TermLoanMember 2021-03-18 2021-03-19 0000737207 atrx:TermLoanMember 2021-03-19 0000737207 atrx:ConvertibleNoteInvestorMember 2021-08-10 2021-08-11 0000737207 atrx:ConvertibleNoteInvestorMember 2021-08-15 2021-08-18 0000737207 atrx:BankingAgreementMember 2021-09-21 2021-09-22 0000737207 atrx:FebruaryTwoThousandTwentyConvertibleNoteMember 2021-07-01 2021-09-30 0000737207 atrx:FebruaryTwoThousandTwentyConvertibleNoteMember 2021-09-30 0000737207 us-gaap:SeriesEPreferredStockMember 2021-09-30 0000737207 us-gaap:SeriesFPreferredStockMember 2021-09-30 0000737207 atrx:ConvertibleNotesMember 2021-09-30 0000737207 atrx:OtherMember 2021-09-30 0000737207 us-gaap:WarrantMember 2021-09-30 0000737207 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000737207 atrx:RangeOneMember 2021-01-01 2021-09-30 0000737207 atrx:RangeOneMember 2021-09-30 0000737207 atrx:RangeTwoMember 2021-01-01 2021-09-30 0000737207 atrx:RangeTwoMember 2021-09-30 0000737207 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000737207 atrx:LicensingAgreementMLR1019Member 2021-07-27 2021-07-28 0000737207 atrx:LicensingAgreementMLR1019Member 2021-07-28 0000737207 atrx:LicensingAgreementMLR1023Member 2021-08-21 2021-08-24 0000737207 srt:MinimumMember atrx:LicensingAgreementMLR1019Member 2021-07-28 0000737207 srt:MaximumMember atrx:LicensingAgreementMLR1019Member 2021-07-28 0000737207 atrx:JanuaryConvertibleNoteMember us-gaap:SubsequentEventMember 2021-10-03 2021-10-04 0000737207 atrx:SecuredPromissoryNoteMember 2021-07-30 0000737207 us-gaap:SubsequentEventMember 2021-10-03 2021-10-04 0000737207 us-gaap:SeriesEPreferredStockMember us-gaap:SubsequentEventMember 2021-10-03 2021-10-04 0000737207 us-gaap:SubsequentEventMember 2021-10-14 2021-10-15 0000737207 us-gaap:SeriesFPreferredStockMember us-gaap:SubsequentEventMember 2021-10-14 2021-10-15 0000737207 atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 atrx:InstitutionalInvestorMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-06 2021-10-07 0000737207 atrx:BuyerMember us-gaap:SubsequentEventMember 2021-10-06 2021-10-07 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-06 2021-10-07 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-07 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-05 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-03 2021-10-05 0000737207 atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-13 0000737207 atrx:ConvertibleRedeemableNoteMember atrx:InstitutionalInvestorMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-11 2021-10-13 0000737207 atrx:BuyerMember us-gaap:SubsequentEventMember 2021-10-11 2021-10-13 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-11 2021-10-13 0000737207 atrx:ConvertibleRedeemableNoteMember us-gaap:SubsequentEventMember atrx:SecuritiesPurchaseAgreementMember 2021-10-13 0000737207 us-gaap:SubsequentEventMember 2021-10-25 2021-10-27 0000737207 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2021-11-02 2021-11-04 0000737207 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2021-11-04 0000737207 us-gaap:SubsequentEventMember atrx:LicensingAgreementMLR1023Member 2021-11-15 2021-11-17 iso4217:USD shares iso4217:USD shares pure atrx:Integer 0000737207 false --12-31 Q3 52500 34000 three 209 253 247000 P3Y P3Y P3Y P3Y 10-Q true 2021-09-30 2021 false 000-13789 ADHERA THERAPEUTICS, INC. DE 11-2658569 8000 Innovation Parkway Baton Rouge LA 70820 (919) 518-3748 Yes Yes Non-accelerated Filer true false false 15575294 151000 1000 151000 1000 151000 1000 2287000 2257000 4000 4000 2874000 2112000 5211000 4083000 5677000 5677000 862000 641000 3475000 20390000 14774000 20390000 14774000 0.01 0.01 100000 100000 0.01 0.01 1200 1200 100 100 100 100 510000000 510000000 0.01 0.01 220 220 40 40 40 40 12000000 12000000 0.01 0.01 3500 3500 3400 3400 3458 3458 17000000000 17000000000 0.01 0.01 2200 2200 361 361 361 361 1805000000 1805000000 0.01 0.01 6000 6000 0 0 0.006 0.006 180000000 180000000 14485438 14485438 11112709 11112709 87000 67000 30647000 29772000 -50973000 -44612000 -20239000 -14773000 151000 1000 20000 17000 818000 232000 174000 454000 1055000 231000 194000 471000 1873000 -231000 -194000 -471000 -1873000 261000 255000 749000 1082000 5000 45000 177000 177000 2968000 3055000 101000 95000 230000 373000 -3507000 -345000 -4211000 -1410000 -3739000 -539000 -4682000 -3283000 406000 388000 1679000 1153000 -4145000 -927000 -6361000 -4436000 -0.32 -0.09 -0.54 -0.41 12986391 10869530 11742315 10869530 100 40 3478 361 10869530 65000 29375000 -39327000 -9887000 383000 383000 239000 239000 36000 36000 -1838000 -1838000 100 40 3478 361 10869530 65000 29650000 -41548000 -11833000 382000 382000 50000 50000 -26000 -26000 -906000 -906000 100 40 3478 361 10869530 65000 29674000 -42836000 -13097000 388000 388000 -2000 -2000 -539000 -539000 100 40 3478 361 10869530 65000 29672000 -43763000 -14026000 100 40 3458 361 11112709 67000 29772000 -44612000 -14773000 505000 -882000 -377000 518000 3000 23000 26000 28000 28000 -428000 -428000 100 40 3458 361 11630709 70000 30328000 -45922000 -15524000 11000 -392000 -381000 69000 69000 53571 -8 101010 1000 9000 10000 -514000 -514000 100 40 3450 361 11785290 71000 30417000 -46828000 -16340000 -25000 406000 381000 500148000 3 154000 157000 1700000 10000 75000 85000 -21000 -21000 -50 500000 3000 -3000 -3739000 -3739000 100 40 3400 361 14485438 87000 30647000 -50973000 -20239000 -4682000 -3283000 8000 177000 230000 765000 3055000 -316000 30000 850000 749000 689000 72000 157000 -369000 -498000 591000 553000 72000 105000 519000 448000 150000 -50000 1000 50000 151000 1679000 1153000 -4000 -50000 -4000 111000 -473000 -239000 <p id="xdx_802_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zPfXQQNpIHKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 1 – <span id="xdx_82A_zXKUEc1ACkw7">Nature of Operations, Basis of Presentation and Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Business Overview</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Previously, the Company was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. On January 4, 2021, the licensor terminated the licensing agreement for the product candidate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. In October 2021, the company commenced the manufacturing of drug product for use in the development of MLR-1019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 20, 2021 the Company as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Melior’s Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To the extent that resources have been available, the Company has continued to work with its advisors to restructure our company and to identify potential strategic transactions, including the Melior transactions described above. There can be no assurance that the Company will be successful in raising sufficient capital to meet its obligations under the Melior license agreements. If the Company does not raise substantial additional capital to develop and commercialize repay its indebtedness which is in default or restructure the indebtedness, it is likely that the Company will discontinue all operations and seek bankruptcy protection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Basis of Presentation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the Nine months ended September 30, 2021, are not necessarily indicative of the results for the year ending December 31, 2021 or for any future period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Principles of Consolidation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Going Concern and Management’s Liquidity Plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2021, the Company had cash and cash equivalents of approximately $<span id="xdx_90F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20210930_zrZNQmIkhdOj">151,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and has negative working capital of approximately $<span id="xdx_907_ecustom--WorkingCapital_iI_pn5n6_c20210930_zh1WFoToB1c5">20.2</span> </span><span style="font: 10pt Times New Roman, Times, Serif">million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $<span id="xdx_90A_eus-gaap--ProfitLoss_iN_pn5n6_di_c20210101__20210930_zSveRuVljojk" title="Net loss">4.7</span> million for the nine months ended September 30, 2021. The Company had an accumulated deficit of approximately $<span id="xdx_902_ecustom--RetainedEarningsAccumulatedDeficits_iI_pn5n6_c20210930_zhKkpyqEmGkk" title="Accumulated deficit">51.0 million as of September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to us or at all. General market conditions, as well as market conditions for companies in our financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Summary of Significant Accounting Policies</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z8pWFjfkf0lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zUPWNBR2k3Lf">Reclassification</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zicPKDfLtma4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zsDrtPspXJj8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zMBhLGV3GWj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_862_zlwAZo2IInd">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company measured conversion features on outstanding convertible notes as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $<span id="xdx_90A_eus-gaap--LongTermDebtFairValue_iI_pn5n6_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQpqQPlqQFkg">3.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. The value of the derivative liability as of September 30, 2021 was determined by using the binomial lattice model using the following inputs: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930_znGy82bVQGD3">0.09</span></span><span style="font: 10pt Times New Roman, Times, Serif">% risk free rate, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_uPure_c20210101__20210930_zOul8MPbIyt2">404</span></span><span style="font: 10pt Times New Roman, Times, Serif">% and time to maturity of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zwxTWZV2iSdk">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">- .<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_zCyvkhbBadv2">18 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span><span style="font: 10pt Times New Roman, Times, Serif"> There were <span id="xdx_900_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20210930_zFeLFmz8kTk1">no </span></span><span style="font: 10pt Times New Roman, Times, Serif">liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2021, and there were <span id="xdx_903_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20201231_ziPWkgzbmgo3">no </span></span><span style="font: 10pt Times New Roman, Times, Serif">liabilities or assets measured at fair value on a reoccurring or non-recurring basis as of December 31, 2020.</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zzkGdWxXbnQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zKIcqln7pr0i" style="display: none">Schedule of Fair Value Measurements</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHjYLLXwJHZ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQN80ABgbiZ" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpqXitMpWRMi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20210930_zcb6jCYPByqd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measurements at September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted Prices in Active Markets for Identical Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other Observable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant Unobservable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn3n3_zGyWhKvvmX6k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--FairValueOfDerivativeLiability_iI_pn3n3_z9ykQdGRJUU8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zCzfRlx4H0m6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_ecustom--ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock_z6OwirI5SnJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A roll forward of the level 3 valuation financial instruments is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zyYpdIBZNjEh" style="display: none">Schedule of Roll Forward of Level 3 Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--WarrantsMember_zcGPGryuLBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B6_us-gaap--DebtInstrumentAxis_custom--ConvertibleNotesMember_zEKP6iOas4F" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4BC_zKLgqiKRuydi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months Ended</b></span></p> <span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Notes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_43D_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_zIM4BwTnQYt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0964">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount_ztNzqwO8YW8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense_ztxlbNCFwdVa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0972">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment_z1JiGAu5anc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclassification of derivative liabilities to gain on debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_ecustom--ReclassificationOfAdditionalPaidInCapital_zAOWIdpn4e3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclass from Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">290</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td></tr> <tr id="xdx_40B_ecustom--ChangeInFairValueIncludedInDerivativeExpense_zKR1XuEwZJme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">361</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,074</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,435</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_436_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_zlOHOOK8uXt5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">407</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,068</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_8A7_ze4wLMhvG9R" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_849_eus-gaap--DebtPolicyTextBlock_z2qaTAJM2K42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_zCgBTYLpSQvf">Convertible Debt and Warrant Accounting</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Debt with warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible debt – derivative treatment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet that requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible debt – beneficial conversion feature</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior to the Company’s adoption of ASU No. 2020-06, <i>Debt—Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i> (Subtopic 815-40): <i>Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i> (“ASU 2020-06”) on January 1, 2021, if the conversion feature was not treated as a derivative, the Company assessed whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBWi1LW2Qv5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_860_z07B18PT7s46">Recently Issued Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Recently Adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zKRlgkXGYWX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zdBRIz2JrwZ4">Net Loss per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzJAukDcXtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table presents the computation of net loss per share (in thousands, except share and per share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zqtVFGKHj6Zg" style="display: none">Schedule of Earnings Per Share, Basic and Diluted</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210701__20210930_zeYOj9gvlxT7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20200701__20200930_zSkrmFp560Pe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210101__20210930_zXb62ctaBcWg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20200101__20200930_z4fNLLMiJT09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>September 30,</b></p> <span style="font-family: Times New Roman, Times, Serif"/></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zd62jkSu2G43" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,739</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(539</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,682</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,283</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--DividendsPreferredStock_iN_pn3n3_di_zK9ufa7i9gIa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dividends</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(406</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(388</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,679</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z2wZn1W5JYVi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss allocable to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,145</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(927</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(6,361</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,436</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zhTYA5JRb3Q5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,986,391</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,742,315</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per share of common stock, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDiluted_pid_z69HfQ99gVP2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.09</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.54</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.41</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8AE_zYCiCWfXArd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zizT2lvMo9Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zVbdwO1Jv53l" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20210101__20210930_zsXtEpUroAuh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20200101__20200930_zGXEcNbqvaf6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_ztq9DsXvwhl2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,332,784</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,690,018</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsOutstandingMember_z2OHdH1XNOf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,216,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zq2czuvuf0dg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,306,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,047,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zQYHzswDpzBg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_z9DG4L6UP6U4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zsqmQCk2HE5j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,514,922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,597,256</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_z5mCH04iOBfd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series F Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,519,872</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,230,973</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zV4SWOeg7pb3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">134,178,046</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,898,264</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_8AD_zvyu0SVxdpR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 151000 20200000 -4700000 51000000.0 <p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z8pWFjfkf0lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zUPWNBR2k3Lf">Reclassification</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84D_eus-gaap--UseOfEstimates_zicPKDfLtma4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zsDrtPspXJj8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_844_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zMBhLGV3GWj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_862_zlwAZo2IInd">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 1:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 2:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level 3:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company measured conversion features on outstanding convertible notes as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $<span id="xdx_90A_eus-gaap--LongTermDebtFairValue_iI_pn5n6_c20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQpqQPlqQFkg">3.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. The value of the derivative liability as of September 30, 2021 was determined by using the binomial lattice model using the following inputs: <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20210930_znGy82bVQGD3">0.09</span></span><span style="font: 10pt Times New Roman, Times, Serif">% risk free rate, volatility of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dp_uPure_c20210101__20210930_zOul8MPbIyt2">404</span></span><span style="font: 10pt Times New Roman, Times, Serif">% and time to maturity of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zwxTWZV2iSdk">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">- .<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_zCyvkhbBadv2">18 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span><span style="font: 10pt Times New Roman, Times, Serif"> There were <span id="xdx_900_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20210930_zFeLFmz8kTk1">no </span></span><span style="font: 10pt Times New Roman, Times, Serif">liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2021, and there were <span id="xdx_903_eus-gaap--FairValueNetAssetLiability_iI_pp0p0_do_c20201231_ziPWkgzbmgo3">no </span></span><span style="font: 10pt Times New Roman, Times, Serif">liabilities or assets measured at fair value on a reoccurring or non-recurring basis as of December 31, 2020.</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zzkGdWxXbnQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zKIcqln7pr0i" style="display: none">Schedule of Fair Value Measurements</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHjYLLXwJHZ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQN80ABgbiZ" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpqXitMpWRMi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20210930_zcb6jCYPByqd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measurements at September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted Prices in Active Markets for Identical Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other Observable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant Unobservable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn3n3_zGyWhKvvmX6k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--FairValueOfDerivativeLiability_iI_pn3n3_z9ykQdGRJUU8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zCzfRlx4H0m6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_897_ecustom--ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock_z6OwirI5SnJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A roll forward of the level 3 valuation financial instruments is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zyYpdIBZNjEh" style="display: none">Schedule of Roll Forward of Level 3 Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--WarrantsMember_zcGPGryuLBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B6_us-gaap--DebtInstrumentAxis_custom--ConvertibleNotesMember_zEKP6iOas4F" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4BC_zKLgqiKRuydi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months Ended</b></span></p> <span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Notes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_43D_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_zIM4BwTnQYt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0964">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount_ztNzqwO8YW8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense_ztxlbNCFwdVa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0972">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment_z1JiGAu5anc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclassification of derivative liabilities to gain on debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_ecustom--ReclassificationOfAdditionalPaidInCapital_zAOWIdpn4e3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclass from Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">290</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td></tr> <tr id="xdx_40B_ecustom--ChangeInFairValueIncludedInDerivativeExpense_zKR1XuEwZJme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">361</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,074</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,435</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_436_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_zlOHOOK8uXt5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">407</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,068</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p id="xdx_8A7_ze4wLMhvG9R" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 3500000 0.0009 4.04 P0Y P18Y 0 0 <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zzkGdWxXbnQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_8B8_zKIcqln7pr0i" style="display: none">Schedule of Fair Value Measurements</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zHjYLLXwJHZ7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQN80ABgbiZ" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zpqXitMpWRMi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20210930_zcb6jCYPByqd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measurements at September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Quoted Prices in Active Markets for Identical Assets</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Other Observable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Significant Unobservable Inputs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 1)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 2)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(Level 3)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DerivativeFairValueOfDerivativeLiability_iI_pn3n3_zGyWhKvvmX6k" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 40%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Derivative liability</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_ecustom--FairValueOfDerivativeLiability_iI_pn3n3_z9ykQdGRJUU8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,475</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 3475000 3475000 3475000 3475000 <p id="xdx_897_ecustom--ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock_z6OwirI5SnJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A roll forward of the level 3 valuation financial instruments is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zyYpdIBZNjEh" style="display: none">Schedule of Roll Forward of Level 3 Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B0_us-gaap--DebtInstrumentAxis_custom--WarrantsMember_zcGPGryuLBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4B6_us-gaap--DebtInstrumentAxis_custom--ConvertibleNotesMember_zEKP6iOas4F" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_4BC_zKLgqiKRuydi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nine months Ended</b></span></p> <span style="font: 10pt Times New Roman, Times, Serif"><b>September 30, 2021</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(In thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Warrants</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Notes</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_43D_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iS_zIM4BwTnQYt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0964">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount_ztNzqwO8YW8j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">223</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense_ztxlbNCFwdVa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Initial valuation of derivative liabilities included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0972">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">619</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment_z1JiGAu5anc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclassification of derivative liabilities to gain on debt extinguishment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(92</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_ecustom--ReclassificationOfAdditionalPaidInCapital_zAOWIdpn4e3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Reclass from Additional paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">290</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"/></td></tr> <tr id="xdx_40B_ecustom--ChangeInFairValueIncludedInDerivativeExpense_zKR1XuEwZJme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Change in fair value included in derivative expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">361</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,074</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,435</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_436_c20210101__20210930_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iE_zlOHOOK8uXt5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance at September 30, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">407</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,068</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,475</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> 223000 223000 619000 619000 -92000 -92000 46000 244000 290000 361000 2074000 2435000 407000 3068000 3475000 <p id="xdx_849_eus-gaap--DebtPolicyTextBlock_z2qaTAJM2K42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_86E_zCgBTYLpSQvf">Convertible Debt and Warrant Accounting</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Debt with warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible debt – derivative treatment</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet that requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Convertible debt – beneficial conversion feature</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior to the Company’s adoption of ASU No. 2020-06, <i>Debt—Debt with Conversion and Other Options</i> (Subtopic 470-20) and <i>Derivatives and Hedging—Contracts in Entity’s Own Equity</i> (Subtopic 815-40): <i>Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i> (“ASU 2020-06”) on January 1, 2021, if the conversion feature was not treated as a derivative, the Company assessed whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBWi1LW2Qv5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i><span id="xdx_860_z07B18PT7s46">Recently Issued Accounting Pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">Recently Adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Not Yet Adopted</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows:</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">a.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">b.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">c.</span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_zKRlgkXGYWX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_863_zdBRIz2JrwZ4">Net Loss per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzJAukDcXtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table presents the computation of net loss per share (in thousands, except share and per share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zqtVFGKHj6Zg" style="display: none">Schedule of Earnings Per Share, Basic and Diluted</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210701__20210930_zeYOj9gvlxT7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20200701__20200930_zSkrmFp560Pe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210101__20210930_zXb62ctaBcWg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20200101__20200930_z4fNLLMiJT09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>September 30,</b></p> <span style="font-family: Times New Roman, Times, Serif"/></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zd62jkSu2G43" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,739</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(539</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,682</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,283</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--DividendsPreferredStock_iN_pn3n3_di_zK9ufa7i9gIa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dividends</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(406</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(388</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,679</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z2wZn1W5JYVi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss allocable to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,145</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(927</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(6,361</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,436</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zhTYA5JRb3Q5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,986,391</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,742,315</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per share of common stock, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDiluted_pid_z69HfQ99gVP2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.09</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.54</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.41</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8AE_zYCiCWfXArd4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zizT2lvMo9Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zVbdwO1Jv53l" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20210101__20210930_zsXtEpUroAuh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20200101__20200930_zGXEcNbqvaf6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_ztq9DsXvwhl2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,332,784</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,690,018</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsOutstandingMember_z2OHdH1XNOf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,216,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zq2czuvuf0dg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,306,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,047,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zQYHzswDpzBg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_z9DG4L6UP6U4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zsqmQCk2HE5j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,514,922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,597,256</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_z5mCH04iOBfd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series F Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,519,872</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,230,973</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zV4SWOeg7pb3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">134,178,046</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,898,264</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_8AD_zvyu0SVxdpR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zzJAukDcXtY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table presents the computation of net loss per share (in thousands, except share and per share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zqtVFGKHj6Zg" style="display: none">Schedule of Earnings Per Share, Basic and Diluted</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20210701__20210930_zeYOj9gvlxT7" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20200701__20200930_zSkrmFp560Pe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210101__20210930_zXb62ctaBcWg" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20200101__20200930_z4fNLLMiJT09" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">September 30,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>September 30,</b></p> <span style="font-family: Times New Roman, Times, Serif"/></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Numerator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_pn3n3_zd62jkSu2G43" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,739</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(539</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,682</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,283</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--DividendsPreferredStock_iN_pn3n3_di_zK9ufa7i9gIa" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Dividends</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(406</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(388</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,679</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_z2wZn1W5JYVi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net Loss allocable to common stockholders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,145</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(927</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right">(6,361</td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,436</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Denominator</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_pid_zhTYA5JRb3Q5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted average common shares outstanding used to compute net loss per share, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,986,391</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,742,315</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,869,530</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per share of common stock, basic and diluted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--EarningsPerShareBasicAndDiluted_pid_z69HfQ99gVP2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Net loss per share</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.32</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.09</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.54</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.41</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> -3739000 -539000 -4682000 -3283000 406000 388000 1679000 1153000 -4145000 -927000 -6361000 -4436000 12986391 10869530 11742315 10869530 -0.32 -0.09 -0.54 -0.41 <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zizT2lvMo9Uj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zVbdwO1Jv53l" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20210101__20210930_zsXtEpUroAuh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20200101__20200930_zGXEcNbqvaf6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleNotesPayableMember_ztq9DsXvwhl2" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,332,784</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,690,018</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsOutstandingMember_z2OHdH1XNOf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options outstanding</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,216,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zq2czuvuf0dg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61,306,350</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69,047,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zQYHzswDpzBg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series C Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66,667</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesDPreferredStockMember_z9DG4L6UP6U4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series D Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesEPreferredStockMember_zsqmQCk2HE5j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,514,922</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">41,597,256</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesFPreferredStockMember_z5mCH04iOBfd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Series F Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,519,872</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,230,973</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zV4SWOeg7pb3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">134,178,046</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,898,264</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> 24332784 23690018 387550 1216350 61306350 69047000 66667 66667 50000 50000 43514922 41597256 4519872 4230973 134178046 139898264 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zVSxJmmi7leg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 2 – <span id="xdx_829_zm4QHgvr36Vc">Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>2019 Term Loan</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20191231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zD6KyoPNJFzd">5.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million. The Company paid $<span id="xdx_90A_eus-gaap--DeferredFinanceCostsNet_iI_c20191231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zv0e898EgT95" title="Debt issuance costs, net">707,000</span> in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Notes accrue interest at a rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20191231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zMh2MSIMRL5k" title="Debt instrument, interest rate">12%</span> per annum. Interest is payable quarterly with the first interest payment to be made on December 28, 2019, and each subsequent payment every three months thereafter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, matured on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_z623uvZINzzi">June 28, 2020</span>. The Notes are secured by a first lien and security interest on all the assets of the Company and certain of its wholly owned subsidiaries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On December 28, 2019, the Company defaulted on the initial interest payment on the loan and the interest rate per annum increased to the default rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20191228__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zKL8MArNHI8d" title="Debt instrument, effective percentage">15%</span>. On June 28, 2020, the Company defaulted on the maturity date principal payment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized approximately $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200701__20200930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zDHKq5mH9D33">215,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20200101__20200930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zJ5qoaTT2dZ7">986,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense related to Notes for the three and nine months ended September 30, 2020, including $<span id="xdx_90F_eus-gaap--AmortizationOfFinancingCosts_c20200701__20200930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zEwibQIhuHfk">0 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20200101__20200930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zXHFCG7LJddl">347,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to the amortization of debt issuance costs. The Company recognized approximately $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20210701__20210930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zjYdTbzxKZG6">215,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20210101__20210930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zJE5UskGtFkl">637,000</span> in interest expense related to the Notes for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discount and issuance costs for this term loan were fully amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had approximately $<span id="xdx_908_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20210930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zlQBuJ6SJX1b">1.8 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million of accrued interest on the Notes included in accrued expenses and remains in default on the repayment of approximately $<span id="xdx_901_eus-gaap--RepaymentsOfDebt_pn5n6_c20210101__20210930__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zxZinjeP8xTa">5.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in principal and interest on the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>CONVERTIBLE PROMISSORY NOTES</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_z4YixMBnJqBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the Company’s outstanding convertible notes as of September 30, 2021, and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2jbF7PxVXCd" style="display: none">Schedule of Convertible Promissory Notes</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210930_zxdgGNPYTIra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zBFPWBZR41L6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,296</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">720</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zz0Mxqy8zUok" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Unamortized discounts</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(434</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(79</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Convertible Notes Payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">862</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">641</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zQ4NBZIcd2O2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Five convertible notes with outstanding principal of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--FourConvertibleNotesMember_zgeRm0Fwtdvl" title="Principal amount">788,000</span> were in default as of the issuance date of this report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – February 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes (the “Convertible Notes”), with a principal of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zkHg6V8q3MSe">550,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">issued at a <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zj4raM1iLpFj">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discount, for a total purchase price of $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zoOmAmpIuci8">499,950</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and (ii) warrants to purchase up to such number of shares of the common stock of the Company as is equal to the product obtained by multiplying 1.75 by the quotient obtained by dividing (A) the principal amount of the Notes by (B) the then applicable conversion price of the Notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The maturity date was August 5, 2020. Interest shall accrue to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zj7lHgJKILv">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">per annum, calculated on the basis of a 360-day year and accrues daily. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On or after May 5, 2020, until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zL85mbfi01D3">0.50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share of Common Stock and (ii) <span id="xdx_906_ecustom--WeightedAveragePriceOfCommonStock_dp_uPure_c20200504__20200505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zLVWxMbi5Sy">70% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the volume weighted average price of the Common Stock on the trading market on which the Common Stock is then listed or quoted for trading for the prior ten (10) trading days (as adjusted for stock splits, stock combinations and similar events); provided, that if the Notes are not prepaid on or before May 5, 2020, then the conversion price shall be the lower of (x) <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_dp_uPure_c20200504__20200505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zD4MTlqYV9P3">60% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the conversion price as calculated above or (y) $<span id="xdx_908_ecustom--ConversionPriceAdjustedForStockSplitsStockCombinationsAndSimilarEventsPricePerShare_iI_pid_c20200505__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zLMKp38IUuPf">0.05 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(as adjusted for stock splits, stock combinations and similar events). The conversion price of the Convertible Notes shall also be adjusted as a result of subsequent equity sales by the Company, with customary exceptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGy4wYHGdJG6">5</span></span><span style="font: 10pt Times New Roman, Times, Serif">-year term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded a discount related to the Warrants of approximately $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4FaoGqOj431">322,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, which includes an allocation of OID and issue costs of $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_c20200204__20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfJNmOgpQail">30,000</span> and $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7wxcTYdFjnf">53,000</span> based on the relative fair value of the instruments as determined by using the Monte-Carlo simulation model. The Company also recorded the remaining debt discount related to the convertible debt OID of approximately $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20200204__20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zMv0GC12RWwd">21,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and debt issuance costs of $<span id="xdx_90E_eus-gaap--AmortizationOfFinancingCosts_c20200204__20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxr8Xk4UbFPl">38,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. Total discounts recorded were $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20200205__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zBivP9HFArl3">380,593</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of <span id="xdx_901_ecustom--DebtDefaultInterestRate_dp_uPure_c20200614__20200615__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zja77oxGcTR8" title="Debt default interest rate">18%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZmVhgq2ugpg">31,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYGui2kbhyTl">86,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense related to the notes for the three and nine months ended September 30, 2020, respectively including $<span id="xdx_901_eus-gaap--AmortizationOfFinancingCosts_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zsWCgmLMunyf">7,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxrgnvJqDCP3">38,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to the amortization of debt issuance costs. The Company amortized $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zV5mv8DRBAUb">67,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_908_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyes0vs5EJR">343,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of debt discount for the three and nine months ended September 30, 2020, respectively. The Company recognized approximately $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zf3v3nXquWk1">25,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z7rodmbZY1H2">75,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense related to the notes for the three and Nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discounts for this Convertible Note were fully amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 19, 2021, the holder of the Convertible Note converted $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210318__20210319__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zKT1sci3UEW9">25,900 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of interest into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210318__20210319__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_z5seV0mWmzDl">518,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 29, 2021, the holder of the Convertible Note converted $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210727__20210729__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zr4932FH1Ya8">27,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of interest into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210727__20210729__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zKKsN3GbBGb5">550,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 16, 2021, the holder of the Convertible Note converted $<span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210815__20210816__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_z0pF51grMGid">25,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of principal and interest into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210815__20210816__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zgVHWFBg6ls4">500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On September 13, 2021, the holder of the Convertible Note converted $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210912__20210913__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zQOPONOBf9U8">32,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of principal and interest into <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210912__20210913__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zXczayYfwnq7">650,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The total note principal and interest converted during the nine months ended September 30, 2021 was $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbIUB8UnAuvj" title="Debt principal and interest">110,900</span> and <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zJBj1yZofGjk">2,218,000</span> common shares issued were valued at fair value based on the quoted trading prices on the conversion dates aggregating $<span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zOf6zu1Bth7e" title="Debt conversion amount">379,422</span> resulting on a loss on debt extinguishment of $<span id="xdx_908_ecustom--LossOnExtinguishmentOfDebt_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zAyxVefgOCmg" title="Loss on extinguishment of debt">268,522</span>. In addition, derivative fair value of $<span id="xdx_902_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zETB7I4jK9Fa" title="Derivative fair value">91,890</span> relating to the portion of the Note converted was settled resulting in gain on extinguishment of $<span id="xdx_907_ecustom--GainOnExtinguishmentOfDebt_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z58Mi18eYqWi" title="Gain on extinguishment of debt">91,890</span>. The net loss on extinguishment was $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeWlgSYJnVDl" title="Net loss on extinguishment">176,632</span>. The total shares issued upon conversion during the nine months ended September 30, 2021, was $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zSDIWCKl7krb" title="Conversion of convertible debt">2,218,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_pn5n6_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zACbjDqrgWpl" title="Conversion feature">2.0</span> million as a derivative liability on the accompanying balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had accrued interest on the Convertible Note of approximately $<span id="xdx_905_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zODMj1Itpt39">90,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company remains in default on the repayment of remaining principal of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zMGuif1xX7q4">499,615 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and accrued interest on the Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--HoldersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zubX6sJxq4Je">140% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. <span id="xdx_900_ecustom--ConvertibleNotePremimumDescription_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zHYki7Qk1ks4" title="Convertible note, premimum description">The 40% premium will be recorded once a demand occurs</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – June 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 26, 2020, the Company issued to an existing investor in the Company a <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zHEqDqngulBg">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discount Senior Secured Convertible Promissory Note with a principal of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zMUz2yNz4YXk">58,055</span></span><span style="font: 10pt Times New Roman, Times, Serif">, for a purchase price of $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_z69fXK33lA94" title="Original issue discount"><span style="-sec-ix-hidden: xdx2ixbrl1139">52,500, net of the original issue discount of $5,555</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">. The Convertible Note matured on December 26, 2020. Interest accrues</span><span style="font: 10pt Times New Roman, Times, Serif"> on the aggregate unconverted and then outstanding principal amount of the Note at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zNWv0ACRZyOe">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">per annum, calculated on the basis of a 360-day year. The Company incurred approximately $<span id="xdx_901_eus-gaap--DeferredFinanceCostsNet_iI_c20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNoteMember_zgTDc9QF9vk9">14,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in debt issuance costs. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20200924__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zILn050xkCle">0.02 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20200923__20200924__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0dW28pbs4k3">65% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered. The conversion price shall also be adjusted for subsequent equity sales by the Company. Because the share price on the commitment date was in excess of the conversion price, the Company recorded a beneficial conversion feature of $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20200625__20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zOz2Xo4QUzK5">50,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to this note that was credited to additional paid in capital and reduced the carrying amount. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $<span id="xdx_90E_ecustom--DebtInstrumentConvertibleIntrinsicValueOfBeneficialConversionFeature_c20200625__20200626__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8vOuSpyqlqa">203,000</span>. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20200626__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--TermLoanSubscriptionAgreementsMember_zdWaDBdD9Reh" title="Principal amount">5.7</span> million agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019 that such holders entered into with the Company and its subsidiaries to the security interest granted to the holder of the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2020, the Company recognized approximately $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zJL2QJCaRjJ1">9,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--InterestExpenseDebt_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z9Nd79NxVKe5">10,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense including $<span id="xdx_909_eus-gaap--AmortizationOfFinancingCosts_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeSFfYgCRGO">7,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--AmortizationOfFinancingCosts_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z4iqRbfy6V6d">8,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">related to the amortization of debt issuance costs, respectively. For the three and nine months ended September 30, 2020, the Company recognized $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20200701__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zspvPJKo9fql">28,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zomiwVXVkYzd">30,000</span> related to the amortization of debt discount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of <span id="xdx_907_ecustom--DebtDefaultInterestRate_pid_dp_uPure_c20200804__20200805__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqlA4jOiiUeb" title="Debt default interest rate">18%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2021, the Company recognized approximately $<span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlQNSR9kJUkb" title="Interest expense">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zki8DdtHZle" title="Interest expense">8,000</span> in interest expense related to the note, respectively. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company remains in default on the repayment of principal of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z9DPJX5wH7D6">58,055 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and approximately $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20200930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zQVFP8RMVOU3">13,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zPd0DDC6HOkl">140% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. <span id="xdx_902_ecustom--ConvertibleNotePremimumDescription_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxWcXBiyeLrl">The 40% premium will be recorded once a demand occurs.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – October 2020</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 30, 2020, the Company issued to an existing investor in and lender to the Company a <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zVsAdByVyy5f">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discount senior secured convertible promissory note with a principal of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zpQZ1Q6O5K7f">111,111</span></span><span style="font: 10pt Times New Roman, Times, Serif">, for a purchase price of $<span id="xdx_909_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zi0ZdqMD2XV7" title="Convertible notes payable, current">100,000</span>. The note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_z9EsrvzlZMad">0.07 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_pid_dp_uPure_c20201029__20201030_ztKIbJ7f5BJf">70% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of then conversion price. The conversion price of the notes is subject to anti-dilution price protection and on March 19, 2021, the conversion price of the notes was adjusted to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zYgvWJRgaMbg">0.05</span> per share. as a result of subsequent equity sales by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded approximately $<span id="xdx_903_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zHlvkuFVNoKe" title="Unamortized debt issuance expense">9,000</span> in debt issuance cost to be amortized over the life of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The interest rate on the note was <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zEleUF1zB9Ia" title="Debt instrument, interest rate">10%</span> per annum, calculated on the basis of a 360-day year. On April 30, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210430__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zK1tdyf9Ikk8" title="Debt instrument, effective percentage">18%</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally, the Company issued the noteholder <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zZwzMLORMDF">1,587,301 </span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants to purchase the Company’s common stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zGFx9I1VmpX4">0.08 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zSx2e0Tc8qZf">0.05 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and the Company issued an additional <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_z7i0Eax0Hne2">634,919 </span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants to the note holder. The Company recorded approximately $<span id="xdx_904_ecustom--DeemedDividend_iI_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zy0cVbmu9Sb6">57,000</span> as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uInteger_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z6hNCu2VMWr3">0.16%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, volatility of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uInteger_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zs52Ppi5v8Hl">262.27%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and expected term of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_z5RLNOstVFjg">0.92 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded a discount related to the warrants of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHD24o8UMeR8" title="Debt discount to be amortized">66,000</span>, including a discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_za9z2PpKBVqg" title="Debt discount to be amortized">6,000</span> and issuance costs of $<span id="xdx_90B_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--ValuationTechniqueAxis__us-gaap--ValuationTechniqueOptionPricingModelMember_zbgju7cnXgE6" title="Unamortized debt issuance expense">5,000</span> based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The Company recorded a beneficial conversion feature of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20201029__20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zMWLpZPB3Ln3" title="Debt instrument, convertible, beneficial conversion feature">45,000</span> related to the note that was credited to additional paid in capital and reduced the carrying amount. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $<span id="xdx_905_ecustom--DebtInstrumentConvertibleIntrinsicValueOfBeneficialConversionFeature_c20201029__20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_ztEEQaCJxGdi" title="Intrinsic value of the beneficial conversion feature">69,000</span>. The Company also recorded a debt discount related to the convertible debt of approximately $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20201029__20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyapvyOxKijh" title="Amortization of debt discount">5,000</span> and debt issuance cost of $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsNet_iI_c20201030__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z0jEOGrHYUU3" title="Debt issuance costs, net">4,000</span> using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine months ended September 30, 2021, the Company recognized approximately $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zBB1lmaHOKk9" title="Interest expense">5,000</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zUux3PtAw9x4" title="Interest expense">15,600</span> in interest expense including $<span id="xdx_90D_eus-gaap--AmortizationOfFinancingCosts_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_pp0p0" title="Amortization of debt issuance costs">0</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfFinancingCosts_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_pp0p0" title="Amortization of debt issuance costs">2,600</span> related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $<span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zQw9m20BgNGb" title="Amortization of debt discount">0</span> and $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zCADbTQRCuze" title="Amortization of debt discount">79,000</span> and related to the amortization of debt discount. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized. No interest expense or debt discount was recognized for the same period of 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $<span id="xdx_909_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--ConversionFeatureMember_zTIOMj0i39Vj" title="Derivative liability">76,000</span> as a derivative liability on the accompanying balance sheet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company has outstanding principal of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zHipvTW77zC8" title="Principal amount">111,111</span> and accrued interest on the note of approximately $<span id="xdx_900_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zsbVp11mhm1b" title="Accured interest">13,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zxUgqNa8lue6">125%</span> of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. <span id="xdx_90D_ecustom--ConvertibleNotePremimumDescription_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteOneMember_zEPZRCLEAQSg">The 25% premium will be recorded once a demand occurs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – January 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On January 31, 2021, the Company issued to an existing investor in and lender to the Company a <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zPnD7XQvuOv1">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discounted Senior Secured Convertible Promissory Note with a principal of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zLe8CVUnBDR3">52,778</span></span><span style="font: 10pt Times New Roman, Times, Serif">, for a purchase price of $<span id="xdx_904_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_z4RpY4N23QS6">47,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">, net of original issue discount of $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InvestorAndLenderMember_zdvrXT9Rg0Bf">5,278</span>.</span><span style="font: 10pt Times New Roman, Times, Serif"> The Note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zrLXR6Sgt8F7">0.07 </span></span><span style="font: 10pt Times New Roman, Times, Serif">(as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be <span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20210130__20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zTjhnpCVAK55">70% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the then conversion price. The conversion price of the notes is subject to anti-dilution price protection and will be adjusted upon subsequent equity sales by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally, the Company issued to the investor <span id="xdx_900_ecustom--ClassOfWarrantOrRightIssued_c20210130__20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zLCiarXdSXCe">753,968 </span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants to purchase the Company’s common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zarFcvZ8Xmg2">0.08 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_z4Zzrlb55yj4">0.05 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and the Company issued an additional <span id="xdx_900_ecustom--ClassOfWarrantOrRightIssued_c20210318__20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zk9pYDLq3epc">301,592 </span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants to the note holder. The Company recorded approximately $<span id="xdx_906_ecustom--DeemedDividend_iI_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zRWHjgzo7Ut8">27,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zB9hFCH534hf">0.16</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, volatility of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z0Yw5SD18XZh">262.27</span></span><span style="font: 10pt Times New Roman, Times, Serif">%, and expected term of <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zBEBsKh0DHLl">0.97 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded approximately $<span id="xdx_909_eus-gaap--DeferredFinanceCostsNet_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zAp7SIWJ2Ne" title="Debt issuance costs, net">2,000</span> in debt issuance cost to be amortized over the life of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The interest rate on the note was <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zQI4HcTTW9X5" title="Debt instrument, effective percentage">10%</span> per annum, calculated on the basis of a 360-day year. On July 31, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to the default rate of <span id="xdx_90D_ecustom--DebtDefaultInterestRate_pid_dp_uPure_c20210727__20210731__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zCNDySkCSOV6" title="Debt default interest rate">18%</span> per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded a discount related to the warrants of approximately $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJUuxkxLEVPa">32,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, which includes an allocated original issue discount, of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20210130__20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP2vAgkdkOj">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and allocated issuance costs of $<span id="xdx_908_eus-gaap--DeferredFinanceCostsNet_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVAeSFfgmWMf">1,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjhK138U2Xfd">0.45%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, volatility of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOvwe69xygG8">240.83%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and an expected term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsKBTJka0JNb">one year</span></span> <span style="font: 10pt Times New Roman, Times, Serif">in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company also recorded a debt discount related to the convertible debt of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zskBgJo6Q1Tf">2,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">remaining original issue discount</span><span style="font: 10pt Times New Roman, Times, Serif"> and remaining debt issuance cost of $<span id="xdx_907_ecustom--AmortizedInterestExpenseRelatedToFairValueMethod_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zEBdTOqmnFU1">1,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Total discounts recorded including the original issue discount wer approximately $<span><span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210131__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_ztuJxobjX9Pc">35,000</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zgmla2pavYN1" title="Interest expense">2,900</span> and $<span id="xdx_907_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zvzwOQkmlQy8" title="Interest expense">5,700</span> in interest expense including approximately $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zxAGbP8qqlk4" title="Amortization of debt issuance costs">100</span> and $<span id="xdx_904_eus-gaap--AmortizationOfFinancingCosts_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zua4UYBJoET3" title="Amortization of debt issuance costs">700</span> related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_z9EjCByImddb" title="Amortization of debt discount">5,600</span> and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zW6wkhTnIoG4" title="Amortization of debt discount">34,000</span> related to the amortization of debt discount. No interest expense or debt discount was recognized for the same period of 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company has outstanding principal of $<span id="xdx_900_eus-gaap--NotesPayable_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zWmTJxWTCvX7" title="Notes payable">52,778</span> on the note, has recorded approximately $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zmWTimlDXM32" title="Accured interest">5,000</span> of accrued interest. As of September 30, 2021, the debt discount and issuance costs on the note were fully amortized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zPRnmMjJZ3ff">125% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. <span id="xdx_909_ecustom--ConvertibleNotePremimumDescription_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteTwoMember_zSyUqq1RuKC3">The 25% premium will be recorded once a demand occurs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – April 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zcWDSkSoYty4">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zIGQFTa1v6Fi">66,667</span></span><span style="font: 10pt Times New Roman, Times, Serif">, for a purchase price of $<span id="xdx_902_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zFexv8mShZZg">60,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">net of an original discount of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zORZa31b4xP7">6,667</span></span><span style="font: 10pt Times New Roman, Times, Serif">. Additionally, the Company issued to the investor <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zQxhdXoiDwDl">800,000 </span></span><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zgeVWiWYGIV9" style="font: 10pt Times New Roman, Times, Serif">five</span><span style="font: 10pt Times New Roman, Times, Serif">-year warrants to purchase the Company’s common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_pdd">0.095 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. The warrants have full ratchet protection.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The note matured on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zo5n6m5oAGZ2">October 12, 2021</span></span><span style="font: 10pt Times New Roman, Times, Serif">,</span><span style="font: 10pt Times New Roman, Times, Serif"> Interest accrues on the aggregate unconverted and then outstanding principal amount of the note at the rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zRJ1uVo7lD93">10% </span></span><span style="font: 10pt Times New Roman, Times, Serif">per annum, calculated on-the-basis of a 360-day year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_pdd" title="Debt instrument, convertible, conversion price">0.075</span> (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zGHlDgZdGgqb" title="Debt conversion rate">70%</span> of the then conversion price. The conversion price shall also be adjusted upon subsequent equity sales by the Company. The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded a discount related to the warrants of approximately $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDiUfOngxFE3"><span style="-sec-ix-hidden: xdx2ixbrl1279">34,000, </span></span></span><span style="font: 10pt Times New Roman, Times, Serif">which includes approximately $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3rSlh2numpb">3,700 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of OID discount allocated under the relative fair value method,</span><span style="font: 10pt Times New Roman, Times, Serif"> and a remaining discount related to the OID of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zTuACKiKRw57">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">based on the relative fair value of the instruments. The fair value of the warrants on which the relative fair value is based was determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhr2GT8Xy5a2">0.89%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, volatility of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0w2wPhRIJc2">240.64%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and an expected term of <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_c20210410__20210412__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEgkFCfVNh68">one year</span></span> <span style="font: 10pt Times New Roman, Times, Serif">in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 25, 2021, the exercise price of the warrants was adjusted to $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfCybbspjjt5" title="Debt instrument, convertible, conversion price">0.075</span> and the Company issued an additional <span id="xdx_90C_ecustom--ClassOfWarrantOrRightIssued_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zftd77MSADld">88,893</span> warrants to the note holder. The Company recorded approximately $<span id="xdx_907_ecustom--DeemedDividend_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbW2wluFrdZ4" title="Deemed dividend">11,000</span> as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3Dn3EcEfSL6">0.92%</span>, volatility of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTKPhjlg2boj">247.52%</span>, and expected term of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z93LxMM2RTMi" title="Warrant term">0.96</span> years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine-month period ended September 30, 2021, the Company recognized approximately $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zVNIMKmMGlg3" title="Amortization of debt discount">19,000</span> and $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zQv8Agtdqti9" title="Amortization of debt discount">35,000</span>, respectively related to the amortization of debt discount. For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_z6B6KZ2X7c4" title="Interest expense">1,700</span> and $<span id="xdx_901_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zM9GyV9VSAGe" title="Interest expense">3,200</span> in interest expense, respectively. No interest expense or debt discount was recognized for the same period of 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company has recorded $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zVucaisR0mjc">66,667 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of principal and approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zRHouHVqaTY3">2,400 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of unamortized debt discount and $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_z822GzLcHR0f">3,200 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of accrued interest for the note on the accompanying balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 12, 2021, the Company defaulted on the note and the interest rate on the note reset to <span id="xdx_90C_ecustom--DebtDefaultInterestRate_pid_dp_uPure_c20211011__20211012__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zQCR6wgvJKbe">18% </span></span><span style="font: 10pt Times New Roman, Times, Serif">per annum. Upon default, and upon demand for repayment at the election of the holder, the holder of the note is due <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211012__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zfJBMaBzWEwh">125% </span></span><span style="font: 10pt Times New Roman, Times, Serif">of the aggregate of outstanding principal, interest, and other expenses due in respect of this note. <span id="xdx_909_ecustom--ConvertibleNotePremimumDescription_c20211011__20211012__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteThreeMember_zeXvWUW33XJ5">The 25% premium will be recorded once a demand occurs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Convertible Promissory Note – June 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z5o1B5iMc1vi">5% </span></span><span style="font: 10pt Times New Roman, Times, Serif">original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zJShFZndw7ba">66,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">, for a purchase price of $<span id="xdx_901_eus-gaap--SecuredDebt_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zOjqQ0kO8fkk">63,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">, net of an original issue discount of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zEChJQ8UYBD4">3,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">. Additionally, the Company issued to the investor <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_pdd">800,000 </span></span><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExpenseOrRevenueRecognized_dtYxL_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zR4bGvBnVubh" style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1313">three</span></span><span style="font: 10pt Times New Roman, Times, Serif">-year warrants to purchase the Company’s common stock at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_pdd">0.095 </span></span><span style="font: 10pt Times New Roman, Times, Serif">per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain $<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zJDlJOFyyTib">76,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">which is a full ratchet price protection provision</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The note matures on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z5QpV2p2pJ8" title="Debt maturity date">June 25, 2022</span>, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zYIE6pLpK4Pg" title="Debt instrument, interest rate">10%</span> per annum, calculated on the basis of a 365-day year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_pdd" title="Debt instrument, convertible, conversion price">0.075</span> (as adjusted for stock splits, stock combinations and similar events); provided, however that in the event, the Company’s Common Stock trades below $0.08 per share for more than three (3) consecutive trading days, the Holder of this Note is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_ziujvo8AXrrj" title="Debt conversion rate">65%</span> of the lowest trading price of the Common Stock for the twenty prior trading days including the day upon which a Notice of Conversion is received. The conversion discount, look back period and other terms of the Note will be adjusted on a ratchet basis if the Company offers a more favorable conversion discount, prepayment rate, interest rate, (whether through a straight discount or in combination with an original issue discount), look back period or other more favorable term to another party for any financings while this Note is in effect</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company incurred approximately $<span id="xdx_909_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zwbXCQmGYB03">9,300 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in debt issuance costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The company also issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_pdd">47,547 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock as a commission fee to the investment banker. The fair value of the common stock which was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zO3w0LnxsLrc">5,040 </span></span><span style="font: 10pt Times New Roman, Times, Serif">was recorded as debt issuance expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $<span id="xdx_90B_eus-gaap--DerivativeLiabilities_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zbICVtclNhSf">102,823</span> with $<span id="xdx_905_ecustom--DerivativeExpense_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z9TxFJ1vxamg">87,039</span> charged to derivative expense and $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zQPDowULgsHl">15,784</span> recorded as a debt discount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Total discounts recorded were $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z9MJB3t7fNc2" title="Debt discount">66,500</span>.</span><span style="font: 10pt Times New Roman, Times, Serif"> The Company recorded an original issue discount of $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zBScIqTqVxK9">3,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">, a discount of $<span id="xdx_909_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z8rPNd2YNVF9">9,300 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for issuance costs, a discount</span><span style="font: 10pt Times New Roman, Times, Serif"> related to the warrants of approximately $<span id="xdx_907_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfOghi3EauXi">37,916 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and a discount related to the derivative of $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210623__20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdGWtF6A20Ck">15,784 </span></span><span style="font: 10pt Times New Roman, Times, Serif">based on the relative fair value of the instruments. The warrant fair value on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4ZixgLKGLo4">0.48%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, volatility of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zemp7IZx3jei">302.11%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and an expected term of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210625__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDtc3EYlDXXe">0.60 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years in calculating the fair value of the warrants. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 11, 2021, the exercise price of the warrants was adjusted to $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqwKTjC57Njg" title="Class of warrant or right, exercise price of warrants or rights">0.075</span> and the Company issued an additional <span id="xdx_902_ecustom--ClassOfWarrantOrRightIssued_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKU9yio2Sb27" title="Warrants issued">213,333</span> warrants to the note holder. The Company recorded approximately $<span id="xdx_90C_ecustom--DeemedDividend_iI_pp0p0_c20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS6s0MqbEKW1" title="Deemed dividend">25,000</span> as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znnBpRUjtEz2" title="Fair value of warrants measurement inputs">0.81</span>, volatility of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDpeeEJQ8dde" title="Fair value of warrants measurement inputs"><span style="-sec-ix-hidden: xdx2ixbrl1348">209%</span></span>, and expected term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210811__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zebONwRl6E11" title="Warrant term">0.57</span> years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine-month period ended September 30, 2021, the Company recognized approximately $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zLJdegwl4082" title="Amortization of debt discount">13,000</span> and $<span id="xdx_906_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z3hqFZ1j1V3a" title="Amortization of debt discount">18,000</span> to the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_z1IKCR2r21Qh" title="Interest expense"><span id="xdx_905_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zEuZCphD5JF9" title="Interest expense">4,000</span></span> in interest expense. No interest expense or debt discount was recognized for the same period of 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021, the Company has recorded $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zjj9iotAVHWj" title="Principal amount">66,500</span> of outstanding principal and approximately $<span id="xdx_901_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zLJ41NovNC7" title="Accured interest">4,000</span> of accrued interest and $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SeniorSecuredConvertiblePromissoryNoteFourMember_zCMNMCUplKuk" title="Debt discount to be amortized">49,000</span> of unamortized discount and issuance expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Convertible Promissory Note – August 11, 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_z9TL7z6WOpHb">220,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zCZ2WOzVsyPg">800,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the common stock of the Company for which the Company received consideration of $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstanding_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zmdYEtefYcxg">210,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">net of</span><span style="font: 10pt Times New Roman, Times, Serif"> an original issued discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_z7cvvzRBLIJ4">10,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">. In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_z705kDPnJ5M7">100,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares as a commitment fee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The note matures <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dc_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_z8cD06MKnn0i" title="Debt term">one year</span> from issuance and provides for an interest rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_z1ZwpwZFM581" title="Debt instrument, interest rate">10%</span> per annum, payable at maturity, and is convertible into common stock of the Company at a price of $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_pdd" title="Debt instrument, convertible, conversion price">0.075</span> per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_ztITv4UYknJl" title="Debt conversion rate">65%</span> of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Warrants are initially exercisable for a period of three years at a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, exercise price of warrants or rights">0.095</span> per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company incurred approximately $<span id="xdx_904_eus-gaap--DeferredFinanceCostsNet_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_z9huE8sb4kB2">30,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in debt issuance costs. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company also issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zdR6HTZc82V4">140,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock to the investment banker as a commission on the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $<span id="xdx_907_eus-gaap--DerivativeLiabilities_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zUqMxjRSHzIa" title="Derivative liabilities">340,893</span> with $<span id="xdx_901_ecustom--DerivativeExpense_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zpoYoNa27hng" title="Derivative expense">234,388</span> charged to derivative expense and $<span id="xdx_900_eus-gaap--AmortizationOfDebtDiscountPremium_c20210810__20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zY2d2t05c2ee">106,505</span> recorded as a debt discount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recorded a total debt discount of $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zYPZqtCFOL2b">220,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">including an original issue discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zzKwAnRVTXUa">10,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">, a</span><span style="font: 10pt Times New Roman, Times, Serif"> discount related to the warrants of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmbFYx48Lol1">56,454 </span></span><span style="font: 10pt Times New Roman, Times, Serif">a discount related to issuance costs of $<span id="xdx_900_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCJxMkvIEKvk">30,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and</span><span style="font: 10pt Times New Roman, Times, Serif"> a discount related to the issuance of common stock of approximately $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYtmPUOI3LUf">17,041</span></span><span style="font: 10pt Times New Roman, Times, Serif">, and a $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zzeVMSCuv5yj">106,505 </span></span><span style="font: 10pt Times New Roman, Times, Serif">discount related to the initial derivative value of the embedded conversion feature on the note all</span><span style="font: 10pt Times New Roman, Times, Serif"> based on the relative fair value of the instruments,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of the warrants on which the relative fair value was based was <span style="font: 10pt Times New Roman, Times, Serif">determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z88p6BZs7GYe">0.81%</span></span><span style="font: 10pt Times New Roman, Times, Serif">, volatility of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7yNB1gJhJN8"><span style="-sec-ix-hidden: xdx2ixbrl1394">253%</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">, and an expected term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210811__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsqcwAi826Fl">one year</span></span> <span style="font: 10pt Times New Roman, Times, Serif">in calculating the fair value of the warrants. The discounts are being amortized over the term of the convertible note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine-month period ended September 30, 2021, the Company recognized approximately $<span id="xdx_903_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zAVPDt57Mo3a">30,810 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for the amortization of the debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zdRJGlIHe3kh">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021, the Company has remaining $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zqQQMx499m4j">220,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of outstanding principal and approximately $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zMTvi2qDvtIe">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of accrued interest and $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteOneMember_zqV8dhHAlrtc">190,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of unamortized discount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Convertible Promissory Note – August 17, 2021</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_z7Yt8cYJICC2">220,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_pdd">800,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the common stock of the Company for which the Company received consideration of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zQTCiXMY8WVj">210,000 net of original discount of $10,500</span></span><span style="font: 10pt Times New Roman, Times, Serif">. </span><span style="font: 10pt Times New Roman, Times, Serif">In addition, the Company entered into a Registration Rights Agreement with the Buyer and issued the Buyer <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--TypeOfArrangementAxis__custom--RegistrationRightsAgreementMember_zswEoWgKcjc1">100,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">common shares as a commitment fee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The note matures <span id="xdx_903_eus-gaap--DebtInstrumentTerm_dc_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zVHafT9LgS89" title="Debt term">one year</span> from issuance and provides for an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zsEHx6SN7tY1" title="Debt instrument, interest rate">10%</span> per annum, payable at maturity, and is convertible into common stock of the Company at a price of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zZtf9dGYYfNb" title="Debt instrument, convertible, conversion price">0.075</span> per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zXjN9D3Z0N3d" title="Debt conversion rate">65%</span> of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. The embedded conversion option will be treated as a bifurcated derivative liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Warrants are initially exercisable for a period of three years at a price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Class of warrant or right, exercise price of warrants or rights">0.095</span> per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company incurred approximately $<span id="xdx_90D_eus-gaap--DeferredFinanceCostsNet_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_z87DSvrJpBxi">30,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in debt issuance costs. The Company also issued <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_znqC3Rs4kbo4">112,601 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock to the investment banker as a commission on the note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $<span id="xdx_90E_eus-gaap--DerivativeLiabilities_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zLyhcW3hv8fi">398,404</span> with $<span id="xdx_90C_ecustom--DerivativeExpense_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zOJmZyWDt4I6">297,833</span> charged to derivative expense and $<span id="xdx_90E_eus-gaap--AmortizationOfDebtDiscountPremium_c20210815__20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zBAfavAx4Yj6">100,571</span> recorded as a debt discount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company recorded a total debt discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_z98yV2gf86P7">220,500</span> including an original issue discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zhwaVvoDLrh9">10,500</span>, a discount related to the warrants of approximately $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCMnxYXSOpBk">62,220</span> a discount related to issuance costs of $<span id="xdx_909_eus-gaap--UnamortizedDebtIssuanceExpense_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbq2fCBPpeq3">30,000</span> a discount related to the issuance of common stock of approximately $<span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z28v4jhaxE43">17,209</span>, and a $<span id="xdx_904_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zdOBYyYrikhd">100,571</span> discount related to the initial derivative value of the embedded conversion feature on the Note all based on the relative fair value of the instruments. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVIUofWeEud8">0.77</span>%, volatility of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXygEGix9rqi">254</span>%, and an expected term of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210817__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdXwKjrlxuPh">one year</span> in calculating the fair value of the warrants. The discounts are being amortized over the life of the convertible note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">At September 30, 2021, the Company has recorded $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zQV7P15Om2p1" title="Principal amount">220,500</span> of outstanding principal and approximately $<span id="xdx_902_eus-gaap--InterestPayableCurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zytSDhQev2X8" title="Accured interest">3,000</span> of accrued interest and $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_z3kyGaykfMs4" title="Debt discount to be amortized">193,000</span> of unamortized discount and issuance expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Derivative Liabilities Pursuant to Convertible Notes and Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion option to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. In accordance with ASC 815-40 –<i>Derivatives and Hedging – Contracts in an Entity’s Own Stock</i>, the embedded conversion option contained in the Notes and Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion options was determined using the Binomial Lattice valuation model. At the end of each period and on note conversion date or repayment, the Company revalues the derivative liabilities resulting from the embedded option.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, in connection with the issuance of the Notes and Warrants, on the initial measurement dates, the fair values of the embedded conversion options of $<span id="xdx_908_eus-gaap--DerivativeLiabilities_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGaBdjnJhsC2">842,120</span> was recorded as derivative liabilities of which $<span id="xdx_900_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znG4cdzFTlpg">222,860</span> was allocated as a debt discount and $<span id="xdx_907_ecustom--InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWMe72Gtv997">619,260</span> as derivative expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with these revaluations, the Company recorded a loss from the change in the derivative liabilities fair value of approximately $<span id="xdx_90B_eus-gaap--DerivativeGainLossOnDerivativeNet_pn5n6_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCC8IcYrfUZe" title="Derivative liability">3.1</span> million </span> for the nine months ended September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zf6oZk4szheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2021, using the Binomial Lattice valuation model with the following assumptions:</span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BF_zigH6dDzhPWk" style="display: none">Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Dividend rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp0_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zigFCbWXRXyc">—</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--LongTermDebtTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z2h2hj2svAia">0.01</span> to <span id="xdx_90E_eus-gaap--LongTermDebtTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zmO1rnXHXnOj">1</span> year</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zpdmles487yd"><span style="-sec-ix-hidden: xdx2ixbrl1445">247%</span></span> to <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zXnrc1UQv92c">412</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zWXTiJtwcZmj">0.07%</span> to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zGmfRPwcXDAj">0.87</span></span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A7_zXroDpL39Fa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">For the three and nine-month period ended September 30, 2021, the Company recognized approximately $<span id="xdx_90C_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zBDJEFT0CmPe">27,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--SecuredConvertiblePromissoryNoteTwoMember_zJT9dJPM7Xz9">3,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 5700000 707000 0.12 2020-06-28 0.15 215000 986000 0 347000 215000 637000 1800000 5700000 <p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_z4YixMBnJqBd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes the Company’s outstanding convertible notes as of September 30, 2021, and December 31, 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_z2jbF7PxVXCd" style="display: none">Schedule of Convertible Promissory Notes</span><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-style: italic"><span style="font-family: Times New Roman, Times, Serif">(in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20210930_zxdgGNPYTIra" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20201231_zBFPWBZR41L6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--ConvertibleNotesPayable_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,296</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">720</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zz0Mxqy8zUok" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Unamortized discounts</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(434</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(79</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Convertible Notes Payable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">862</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">641</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 1296000 720000 434000 79000 862000 641000 788000 550500 0.10 499950 0.10 0.50 0.70 0.60 0.05 P5Y 322000 30000 53000 21000 38000 380593 0.18 31000 86000 7000 38000 67000 343000 25000 75000 25900 518000 27500 550000 25000 500000 32500 650000 110900 2218000 379422 268522 91890 91890 176632 2218000 2000000.0 90000 499615 1.40 The 40% premium will be recorded once a demand occurs 0.10 58055 0.10 14000 0.02 0.65 50000 203000 5700000 9000 10000 7000 8000 28000 30000 0.18 3000 8000 58055 13000 1.40 The 40% premium will be recorded once a demand occurs. 0.10 111111 100000 0.07 0.70 0.05 9000 0.10 0.18 1587301 0.08 0.05 634919 57000 0.16 262.27 P0Y11M1D 66000 6000 5000 45000 69000 5000 4000 5000 15600 0 2600 0 79000 76000 111111 13000 1.25 The 25% premium will be recorded once a demand occurs 0.10 52778 47500 5278 0.07 0.70 753968 0.08 0.05 301592 27000 0.16 262.27 P0Y11M19D 2000 0.10 0.18 32000 3000 1000 0.45 240.83 P1Y 2000 1000 35000 2900 5700 100 700 5600 34000 52778 5000 1.25 The 25% premium will be recorded once a demand occurs 0.10 66667 60000 6667 800000 five 0.095 2021-10-12 0.10 0.075 0.70 3700 3000 0.89 240.64 one year 0.075 88893 11000 0.92 247.52 P0Y11M15D 19000 35000 1700 3200 66667 2400 3200 0.18 1.25 The 25% premium will be recorded once a demand occurs 0.05 66500 63000 3500 800000 0.095 76000 2022-06-25 0.10 0.075 0.65 9300 47547 5040 102823 87039 15784 66500 3500 9300 37916 15784 0.48 302.11 P0Y7M6D 0.075 213333 25000 0.81 P0Y6M25D 13000 18000 4000 4000 66500 4000 49000 220500 800000 210000 10500 100000 P1Y 0.10 0.075 0.65 0.095 30000 140000 340893 234388 106505 220500 10500 56454 30000 17041 106505 0.81 P1Y 30810 3000 220500 3000 190000 220500 800000 210000 100000 P1Y 0.10 0.075 0.65 0.095 30000 112601 398404 297833 100571 220500 10500 62220 30000 17209 100571 0.77 254 P1Y 220500 3000 193000 842120 222860 619260 3100000 <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zf6oZk4szheh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2021, using the Binomial Lattice valuation model with the following assumptions:</span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8BF_zigH6dDzhPWk" style="display: none">Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Dividend rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp0_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zigFCbWXRXyc">—</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--LongTermDebtTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z2h2hj2svAia">0.01</span> to <span id="xdx_90E_eus-gaap--LongTermDebtTerm_iI_dtY_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zmO1rnXHXnOj">1</span> year</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zpdmles487yd"><span style="-sec-ix-hidden: xdx2ixbrl1445">247%</span></span> to <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zXnrc1UQv92c">412</span></span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zWXTiJtwcZmj">0.07%</span> to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_dp_uPure_c20210930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zGmfRPwcXDAj">0.87</span></span></td><td style="text-align: left">%</td></tr> </table> 0 P0Y3D P1Y 4.12 0.07 0.0087 27000 3000 <p id="xdx_80B_ecustom--LicensingAgreementTextBlock_zjTwimLdk6G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 3 - <span id="xdx_827_zOcgSKgMJNV">Licensing Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Les Laboratories Servier</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--PaymentsForRoyalties_do_c20210701__20210930__us-gaap--TypeOfArrangementAxis__custom--LesLaboratoriesServierLicenseAgreementMember_zdyWKtvRAqjf" title="Payments for royalties"><span id="xdx_906_eus-gaap--PaymentsForRoyalties_do_c20210101__20210930__us-gaap--TypeOfArrangementAxis__custom--LesLaboratoriesServierLicenseAgreementMember_zSZSkQIRarS8" title="Payments for royalties"><span id="xdx_904_eus-gaap--PaymentsForRoyalties_do_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--LesLaboratoriesServierLicenseAgreementMember_zVWcOajAQtsf" title="Payments for royalties"><span id="xdx_904_eus-gaap--PaymentsForRoyalties_do_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--LesLaboratoriesServierLicenseAgreementMember_z1sHG4Wfarpl" title="Payments for royalties">No</span></span></span></span> royalties were paid for the three or nine-month periods ended September 30, 2020, or 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Novosom Agreements</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20180501__20180531__dei--LegalEntityAxis__custom--NovosomVerwaltungsGmbHMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_pdd" title="Common stock issued">51,988</span> shares of our common stock, with a fair value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_c20180501__20180531__dei--LegalEntityAxis__custom--NovosomVerwaltungsGmbHMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zZ99FOTkxnh7" title="Fair value of common stock issued">75,000</span>, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017. On December 23, 2019, Novosom repurchased the acquired intellectual property for $<span id="xdx_905_eus-gaap--ProceedsFromSaleOfIntangibleAssets_c20191222__20191223__dei--LegalEntityAxis__custom--NovosomVerwaltungsGmbHMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember_zbcvGcLbPdKc" title="Proceeds form sale of intangible asset">45,000</span> of which $<span id="xdx_907_ecustom--PayablesOnIntellectualProperty_iI_c20200930__dei--LegalEntityAxis__custom--NovosomVerwaltungsGmbHMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__srt--StatementScenarioAxis__custom--UponExecutionOfAgreementMember_zw3vQ9JQ4uu2" title="Payables on intellectual property">20,000</span> was payable upon execution of the agreement and $<span id="xdx_902_ecustom--PayablesOnIntellectualProperty_iI_c20200930__dei--LegalEntityAxis__custom--NovosomVerwaltungsGmbHMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--IntellectualPropertyMember__srt--StatementScenarioAxis__custom--AchievementOfPerformanceObligationMember_zSz7tmeiqhui" title="Payables on intellectual property">25,000</span> was to be paid upon the Company’s achievement of certain performance obligations by September 30, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company recognized $<span id="xdx_90F_eus-gaap--OtherIncome_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--NovosomAgreementMember_zjka9N8V7OHk" title="Other income">5,000</span> and $<span id="xdx_905_eus-gaap--OtherIncome_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--NovosomAgreementMember_zkEkTBQUoiE2" title="Other income">45,000</span> as other income from the agreement for the three and nine-month periods ended September 30, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>License of DiLA<sup>2</sup> Assets</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $<span id="xdx_901_ecustom--UpfrontPaymentAgreementForLicenseAgreement_c20180315__20180316__us-gaap--BalanceSheetLocationAxis__us-gaap--AccruedLiabilitiesMember__us-gaap--TypeOfArrangementAxis__custom--LicenseOfDiLAAssetsMember_zJlwJD7dTSY" title="Upfront payment agreement for license agreement">200,000</span> and future additional consideration for sales and development milestones. The upfront fee was contingent upon the Company obtaining a third-party consent to the agreement within ninety days of execution. As of September 30, 2021, and December 31, 2020, the Company had not obtained consent for the sublicense and has classified the upfront payment it had previously recorded as an accrued liability on its balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 0 0 0 0 51988 75000 45000 20000 25000 5000 45000 200000 <p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zr16n5K1jfsj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 4 - <span id="xdx_826_zC56oPeSXv1i">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Due to Related Party</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">An unpaid balance for previous years services performed under the agreement of approximately $<span id="xdx_903_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20201231_zwOPbUxqG0G1">4,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">is included in due to related party in the accompanying consolidated balance sheets at September 30, 2021, and December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 4000 <p id="xdx_801_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRZGtTQ99wr4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 5 - <span id="xdx_82B_z1HZUgSez5il">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Adhera has authorized <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20210930_pdd">100,000</span></span> <span style="font: 10pt Times New Roman, Times, Serif">shares of preferred stock for issuance and has designated <span id="xdx_90C_ecustom--PreferredStockDesignatedShares_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd">1,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares as Series B Preferred Stock (“Series B Preferred”) and <span id="xdx_905_ecustom--PreferredStockDesignatedShares_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesAJuniorParticipatingPreferredStockMember_pdd">90,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredStockAndSeriesBPreferredStockMember_zGgotyKfHohg" title="Preferred stock shares outstanding">No</span> shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated <span id="xdx_909_ecustom--PreferredStockDesignatedShares_c20140331__us-gaap--StatementClassOfStockAxis__custom--SeriesCconvertiblePreferredStockMember_pdd">1,200 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated <span id="xdx_902_ecustom--PreferredStockDesignatedShares_c20150831__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_pdd">220 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated <span id="xdx_901_ecustom--PreferredStockDesignatedShares_c20180430__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_pdd">3,500 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated <span id="xdx_906_ecustom--PreferredStockDesignatedShares_c20180731__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_pdd">2,200 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated <span id="xdx_904_ecustom--PreferredStockDesignatedShares_c20191231__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredStockMember_pdd">6,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Series C Preferred</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Each share of Series C Preferred has a stated value of $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Stated value per share">5,000</span> per share, has a $<span id="xdx_901_ecustom--PreferredStockLiquidationPreferencePerShare_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5wrIWrerWc8" title="Preferred stock liquidation preference per share">5,100</span> liquidation preference per share, has <span id="xdx_90E_eus-gaap--PreferredStockVotingRights_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember" title="Preferred Stock, Voting Rights">voting rights of 666.67 votes per share</span>, and is convertible into shares of common stock at a conversion price of $<span id="xdx_90E_ecustom--CommonStockAtConversionPrice_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Common stock at a conversion price, per share">7.50</span> per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, and December 31, 2020, <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pdd" title="Preferred stock, shares outstanding">100</span></span> shares of Series C Preferred stock were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Series D Preferred</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Each share of Series D Preferred has a stated value of $<span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Stated value per share">5,000</span> per share, has a liquidation preference of $<span id="xdx_905_ecustom--PreferredStockLiquidationPreferencePerShare_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock liquidation preference per share">300 </span>per share, has <span id="xdx_901_eus-gaap--PreferredStockVotingRights_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember" title="Preferred Stock, Voting Rights">voting rights of 1,250 votes per share</span> and is convertible into shares of common stock at a conversion price of $<span id="xdx_90F_ecustom--CommonStockAtConversionPrice_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Common stock at a conversion price, per share">4.00</span> per share. The Series D Preferred has a <span id="xdx_90D_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zSjLOj2CdnJh" title="Preferred stock stated dividend rate">5%</span> stated dividend rate when, and if declared by the Board of Directors, is not redeemable and has voting rights on an as-converted basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, and December 31, 2020, <span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_pdd" title="Preferred stock, shares outstanding">40</span></span> shares of Series D Preferred were outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Series E Convertible Preferred Stock and Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Series E Preferred Stock has a stated value of $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockAndWarrantsMember_pdd" title="Stated value per share">5,000</span> per share and accrues <span id="xdx_905_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockAndWarrantsMember_zAjIw9Jq711i" title="Preferred stock stated dividend rate">8%</span> dividends per annum that are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series E Preferred stock is convertible into shares of common stock at $<span id="xdx_909_ecustom--CommonStockAtConversionPrice_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockAndWarrantsMember_pdd" title="Common stock at a conversion price, per share">0.50</span>. Anti-dilution price protection on Series E Preferred stock expired on <span id="xdx_90B_ecustom--AntidilutionPriceProtectionExpirationDate_dd_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockAndWarrantsMember_zo5dpaPOsra9" title="Anti-dilution price protection, expiration date">February 10, 2020</span>. Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 19, 2021, the exercise price of the Series E warrants was adjusted from $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Warrant exercise price shares upon conversion of debt">0.50</span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Warrant exercise price shares upon conversion of debt">0.05</span> per share upon the conversion of $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20210318__20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember_pdp0" title="Common stock converted, value">25,900</span> debt for <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20210318__20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember_pdd" title="Number of shares converted">518,000</span> shares common stock. The Company recorded approximately $<span id="xdx_90E_eus-gaap--DividendsPreferredStockStock_c20210318__20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_pdp0" title="Deemed dividend">390,000</span> as a deemed dividend based upon the change in fair value of the Series E Preferred stock warrants using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zzrbB7YYTPk3" title="Fair value of warrants measurement inputs">0.16%</span>, volatility of <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zGfw5CRdmQXk" title="Fair value of warrants measurement inputs">262.27</span>%, and expected term of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--RangeAxis__srt--MinimumMember_z8R8ikmwYCp8" title="Warrant term">.41</span> to <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zZjSzWmJ0zw5" title="Warrant term">.43</span> years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 8, 2021, an investor converted <span id="xdx_908_eus-gaap--ConversionOfStockSharesConverted1_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_pdd" title="Number of shares converted">8</span> shares of Series E Preferred and accrued dividends of approximately $<span id="xdx_90D_eus-gaap--AccruedInvestmentIncomeReceivable_iI_pp0p0_c20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zldmKgxhOw49" title="Accrued dividends">10,000</span> into <span id="xdx_907_eus-gaap--CommonStockDividendsShares_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zec76pFXZVDi" title="Number of shares in accrued dividends">101,010</span> shares of common stock. In addition, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zsrjOUxThSV8" title="Number of shares issued">53,571</span> shares of common stock to the investor for a cashless exercise of <span id="xdx_903_ecustom--CommonStockForCashlessExercise_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Common stock for a cashless exercise">75,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 30, 2021, and investor converted <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zWNglKw9IB29" title="Number of shares converted">50</span> shares of Series E Preferred stock with a state value of $<span id="xdx_90A_eus-gaap--ConversionOfStockAmountConverted1_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zouMNlaiXJdg" title="Number of shares converted, value">250,000</span> into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6H73aqfvXPi" title="Number of shares converted">500,000</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had a total of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_c20210930__us-gaap--StatementEquityComponentsAxis__custom--SeriesEWarrantsMember_pdd" title="Warrants outstanding">30,405,600</span> warrants issued with Series E Preferred stock outstanding. The warrants expire in 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company had accrued dividends on the Series E Preferred stock of approximately $<span id="xdx_904_eus-gaap--DividendsPreferredStock_pn5n6_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zqVq2KJi37m4">4,756,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_90C_eus-gaap--DividendsPreferredStock_pn5n6_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zjGNkLARYl3b">3.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million, as of September 30, 2021, and December 31, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021 and December 31, 2020, there were <span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_pp0d" title="Preferred stock, shares outstanding">3,400</span> and <span id="xdx_90E_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesEConvertiblePreferredStockMember_pdd" title="Preferred stock, shares outstanding">3,458</span> Series E shares outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Series F Convertible Preferred Shares and Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Series F Preferred Stock has a stated value of $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockAndWarrantsMember_pdd" title="Stated value per share">5,000</span> per share and accrues <span id="xdx_90C_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockAndWarrantsMember_zr06D9VHzFr4" title="Preferred stock stated dividend rate">8%</span> dividends per annum that are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series F Preferred stock is convertible into shares of common stock at $<span id="xdx_906_ecustom--CommonStockAtConversionPrice_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockAndWarrantsMember_pdd" title="Common stock at a conversion price, per share">0.50</span>. Anti-dilution price protection on Series F Preferred stock expired on <span id="xdx_903_ecustom--AntidilutionPriceProtectionExpirationDate_dd_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockAndWarrantsMember_zXx3sg37PPZ5" title="Anti-dilution price protection, expiration date">February 10, 2020</span>. The Series F Preferred stock includes a mandatory conversion feature on November 9, 2021, which is the <span id="xdx_902_ecustom--ClassOfWarrantOrRightTermDescriptions_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockAndWarrantsMember" title="Warrants term description">three-year</span> anniversary of the closing of the issuance. Warrants issued with Series F Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 30, 2019, the Company repurchased <span id="xdx_90C_eus-gaap--StockRepurchasedDuringPeriodShares_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_pdd" title="Number of shares repurchased">20</span> shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_pdd" title="Warrants to purchase shares of common stock">150,000</span> shares of common stock for $<span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodValue_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zIgcg4LpRota" title="Stock repurchase">100,000</span> from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $<span id="xdx_90A_ecustom--ValueOfWarrantsHeld_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zdwevm4D9r96" title="Value of warrants held">100,000</span> by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 19, 2021, the exercise price of the Series F warrants was adjusted from $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Warrant exercise price shares upon conversion of debt">0.50</span> to $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Warrant exercise price shares upon conversion of debt">0.05</span> upon the conversion of $<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210318__20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_pp0p0" title="Value of converted shares">25,900</span> of debt for <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20210318__20210319__us-gaap--StatementEquityComponentsAxis__custom--SeriesFWarrantsMember_pdd" title="Number of shares issued upon conversion">518,000</span> shares of common stock. The Company recorded approximately $<span id="xdx_905_eus-gaap--DividendsPreferredStockStock_c20210318__20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_pp0p0" title="Deemed dividend">31,000</span> as a deemed dividend based upon the change in fair value of the Series F Preferred stock using a binomial valuation model. The Company used a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zdO1UpXHGYm5" title="Fair value of warrants measurement inputs">0.16</span>%, volatility of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210319__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_z1tNNPVCQmD6" title="Fair value of warrants measurement inputs">262.27</span>%, and an expected term of <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__srt--RangeAxis__srt--MinimumMember_zd1H1HxIpYEk" title="Warrant term">.46</span> to <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210319__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember__srt--RangeAxis__srt--MaximumMember_zcpQyxtqyDSk" title="Warrant term">.53</span> years in calculating the fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had a total of <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20210930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--SeriesFPreferredStockMember_pdd" title="Warrants outstanding">3,088,500</span> Series F Preferred stock warrants outstanding. The warrants expire in 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company had accrued dividends on the Series F Preferred stock of approximately $<span id="xdx_909_eus-gaap--DividendsPreferredStockCash_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_pp0p0" title="Accrued dividends">455,000</span> and $<span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_pp0p0" title="Accrued dividends">347,000</span>, as of September 30, 2021, and December 31, 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">At September 30, 2021 and December 31, 2020, there were <span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zhPhKlWJ9zek" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_z7n91dTjepQk" title="Preferred stock, shares outstanding">361</span></span> Series F Preferred shares outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Series G Convertible Preferred Shares </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Series G Preferred Stock has a stated value of $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredSharesMember_pdd" title="Stated value per share">5,000</span> per share and accrues <span id="xdx_90A_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20210101__20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredSharesMember_zuwAJJoCK4Zg" title="Preferred stock stated dividend rate">8%</span> dividends per annum that are payable in cash or stock at the Company’s discretion. The Series G Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series G Preferred stock is convertible into shares of common stock at $<span id="xdx_904_ecustom--CommonStockAtConversionPrice_c20210930__us-gaap--StatementClassOfStockAxis__custom--SeriesGConvertiblePreferredSharesMember_pdd" title="Common stock at a conversion price, per share">0.50</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, no Series G Preferred Stock has been issued by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On March 19, 2021, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210318__20210319__us-gaap--ShortTermDebtTypeAxis__custom--TermLoanMember_pdd">518,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">unregistered shares of common stock to the holder of the January 2020 convertible note for conversion of $<span id="xdx_902_eus-gaap--InterestPayableCurrentAndNoncurrent_c20210319__us-gaap--ShortTermDebtTypeAxis__custom--TermLoanMember_pp0p0">25,900 </span></span><span style="font: 10pt Times New Roman, Times, Serif">in accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On June 8, 2021, an investor converted <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zc0BzDT3syF5" title="Number of shares converted">8</span> shares of Series E Preferred and accrued dividends of approximately $<span id="xdx_90B_eus-gaap--AccruedInvestmentIncomeReceivable_c20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_pp0p0" title="Accrued dividends">10,000</span> into <span id="xdx_902_eus-gaap--CommonStockDividendsShares_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_pdd" title="Number of shares in accrued dividends">101,010</span> shares of common stock. In addition, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_pdd" title="Number of shares issued">53,571</span> shares of common stock to the investor for a cashless exercise of <span id="xdx_904_ecustom--CommonStockForCashlessExercise_c20210607__20210608__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXfO2AAQuDMd" title="Common stock for a cashless exercise">75,000</span> warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 30, 2021, and investor converted <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zzSMXbwckzpk">50 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series E Preferred stock with a stated value of $<span id="xdx_909_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__custom--SeriesEPreferredMember_zPKmmLREAA93">250,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">into <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20210727__20210730__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zonqo068TkG2">500,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 11, 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210810__20210811__srt--TitleOfIndividualAxis__custom--ConvertibleNoteInvestorMember_zsWJ1apw3bG4">100,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock to a convertible note investor as a commitment fee which was valued at it relative fair value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210810__20210811__srt--TitleOfIndividualAxis__custom--ConvertibleNoteInvestorMember_zipBpY5EPpHb" title="Fair value">56,464</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On August 18, 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210815__20210818__srt--TitleOfIndividualAxis__custom--ConvertibleNoteInvestorMember_za9BUuF6NLHa">100,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock to a convertible note investor as a commitment fee which was valued at its relative fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210815__20210818__srt--TitleOfIndividualAxis__custom--ConvertibleNoteInvestorMember_zT1BGxVM1vmb" title="Fair value">62,220</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On September 22, 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210921__20210922__us-gaap--TypeOfArrangementAxis__custom--BankingAgreementMember_zY85DwXrijt1">300,148 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock to an investment banker for commissions due under a banking agreement. The shares were recorded at their relative fair value of approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210921__20210922__us-gaap--TypeOfArrangementAxis__custom--BankingAgreementMember_zgYitpnwVjl7">39,290</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the three-month period ending September 30, 2021 the company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pn5n6_c20210701__20210930__us-gaap--DebtInstrumentAxis__custom--FebruaryTwoThousandTwentyConvertibleNoteMember_zTaIFiAjWxfh">1.7 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million common shares upon the conversion of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--FebruaryTwoThousandTwentyConvertibleNoteMember_zvKsCiuD28D2" title="Principal amount">50,855</span> principal and $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210930__us-gaap--DebtInstrumentAxis__custom--FebruaryTwoThousandTwentyConvertibleNoteMember_zoUCCHKAmwK7" title="Interest payable">34,155</span> accrued interest on the February 2020 convertible note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The common shares issued upon conversions of convertible notes for the nine months ended September 30,2021 were valued at fair value based on the quoted trading prices on the conversion dates aggregating $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z920YIAFehA3">379,422</span> resulting in a loss on debt extinguishment of $<span id="xdx_903_ecustom--LossOnExtinguishmentOfDebt_c20210101__20210930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zWIVirULp2Yi">268,522</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, there were <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20210930_pdd" title="Warrants outstanding">61,306,350</span> warrants outstanding, with a weighted average exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930_ztQxSgzUwAD3" title="Warrant exercise price per share">0.07</span> per share, and annual expirations as follows:</span></p> <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPx6GvlukU7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zVkKw3ZvYsYc" style="display: none">Schedule of Stockholders' Equity Note, Warrants or Rights</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrant Summary:</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E Preferred </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zqN8vDQpNjp5" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">30,405,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zIIx8Abyn3Bg" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">30,405,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series F Preferred</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zYwRLj4gUtz6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">3,088,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zzvDkB1hkKN2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">3,088,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zhZI8M7oGuUi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">27,463,517</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_ztjkhgxBEqJ2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">1,013,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zR1mLSpU2M7e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">22,905,731</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ClassOfWarrantOrRightExpiringInYearFive_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zyKjvypKhcO3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2026"><span style="font-family: Times New Roman, Times, Serif">3,544,453</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zYm02IbFiC1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">348,733</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zYMEwAd0C908" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">10,080</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zcJhDErY45Se" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">335,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zGZFpdaBLB1i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">3,201</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJoo1uhtot94" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">61,306,350</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHn2te0wSCfk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">33,504,180</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmxcdVRum40h" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">1,348,785</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfUvpWvFqLe8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">22,908,932</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExpiringInYearFive_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9rQlLqI1i0l" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2026"><span style="font-family: Times New Roman, Times, Serif">3,544,453</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zz7h06ji2nB8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The above includes <span id="xdx_908_ecustom--AdjustableWarrantsShare_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Adjustable warrants, shares">60,957,617</span> price adjustable warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">A total of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoo7HuQJ7oF6">343,750 </span></span><span style="font: 10pt Times New Roman, Times, Serif">warrants expired during the period. There were <span id="xdx_900_ecustom--NumberOfWarrantsExercised_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBtU62YpT0jb">75,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">Series E warrants exercised as of September 30, 2021 on a cashless basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> 100000 1000 90000 0 1200 220 3500 2200 6000 5000 5100 voting rights of 666.67 votes per share 7.50 100 100 5000 300 voting rights of 1,250 votes per share 4.00 0.05 40 40 5000 0.08 0.50 2020-02-10 0.50 0.05 25900 518000 390000 0.16 262.27 P0Y4M28D P0Y5M4D 8 10000 101010 53571 75000 50 250000 500000 30405600 4756000000000 3700000 3400 3458 5000 0.08 0.50 2020-02-10 three-year 20 150000 100000 100000 0.50 0.05 25900 518000 31000 0.16 262.27 P0Y5M15D P0Y6M10D 3088500 455000 347000 361 361 5000 0.08 0.50 518000 25900 8 10000 101010 53571 75000 50 250000 500000 100000 56464 100000 62220 300148 39290 1700000 50855 34155 379422 268522 61306350 0.07 <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPx6GvlukU7f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BC_zVkKw3ZvYsYc" style="display: none">Schedule of Stockholders' Equity Note, Warrants or Rights</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Warrant Summary:</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 35%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series E Preferred </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zqN8vDQpNjp5" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">30,405,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zIIx8Abyn3Bg" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">30,405,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Series F Preferred</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zYwRLj4gUtz6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">3,088,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zzvDkB1hkKN2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">3,088,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible Notes</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zhZI8M7oGuUi" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">27,463,517</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_ztjkhgxBEqJ2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">1,013,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zR1mLSpU2M7e" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">22,905,731</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_ecustom--ClassOfWarrantOrRightExpiringInYearFive_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesMember_zyKjvypKhcO3" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2026"><span style="font-family: Times New Roman, Times, Serif">3,544,453</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zYm02IbFiC1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">348,733</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zYMEwAd0C908" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">10,080</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zcJhDErY45Se" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">335,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--OtherMember_zGZFpdaBLB1i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">3,201</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJoo1uhtot94" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant shares"><span style="font-family: Times New Roman, Times, Serif">61,306,350</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_ecustom--ClassOfWarrantOrRightExpiringInYearTwo_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHn2te0wSCfk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2023"><span style="font-family: Times New Roman, Times, Serif">33,504,180</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--ClassOfWarrantOrRightExpiringInYearThree_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmxcdVRum40h" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2024"><span style="font-family: Times New Roman, Times, Serif">1,348,785</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_ecustom--ClassOfWarrantOrRightExpiringInYearFour_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfUvpWvFqLe8" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2025"><span style="font-family: Times New Roman, Times, Serif">22,908,932</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--ClassOfWarrantOrRightExpiringInYearFive_iI_pid_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9rQlLqI1i0l" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Expiring in 2026"><span style="font-family: Times New Roman, Times, Serif">3,544,453</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 30405600 30405600 3088500 3088500 27463517 1013333 22905731 3544453 348733 10080 335452 3201 61306350 33504180 1348785 22908932 3544453 60957617 343750 75000 <p id="xdx_80F_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zF042iaUzJh9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 6 - <span id="xdx_825_zgN5K1fj5x0f">Stock Incentive Plans</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zC0TRgEXsUm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes stock option activity for the Nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zcjN41soesOf" style="display: none">Schedule of Share-based Payment Arrangement, Option, Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif">Outstanding, December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_z9eK0cYdAid4" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Options Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">391,350</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_zeevXEb4YQz2" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Options outstanding, weighted average exercise price, beginning"><span style="font-family: Times New Roman, Times, Serif">0.58</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_ztyJ4Qh7ylQc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Options granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1703">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_d0_c20210101__20210930_z4yq5p0MMTG2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Options granted, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Options expired / forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20210930_zs2vMdNd4j7f" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options expired / forfeited"><span style="font-family: Times New Roman, Times, Serif">(3,800</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zlTP2F7JX1ih" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options expired/forfeited, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">2.60</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding, September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_z5te6iTYqc6c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_z8Cl9UON3VLe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options outstanding, weighted average exercise price, ending"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210930_z0ZrnRz1NkCh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zqTdTCHDQ0R3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zc9huAy4is63" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWqXeQ129grg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes additional information on stock options outstanding as of September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zNnx488wRSMe" style="display: none">Schedule of Share-based Payment Arrangement, Option, Exercise Price Range</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td colspan="9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options Exercisable</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise Prices </b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number Outstanding</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted- Average Remaining Contractual Life (Years)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Exercise Price</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number Exercisable</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Exercise Price</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeg2LABw6X34" title="Range of exercise prices, lower">0.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgaXoBPcgBT" title="Range of exercise prices, upper">1.00</span>  </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2jOHAt0or3c" title="Numbers outstanding">383,500</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4ByMK2y0X1h" title="Weighted- Average Remaining Contractual Life (Years)">1.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zAwbXs9q1M9j" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIwRgGBuHdTj" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">383,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zikSU7DxPeik" title="Range of exercise prices, upper">1.70</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLtxp0qxgbp" title="Numbers outstanding">4,050</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z5cDeoI2nMwi" title="Weighted- Average Remaining Contractual Life (Years)">.27</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zE9wIIuMVsL1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">1.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zbTygrQ5sky" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">4,050</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">1.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Totals</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930_zyRKgeKKktWh" title="Numbers outstanding">387,550</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_z3Ux4f7oGj7" title="Weighted- Average Remaining Contractual Life (Years)">1.56</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930_zN1mv3JiMmpj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930_zOP6OjFSU5lb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">387,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_zmAsbPN3seRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2021, the Company granted no stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Total expense related to stock options was approximately $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwo1DvYSPQih">8,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">for the nine months ended September 30, 2020, respectively. <span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_do_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1Xe1q6g8vBf">No </span></span><span style="font: 10pt Times New Roman, Times, Serif">stock-based compensation expense was recognized for the nine-month period ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the Company had no unrecognized compensation expense related to unvested stock options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As of September 30, 2021, the intrinsic value of stock options outstanding was zero.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zC0TRgEXsUm8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes stock option activity for the Nine months ended September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_zcjN41soesOf" style="display: none">Schedule of Share-based Payment Arrangement, Option, Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif">Outstanding, December 31, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210930_z9eK0cYdAid4" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Options Outstanding Beginning"><span style="font-family: Times New Roman, Times, Serif">391,350</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930_zeevXEb4YQz2" style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: right" title="Options outstanding, weighted average exercise price, beginning"><span style="font-family: Times New Roman, Times, Serif">0.58</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options granted</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210930_ztyJ4Qh7ylQc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Options granted"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1703">—</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_d0_c20210101__20210930_z4yq5p0MMTG2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Options granted, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">—</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Options expired / forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210101__20210930_zs2vMdNd4j7f" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options expired / forfeited"><span style="font-family: Times New Roman, Times, Serif">(3,800</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930_zlTP2F7JX1ih" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options expired/forfeited, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">2.60</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding, September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210930_z5te6iTYqc6c" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options Outstanding Ending"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930_z8Cl9UON3VLe" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Options outstanding, weighted average exercise price, ending"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210930_z0ZrnRz1NkCh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">387,550</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210930_zqTdTCHDQ0R3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">0.99</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 391350000 0.58 0 3800000 2.60 387550000 0.99 387550000 0.99 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zWqXeQ129grg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The following table summarizes additional information on stock options outstanding as of September 30, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> <span id="xdx_8BF_zNnx488wRSMe" style="display: none">Schedule of Share-based Payment Arrangement, Option, Exercise Price Range</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td colspan="9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options Outstanding</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Options Exercisable</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise Prices </b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number Outstanding</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted- Average Remaining Contractual Life (Years)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Exercise Price</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number Exercisable</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted Average Exercise Price</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zeg2LABw6X34" title="Range of exercise prices, lower">0.98</span> - $<span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zgaXoBPcgBT" title="Range of exercise prices, upper">1.00</span>  </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z2jOHAt0or3c" title="Numbers outstanding">383,500</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_z4ByMK2y0X1h" title="Weighted- Average Remaining Contractual Life (Years)">1.57</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zAwbXs9q1M9j" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zIwRgGBuHdTj" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">383,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.98</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zikSU7DxPeik" title="Range of exercise prices, upper">1.70</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zLtxp0qxgbp" title="Numbers outstanding">4,050</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_z5cDeoI2nMwi" title="Weighted- Average Remaining Contractual Life (Years)">.27</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zE9wIIuMVsL1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">1.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zbTygrQ5sky" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">4,050</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pdd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">1.70</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Totals</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20210930_zyRKgeKKktWh" title="Numbers outstanding">387,550</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210930_z3Ux4f7oGj7" title="Weighted- Average Remaining Contractual Life (Years)">1.56</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20210930_zN1mv3JiMmpj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20210930_zOP6OjFSU5lb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number exercisable"><span style="font: 10pt Times New Roman, Times, Serif">387,550</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20210930_pdd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price"><span style="font: 10pt Times New Roman, Times, Serif">0.99</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"> </span></td></tr> </table> 0.98 1.00 383500000 P1Y6M25D 0.98 383500000 0.98 1.70 4050000 P0Y3M7D 1.70 4050000 1.70 387550000 P1Y6M21D 0.99 387550000 0.99 8000 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zZHqjWqW23W8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 7 - <span id="xdx_82C_zxIOGAa2wnn7">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Litigation</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Share Repurchase Agreement</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 30, 2019, the Company repurchased <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_z3eIWppkWZ5h" title="Number of shares repurchased">20</span> shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zLn3jh2IATOl" title="Warrants to purchase shares of common stock">150,000</span> shares of common stock for $<span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodValue_pp0p0_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_z7PkQITP5ZM7" title="Stock repurchase">100,000</span> from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $<span id="xdx_905_ecustom--ValueOfWarrantsHeld_pp0p0_c20191028__20191030__us-gaap--StatementClassOfStockAxis__custom--SeriesFConvertiblePreferredStockMember_zjC6g09g7kO3" title="Value of warrants held">100,000</span> by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Licensing Agreement– MLR 1019</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $<span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20210727__20210728__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1019Member_zaVSZxDBqLSb" title="Debt instrument cash payment">21,750,000</span> upon meeting certain performance milestones, as well as a royalty of <span id="xdx_903_ecustom--GrossSalesPercentage_iI_uPure_c20210728__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1019Member_zcN99uRm5Yk5" title="Gross sales percentage">5%</span> of gross sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to get its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to affect an Uplisting Event, the Company will have the option to purchase the all rights held by MP on the MLR-1019 licensed products in consideration for 10% of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5% royalty of future gross product sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">As of September 30, 2021, no performance milestones had been met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Licensing Agreement – MLR 1023</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $<span id="xdx_900_eus-gaap--DebtInstrumentPeriodicPayment_c20210821__20210824__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1023Member_zOe1WZcpc4mc">21,750,000</span> upon meeting certain performance milestones, as well as a tiered royalty of <span id="xdx_902_ecustom--GrossSalesPercentage_iI_dp_uPure_c20210728__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1019Member__srt--RangeAxis__srt--MinimumMember_zhh3z69nart8">8</span>-<span id="xdx_906_ecustom--GrossSalesPercentage_iI_uPure_c20210728__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1019Member__srt--RangeAxis__srt--MaximumMember_zphDdBznrnsg">12%</span> of gross sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span id="xdx_90A_ecustom--LicenseAgreementCommitmentsDescription_c20210821__20210824__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1023Member_zaAdSbAhbCO1" title="License agreement commitments description">If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> 20 150000 100000 100000 21750000 0.05 21750000 0.08 0.12 If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising. <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zn84tRBYcth" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note 8 - <span id="xdx_82F_zsFgMJJpE9O5">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Except for the events discussed below, there were no subsequent events that required recognition or disclosure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance of Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 4, 2021, the Company issued <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211003__20211004__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--JanuaryConvertibleNoteMember_zR9nWoFgZd3">525,000 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock upon the conversion of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20211003__20211004__us-gaap--DebtInstrumentAxis__custom--JanuaryConvertibleNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8VoFYqIJizc">26,250 </span></span><span style="font: 10pt Times New Roman, Times, Serif">of principal and interest on the January 2020 convertible note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Secured Note Default</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On July 30, 2021, the Company defaulted under the Secured Convertible Promissory Note from January 2021 and the interest rate on the note reset to <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20210730__us-gaap--DebtInstrumentAxis__custom--SecuredPromissoryNoteMember_zq7e3Gw7d2s5" title="Debt instrument effective percentage">18</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance of Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 4, 2021, the Company issued <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211003__20211004__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zG1t7qoJfFl4">255,540 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock upon the conversion of <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211003__20211004__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesEPreferredStockMember_zJVw3DkAoXmg">20 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares Series E Preferred stock and accrued dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance of Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On October 15, 2021, the Company issued <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211014__20211015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zShE7rc2z9ub">37,043 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock upon the conversion of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211014__20211015__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesFPreferredStockMember_zW8TpIwaoiQl">3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of Series F Preferred stock and accrued dividends.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance of a Convertible Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRWS4SK9bWq1">10</span></span><span style="font: 10pt Times New Roman, Times, Serif">% Convertible Redeemable Note in the principal amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zyyBXGa8lZu3">131,250 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and a <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1wv1jhZWp45" title="::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1789">three</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">-year warrant to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdM2OzsL3Bn3">476,190 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock of the Company for which the Company received consideration of $<span id="xdx_901_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20211006__20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlK6TZ1Y0JS5">110,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">. </span>In addition, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211006__20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BuyerMember_zOwvrWi6EEof">59,523</span> shares of common stock as a commitment fee to the Buyer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Note is due <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20211006__20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z9Hi9KAlGlp9">October 5, 2022</span>. The Note provides for guaranteed interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTxRTxLQfI9">10</span>% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGB58fS7oHje">0.075</span> per share, subject to certain adjustments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Warrants are exercisable for <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211005__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ziKv0f8StkQ" title="::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1796">three</span></span>-years from October 5, 2021, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211005__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zxQWrATbgSX2">0.095</span> per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $<span title="Aggregate exercise price of warrants"><span id="xdx_908_ecustom--AggregateExercisePriceOfWarrants_c20211003__20211005__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zExxw55X0kHk">45,238</span>.05</span>. The company will record a debt discount related to the relative fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Issuance of a Convertible Note</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On October 13, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_uPure_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember_zd7iQnxTgjsc">10</span></span><span style="font: 10pt Times New Roman, Times, Serif">% Convertible Redeemable Note in the principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zthtKmEr79dh">131,250 </span></span><span style="font: 10pt Times New Roman, Times, Serif">and a <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember_zRczZZxtFjh4" title="::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1801">three</span></span></span><span style="font: 10pt Times New Roman, Times, Serif">-year warrant to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z48pFfn9vVmj">476,190 </span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock of the Company for which the Company received consideration of $<span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20211011__20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztguuvOBZfS7">110,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">. In addition, the Company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211011__20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--BuyerMember_zF3Em91bCjg9">59,523</span> shares of common stock as a commitment fee to the Buyer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Note is due <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_pp0p0_dd_c20211011__20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z7ftOqgEZxZc">October 7, 2022</span>. The Note provides for guaranteed interest at the rate of <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwzAnhe2Tg2f">10</span>% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20211013__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zlAuLU8GnFK4">0.075</span> per share, subject to certain adjustments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The Warrants are exercisable for <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtYxL_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zJ5oADaeYqxa" title="::XDX::3"><span style="-sec-ix-hidden: xdx2ixbrl1808">three</span></span>-years from October 7, 2021, at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zGRnMo9dN2J1">0.095</span> per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $<span><span id="xdx_90A_ecustom--AggregateExercisePriceOfWarrants_c20211006__20211007__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleRedeemableNoteMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZHQln7ivcK7">45,238</span>.05</span>. The company will record a debt discount related to the relative fair value of the warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>Extension of Notes Maturity Date</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20211025__20211027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0OPXmkxHEsc" title="Maturity date description">On October 27, 2021, the Company and the institutional investor who holds two convertible promissory notes agreed to extend the maturity date of each of the Notes by six months. The $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20211025__20211027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIUmxbOrTCy4" title="Number of stock issued conversion">220,500</span> Note issued in August 2021 had its maturity date extended to <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20211025__20211027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zC4oP1xljMtf" title="Maturity date">February 17, 2023</span>, and the $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20211025__20211027__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7X4uKNofgui" title="Debt conversion converted instrument amount">66,500</span> Note issued in June 2021 had its maturity date extended to December 25, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Issuance of Common Stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in; margin: 0pt">On November 4, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211102__20211104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2cvFClhaTxb" title="Number of share issued">153,227</span> shares of common stock upon a cashless exercise of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDoipSDJhlYj" title="Number of warrant issued">250,000</span> warrants issued with the April 2021 Convertible Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>Licensing Agreement MLR-1023 Amendment</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span id="xdx_904_ecustom--LicenseAgreementCommitmentsDescription_c20211115__20211117__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMLR1023Member__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zX2ePsXi49y4" title="License agreement commitments description">On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.</span></p> 525000 26250 0.18 255540 20 37043 3 0.10 131250 476190 110000 59523 2022-10-05 0.10 0.075 0.095 45238 0.10 131250 476190 110000 59523 2022-10-07 0.10 0.075 0.095 45238 On October 27, 2021, the Company and the institutional investor who holds two convertible promissory notes agreed to extend the maturity date of each of the Notes by six months. The $220,500 Note issued in August 2021 had its maturity date extended to February 17, 2023, and the $66,500 Note issued in June 2021 had its maturity date extended to December 25, 2022. 220500 2023-02-17 66500 153227 250000 On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising. XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
 9 Months Ended
Sep. 30, 2021
Nov. 22, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
Current Fiscal Year End Date --12-31  
Entity File Number 000-13789  
Entity Registrant Name ADHERA THERAPEUTICS, INC.  
Entity Central Index Key 0000737207  
Entity Tax Identification Number 11-2658569  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 8000 Innovation Parkway  
Entity Address, City or Town Baton Rouge  
Entity Address, State or Province LA  
Entity Address, Postal Zip Code 70820  
City Area Code (919)  
Local Phone Number 518-3748  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   15,575,294
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets    
Cash $ 151 $ 1
Total current assets 151 1
Total assets 151 1
Current liabilities    
Accounts payable 2,287 2,257
Due to related party 4 4
Accrued expenses 2,874 2,112
Accrued dividends 5,211 4,083
Term loan 5,677 5,677
Convertible notes payable, net 862 641
Derivative liability 3,475
Total current liabilities 20,390 14,774
Total liabilities 20,390 14,774
Commitments and contingencies (Note 7)  
Stockholders’ deficit    
Common stock, $0.006 par value; 180,000,000 shares authorized, 14,485,438 and 11,112,709 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively 87 67
Additional paid-in capital 30,647 29,772
Accumulated deficit (50,973) (44,612)
Total stockholders’ deficit (20,239) (14,773)
Total liabilities and stockholders’ deficit 151 1
Series C Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock value
Series D Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock value
Series E Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock value
Series F Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock value
Series G Convertible Preferred Stock [Member]    
Stockholders’ deficit    
Preferred stock value
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 100,000 100,000
Common Stock, Par or Stated Value Per Share $ 0.006 $ 0.006
Common Stock, Shares Authorized 180,000,000 180,000,000
Common stock, shares issued 14,485,438 11,112,709
Common Stock, Shares, Outstanding 14,485,438 11,112,709
Series C Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 1,200 1,200
Preferred stock, shares issued 100 100
Preferred stock, shares outstanding 100 100
Preferred stock, liquidation preference value $ 510,000 $ 510,000
Series D Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 220 220
Preferred stock, shares issued 40 40
Preferred stock, shares outstanding 40 40
Preferred stock, liquidation preference value $ 12,000 $ 12,000
Series E Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 3,500 3,500
Preferred stock, shares issued 3,400 3,458
Preferred stock, shares outstanding 3,400 3,458
Preferred stock, liquidation preference value $ 17,000,000 $ 17,000,000
Series F Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 2,200 2,200
Preferred stock, shares issued 361 361
Preferred stock, shares outstanding 361 361
Preferred stock, liquidation preference value $ 1,805,000 $ 1,805,000
Series G Convertible Preferred Stock [Member]    
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 6,000 6,000
Preferred stock, shares outstanding 0 0
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses        
Sales and marketing $ 20 $ 17 $ 818
General and administrative 232 174 454 1,055
Total operating expenses 231 194 471 1,873
Loss from operations (231) (194) (471) (1,873)
Other income (expense)        
Interest expense (261) (255) (749) (1,082)
Other Income 5 45
Loss on extinguishment of debt (177) (177)
Derivative expense (2,968) (3,055)
Amortization of debt discount (101) (95) (230) (373)
Total other income (expense) (3,507) (345) (4,211) (1,410)
Net loss (3,739) (539) (4,682) (3,283)
Dividends (406) (388) (1,679) (1,153)
Net Loss Applicable to Common Stockholders $ (4,145) $ (927) $ (6,361) $ (4,436)
Net loss per share – Common Stockholders - basic and diluted $ (0.32) $ (0.09) $ (0.54) $ (0.41)
Weighted average shares outstanding - basic and diluted 12,986,391 10,869,530 11,742,315 10,869,530
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Preferred Stock [Member]
Series C Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Preferred Stock [Member]
Series E Preferred Stock [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 65 $ 29,375 $ (39,327) $ (9,887)
Balance, shares at Dec. 31, 2019 100 40 3,478 361 10,869,530      
Accrued dividend (383) (383)
Issuance of warrants with notes payable 239 239
Share based compensation 36 36
Net loss (1,838) (1,838)
Ending balance, value at Mar. 31, 2020 $ 65 29,650 (41,548) (11,833)
Balance, shares at Mar. 31, 2020 100 40 3,478 361 10,869,530      
Beginning balance, value at Dec. 31, 2019 $ 65 29,375 (39,327) (9,887)
Balance, shares at Dec. 31, 2019 100 40 3,478 361 10,869,530      
Net loss               (3,283)
Ending balance, value at Sep. 30, 2020 $ 65 29,672 (43,763) (14,026)
Balance, shares at Sep. 30, 2020 100 40 3,478 361 10,869,530      
Beginning balance, value at Mar. 31, 2020 $ 65 29,650 (41,548) (11,833)
Balance, shares at Mar. 31, 2020 100 40 3,478 361 10,869,530      
Accrued dividend (382) (382)
Benefical conversion feature - convertible notes 50 50
Share based compensation (26) (26)
Net loss (906) (906)
Ending balance, value at Jun. 30, 2020 $ 65 29,674 (42,836) (13,097)
Balance, shares at Jun. 30, 2020 100 40 3,478 361 10,869,530      
Accrued dividend (388) (388)
Share based compensation (2) (2)
Net loss (539) (539)
Ending balance, value at Sep. 30, 2020 $ 65 29,672 (43,763) (14,026)
Balance, shares at Sep. 30, 2020 100 40 3,478 361 10,869,530      
Beginning balance, value at Dec. 31, 2020 $ 67 29,772 (44,612) (14,773)
Balance, shares at Dec. 31, 2020 100 40 3,458 361 11,112,709      
Accrued and deemed dividend 505 (882) (377)
Issuance of common stock for convertible note conversion $ 3 23 26
Issuance of common stock for convertible note conversion, shares         518,000      
Issuance of warrants and common stock with convertible notes - 28 28
Net loss (428) (428)
Ending balance, value at Mar. 31, 2021 $ 70 30,328 (45,922) (15,524)
Balance, shares at Mar. 31, 2021 100 40 3,458 361 11,630,709      
Beginning balance, value at Dec. 31, 2020 $ 67 29,772 (44,612) (14,773)
Balance, shares at Dec. 31, 2020 100 40 3,458 361 11,112,709      
Net loss               (4,682)
Ending balance, value at Sep. 30, 2021 $ 87 30,647 (50,973) (20,239)
Balance, shares at Sep. 30, 2021 100 40 3,400 361 14,485,438      
Beginning balance, value at Mar. 31, 2021 $ 70 30,328 (45,922) (15,524)
Balance, shares at Mar. 31, 2021 100 40 3,458 361 11,630,709      
Accrued and deemed dividend 11 (392) (381)
Issuance of warrants and common stock with convertible notes - 69 69
Issuance of common stock for cashless exercise of warrants
Issuance of common stock for cashless exercise of warrants, shares         53,571      
Issuance of common stock for Series E conversion $ 1 9 10
Issuance of common stock for Series E conversion, shares     (8)   101,010      
Net loss (514) (514)
Ending balance, value at Jun. 30, 2021 $ 71 30,417 (46,828) (16,340)
Balance, shares at Jun. 30, 2021 100 40 3,450 361 11,785,290      
Issuance of warrants and common stock with convertible notes - $ 500,148 $ 154     157
Issuance of common stock for Series E conversion $ 3 (3)
Issuance of common stock for Series E conversion, shares     (50)   500,000      
Accrued dividend 25 (406) (381)
Issuance of warrants and common stock with convertible notes, shares         3      
Issuance of common stock for convertible note and interest conversions         $ 10 75   85
Issuance of common stock for convertible note and interest conversions, shares         1,700,000      
Reclassification of derivative           (21)   (21)
Net loss (3,739) (3,739)
Ending balance, value at Sep. 30, 2021 $ 87 $ 30,647 $ (50,973) $ (20,239)
Balance, shares at Sep. 30, 2021 100 40 3,400 361 14,485,438      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows Used in Operating Activities:    
Net loss $ (4,682) $ (3,283)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share based compensation 8
Loss on debt extinguishment 177
Amortization of debt discount 230 765
Derivative expense 3,055
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 316
Accounts payable 30 850
Accrued interest 749 689
Accrued expenses 72 157
Net Cash Used in Operating Activities (369) (498)
Cash Flows Provided By Financing Activities:    
Proceeds from notes payable, net or original issue discounts 591 553
Notes payable issuance costs (72) (105)
Net Cash Provided by Financing Activities 519 448
Net (decrease) in cash 150 (50)
Cash – Beginning of Period 1 50
Cash - End of Period 151
Non-cash Investing and Financing Activities:    
Dividends 1,679 1,153
Conversion of Series E to common stock 4
Beneficial conversion feature on issuance notes payable 50
Cashlesss exercise of Series E warrants 4
Issuance of common stock for conversion of convertible debt 111
Debt discounts for issuance costs, warrants and derivatives $ 473 $ 239
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations, Basis of Presentation and Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Nature of Operations, Basis of Presentation and Significant Accounting Policies

Note 1 – Nature of Operations, Basis of Presentation and Significant Accounting Policies

 

Business Overview

 

Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company.

 

Previously, the Company was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. On January 4, 2021, the licensor terminated the licensing agreement for the product candidate.

 

On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. In October 2021, the company commenced the manufacturing of drug product for use in the development of MLR-1019.

 

On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.

 

On October 20, 2021 the Company as licensee expanded the exclusive licensing agreement with Melior Pharmaceuticals I, Inc. to include two additional clinical indications for Melior’s Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation.

 

To the extent that resources have been available, the Company has continued to work with its advisors to restructure our company and to identify potential strategic transactions, including the Melior transactions described above. There can be no assurance that the Company will be successful in raising sufficient capital to meet its obligations under the Melior license agreements. If the Company does not raise substantial additional capital to develop and commercialize repay its indebtedness which is in default or restructure the indebtedness, it is likely that the Company will discontinue all operations and seek bankruptcy protection.

 

Basis of Presentation

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the Nine months ended September 30, 2021, are not necessarily indicative of the results for the year ending December 31, 2021 or for any future period.

 

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive.

 

Going Concern and Management’s Liquidity Plans

 

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2021, the Company had cash and cash equivalents of approximately $151,000 and has negative working capital of approximately $20.2 million.

 

The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net loss of approximately $4.7 million for the nine months ended September 30, 2021. The Company had an accumulated deficit of approximately $51.0 million as of September 30, 2021.

 

In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for our operations at terms acceptable to us or at all. General market conditions, as well as market conditions for companies in our financial and business position, as well as the ongoing issue arising from the COVID-19 pandemic, may make it difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

 

Summary of Significant Accounting Policies

 

Reclassification

 

Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.

 

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.

 

 

Fair Value of Financial Instruments

 

The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

As of September 30, 2021, the Company measured conversion features on outstanding convertible notes as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $3.5 million. The value of the derivative liability as of September 30, 2021 was determined by using the binomial lattice model using the following inputs: 0.09% risk free rate, volatility of 404% and time to maturity of 0 - .18 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2021, and there were no liabilities or assets measured at fair value on a reoccurring or non-recurring basis as of December 31, 2020.

 

(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at September 30, 2021 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liability  $-   $-   $3,475   $3,475 
Total  $-   $-   $3,475   $3,475 

 

A roll forward of the level 3 valuation financial instruments is as follows:

 

                
  

Nine months Ended

September 30, 2021		 
(In thousands)  Warrants   Notes   Total 
Balance at December 31, 2020  $—   $—   $— 
Initial valuation of derivative liabilities included in debt discount   —    223    223 
Initial valuation of derivative liabilities included in derivative expense   —    619    619 
Reclassification of derivative liabilities to gain on debt extinguishment   —    (92)   (92)
Reclass from Additional paid-in capital   46    244   290
Change in fair value included in derivative expense   361    2,074    2,435 
Balance at September 30, 2021  $407   $3,068   $3,475 

 

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.

 

Convertible Debt and Warrant Accounting

 

Debt with warrants

 

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

Convertible debt – derivative treatment

 

When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet that requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.

 

 

Convertible debt – beneficial conversion feature

 

Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) on January 1, 2021, if the conversion feature was not treated as a derivative, the Company assessed whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.

 

Recently Issued Accounting Pronouncements

 

Recently Adopted

 

In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.

 

Not Yet Adopted

 

In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic:

 

1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument.
   
2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows:
       
  a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider:
       
    i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments.
       
    ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50.
       
  b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged.
       
3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows:
       
  a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs.
     
  b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest.
       
  c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation.

 

An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction.

 

The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

Net Loss per Common Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.

 

 

The following table presents the computation of net loss per share (in thousands, except share and per share data):

 

   2021   2020   2021   2020 
  

Three Months Ended

September 30,

   Nine Months Ended

September 30,

 
   2021   2020   2021   2020 
Numerator                
Net loss  $(3,739)  $(539)  $(4,682)  $(3,283)
Dividends   (406)   (388)   (1,679)   (1,153)
Net Loss allocable to common stockholders  $(4,145)  $(927)  $(6,361)  $(4,436)
Denominator                    
Weighted average common shares outstanding used to compute net loss per share, basic and diluted   12,986,391    10,869,530    11,742,315    10,869,530 
Net loss per share of common stock, basic and diluted                    
Net loss per share  $(0.32)  $(0.09)  $(0.54)  $(0.41)

 

Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:

 

   2021   2020 
Convertible Notes   24,332,784    23,690,018 
Stock options outstanding   387,550    1,216,350 
Warrants   61,306,350    69,047,000 
Series C Preferred Stock   66,667    66,667 
Series D Preferred Stock   50,000    50,000 
Series E Preferred Stock   43,514,922    41,597,256 
Series F Preferred Stock   4,519,872    4,230,973 
Total   134,178,046    139,898,264 

 
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Notes Payable

Note 2 – Notes Payable

 

2019 Term Loan

 

During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $5.7 million. The Company paid $707,000 in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the straight-line method.

 

The Notes accrue interest at a rate of 12% per annum. Interest is payable quarterly with the first interest payment to be made on December 28, 2019, and each subsequent payment every three months thereafter.

 

The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, matured on June 28, 2020. The Notes are secured by a first lien and security interest on all the assets of the Company and certain of its wholly owned subsidiaries.

 

 

On December 28, 2019, the Company defaulted on the initial interest payment on the loan and the interest rate per annum increased to the default rate of 15%. On June 28, 2020, the Company defaulted on the maturity date principal payment.

 

The Company recognized approximately $215,000 and $986,000 in interest expense related to Notes for the three and nine months ended September 30, 2020, including $0 and $347,000 related to the amortization of debt issuance costs. The Company recognized approximately $215,000 and $637,000 in interest expense related to the Notes for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discount and issuance costs for this term loan were fully amortized.

 

As of September 30, 2021, the Company had approximately $1.8 million of accrued interest on the Notes included in accrued expenses and remains in default on the repayment of approximately $5.7 in principal and interest on the Notes.

 

CONVERTIBLE PROMISSORY NOTES

 

The following table summarizes the Company’s outstanding convertible notes as of September 30, 2021, and December 31, 2020:

 

(in thousands)  September 30, 2021   December 31, 2020 
Convertible Notes  $1,296   $720 
Unamortized discounts   (434)   (79)
Convertible Notes Payable  $862   $641 

 

Five convertible notes with outstanding principal of approximately $788,000 were in default as of the issuance date of this report.

 

Secured Convertible Promissory Note – February 2020

 

On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes (the “Convertible Notes”), with a principal of $550,500 issued at a 10% original issue discount, for a total purchase price of $499,950, and (ii) warrants to purchase up to such number of shares of the common stock of the Company as is equal to the product obtained by multiplying 1.75 by the quotient obtained by dividing (A) the principal amount of the Notes by (B) the then applicable conversion price of the Notes.

 

The maturity date was August 5, 2020. Interest shall accrue to the Holders on the aggregate unconverted and then outstanding principal amount of the Notes at the rate of 10% per annum, calculated on the basis of a 360-day year and accrues daily.

 

On or after May 5, 2020, until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $0.50 per share of Common Stock and (ii) 70% of the volume weighted average price of the Common Stock on the trading market on which the Common Stock is then listed or quoted for trading for the prior ten (10) trading days (as adjusted for stock splits, stock combinations and similar events); provided, that if the Notes are not prepaid on or before May 5, 2020, then the conversion price shall be the lower of (x) 60% of the conversion price as calculated above or (y) $0.05 (as adjusted for stock splits, stock combinations and similar events). The conversion price of the Convertible Notes shall also be adjusted as a result of subsequent equity sales by the Company, with customary exceptions.

 

The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5-year term.

 

The Company recorded a discount related to the Warrants of approximately $322,000, which includes an allocation of OID and issue costs of $30,000 and $53,000 based on the relative fair value of the instruments as determined by using the Monte-Carlo simulation model. The Company also recorded the remaining debt discount related to the convertible debt OID of approximately $21,000 and debt issuance costs of $38,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method. Total discounts recorded were $380,593.

 

On June 15, 2020, the Company defaulted on certain covenants in the 2020 term loan and the interest rate reset to the default rate of 18%.

 

  

The Company recognized $31,000 and $86,000 in interest expense related to the notes for the three and nine months ended September 30, 2020, respectively including $7,000 and $38,000 related to the amortization of debt issuance costs. The Company amortized $67,000 and $343,000 of debt discount for the three and nine months ended September 30, 2020, respectively. The Company recognized approximately $25,000 and $75,000 in interest expense related to the notes for the three and Nine months ended September 30, 2021, respectively. As of September 30, 2021, the debt discounts for this Convertible Note were fully amortized.

 

On March 19, 2021, the holder of the Convertible Note converted $25,900 of interest into 518,000 shares of common stock.

 

On July 29, 2021, the holder of the Convertible Note converted $27,500 of interest into 550,000 shares of common stock.

 

On August 16, 2021, the holder of the Convertible Note converted $25,000 of principal and interest into 500,000 shares of common stock.

 

On September 13, 2021, the holder of the Convertible Note converted $32,500 of principal and interest into 650,000 shares of common stock.

 

The total note principal and interest converted during the nine months ended September 30, 2021 was $110,900 and 2,218,000 common shares issued were valued at fair value based on the quoted trading prices on the conversion dates aggregating $379,422 resulting on a loss on debt extinguishment of $268,522. In addition, derivative fair value of $91,890 relating to the portion of the Note converted was settled resulting in gain on extinguishment of $91,890. The net loss on extinguishment was $176,632. The total shares issued upon conversion during the nine months ended September 30, 2021, was $2,218,000.

 

During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $2.0 million as a derivative liability on the accompanying balance sheet.

 

As of September 30, 2021, the Company had accrued interest on the Convertible Note of approximately $90,000.

 

As of September 30, 2021, the Company remains in default on the repayment of remaining principal of $499,615 and accrued interest on the Convertible Notes. Upon demand for repayment at the election of the holder, the holder of the Convertible Note is due 140% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Convertible Note. The 40% premium will be recorded once a demand occurs.

 

Secured Convertible Promissory Note – June 2020

 

On June 26, 2020, the Company issued to an existing investor in the Company a 10% original issue discount Senior Secured Convertible Promissory Note with a principal of $58,055, for a purchase price of $52,500, net of the original issue discount of $5,555. The Convertible Note matured on December 26, 2020. Interest accrues on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10% per annum, calculated on the basis of a 360-day year. The Company incurred approximately $14,000 in debt issuance costs.

 

The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.02 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 65% of the lowest closing bid price of the Company’s common stock as reported on its principal trading market for the twenty consecutive trading day period ending on (and including) the trading day immediately preceding the date on which the conversion notice was delivered. The conversion price shall also be adjusted for subsequent equity sales by the Company. Because the share price on the commitment date was in excess of the conversion price, the Company recorded a beneficial conversion feature of $50,000 related to this note that was credited to additional paid in capital and reduced the carrying amount. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $203,000. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method.

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $5.7 million agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019 that such holders entered into with the Company and its subsidiaries to the security interest granted to the holder of the Note.

 

For the three and nine months ended September 30, 2020, the Company recognized approximately $9,000 and $10,000 in interest expense including $7,000 and $8,000 related to the amortization of debt issuance costs, respectively. For the three and nine months ended September 30, 2020, the Company recognized $28,000 and $30,000 related to the amortization of debt discount.

 

On August 5, 2020, the Company defaulted on certain covenants in the loan and the interest rate reset to the default rate of 18%.

 

For the three and nine months ended September 30, 2021, the Company recognized approximately $3,000 and $8,000 in interest expense related to the note, respectively. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized.

 

As of September 30, 2021, the Company remains in default on the repayment of principal of $58,055 and approximately $13,000 in accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 140% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 40% premium will be recorded once a demand occurs.

 

 

Secured Convertible Promissory Note – October 2020

 

On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10% original issue discount senior secured convertible promissory note with a principal of $111,111, for a purchase price of $100,000. The note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of then conversion price. The conversion price of the notes is subject to anti-dilution price protection and on March 19, 2021, the conversion price of the notes was adjusted to $0.05 per share. as a result of subsequent equity sales by the Company.

 

The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company.

 

The Company recorded approximately $9,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method.

 

The interest rate on the note was 10% per annum, calculated on the basis of a 360-day year. On April 30, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to 18%.

 

Additionally, the Company issued the noteholder 1,587,301 warrants to purchase the Company’s common stock at $0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $0.05 and the Company issued an additional 634,919 warrants to the note holder. The Company recorded approximately $57,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of 0.92 years in calculating the fair value of the warrants.

 

The Company recorded a discount related to the warrants of approximately $66,000, including a discount of $6,000 and issuance costs of $5,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The Company recorded a beneficial conversion feature of $45,000 related to the note that was credited to additional paid in capital and reduced the carrying amount. The discount recorded is being amortized to interest expense over the life of the loan using the straight-line method. At the commitment date, the actual intrinsic value of the beneficial conversion feature was approximately $69,000. The Company also recorded a debt discount related to the convertible debt of approximately $5,000 and debt issuance cost of $4,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.

 

For the three and nine months ended September 30, 2021, the Company recognized approximately $5,000 and $15,600 in interest expense including $0 and $2,600 related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $0 and $79,000 and related to the amortization of debt discount. As of September 30, 2021, the debt discount and issuance costs for the loan were fully amortized. No interest expense or debt discount was recognized for the same period of 2020.

 

During the quarter ended September 30, 2021, the Company reclassified the warrant and conversion feature on the note from equity and recognized approximately $76,000 as a derivative liability on the accompanying balance sheet.

 

As of September 30, 2021, the Company has outstanding principal of $111,111 and accrued interest on the note of approximately $13,000.

 

As of September 30, 2021, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 25% premium will be recorded once a demand occurs

 

 

Secured Convertible Promissory Note – January 2021

 

On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal of $52,778, for a purchase price of $47,500, net of original issue discount of $5,278. The Note is convertible into shares of common stock of the Company at the option of the noteholder at a conversion price of $0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price of the notes is subject to anti-dilution price protection and will be adjusted upon subsequent equity sales by the Company.

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

Additionally, the Company issued to the investor 753,968 warrants to purchase the Company’s common stock at an exercise price of $0.08 per share subject to certain adjustments as defined in the agreement. Until the Notes are no longer outstanding, the warrants have full-ratchet protection, are exercisable for a period of five years, and contain customary exercise limitations. On March 19, 2021, the exercise price of the warrants was adjusted to $0.05 and the Company issued an additional 301,592 warrants to the note holder. The Company recorded approximately $27,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of 0.97 years in calculating the fair value of the warrants.

 

The Company recorded approximately $2,000 in debt issuance cost to be amortized over the life of the loan using the straight-line method.

 

The interest rate on the note was 10% per annum, calculated on the basis of a 360-day year. On July 31, 2021, the note matured and the Company defaulted on the note and the interest rate on the loan reset to the default rate of 18% per annum.

 

The Company recorded a discount related to the warrants of approximately $32,000, which includes an allocated original issue discount, of $3,000 and allocated issuance costs of $1,000 based on the relative fair value of the instruments as determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.45%, volatility of 240.83%, and an expected term of one year in calculating the fair value of the warrants.

 

The Company also recorded a debt discount related to the convertible debt of approximately $2,000 remaining original issue discount and remaining debt issuance cost of $1,000 using the relative fair value method to be amortized as interest expense over the term of the loan using the straight-line method.

 

Total discounts recorded including the original issue discount wer approximately $35,000.

 

For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $2,900 and $5,700 in interest expense including approximately $100 and $700 related to the amortization of debt issuance costs, respectively. For the three and nine-month period ended September 30, 2021, the Company recognized $5,600 and $34,000 related to the amortization of debt discount. No interest expense or debt discount was recognized for the same period of 2020.

 

As of September 30, 2021, the Company has outstanding principal of $52,778 on the note, has recorded approximately $5,000 of accrued interest. As of September 30, 2021, the debt discount and issuance costs on the note were fully amortized.

 

As of September 30, 2021, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this Note. The 25% premium will be recorded once a demand occurs

 

 

Secured Convertible Promissory Note – April 2021

 

On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $66,667, for a purchase price of $60,000 net of an original discount of $6,667. Additionally, the Company issued to the investor 800,000 five-year warrants to purchase the Company’s common stock at an exercise price of $0.095 per share. The warrants have full ratchet protection.

 

The note matured on October 12, 2021, Interest accrues on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on-the-basis of a 360-day year.

 

The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $0.075 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price shall also be adjusted upon subsequent equity sales by the Company. The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

The Company recorded a discount related to the warrants of approximately $34,000, which includes approximately $3,700 of OID discount allocated under the relative fair value method, and a remaining discount related to the OID of $3,000 based on the relative fair value of the instruments. The fair value of the warrants on which the relative fair value is based was determined by using the Black-Scholes valuation model. The assumptions used in the Black-Scholes model were a risk-free rate of 0.89%, volatility of 240.64%, and an expected term of one year in calculating the fair value of the warrants.

 

On June 25, 2021, the exercise price of the warrants was adjusted to $0.075 and the Company issued an additional 88,893 warrants to the note holder. The Company recorded approximately $11,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.92%, volatility of 247.52%, and expected term of 0.96 years in calculating the fair value of the warrants.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $19,000 and $35,000, respectively related to the amortization of debt discount. For the three and nine-month periods ended September 30, 2021, the Company recognized approximately $1,700 and $3,200 in interest expense, respectively. No interest expense or debt discount was recognized for the same period of 2020.

 

As of September 30, 2021, the Company has recorded $66,667 of principal and approximately $2,400 of unamortized debt discount and $3,200 of accrued interest for the note on the accompanying balance sheet.

 

On October 12, 2021, the Company defaulted on the note and the interest rate on the note reset to 18% per annum. Upon default, and upon demand for repayment at the election of the holder, the holder of the note is due 125% of the aggregate of outstanding principal, interest, and other expenses due in respect of this note. The 25% premium will be recorded once a demand occurs

 

Secured Convertible Promissory Note – June 2021

 

On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5% original issue discounted Senior Secured Convertible Promissory Note with a principal amount of $66,500, for a purchase price of $63,000, net of an original issue discount of $3,500. Additionally, the Company issued to the investor 800,000 three-year warrants to purchase the Company’s common stock at an exercise price of $0.095 per share. Upon subsequent down-round equity sales by the Company, the number of shares issuable upon exercise of the Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain $76,000 which is a full ratchet price protection provision

 

The note matures on June 25, 2022, or such earlier date as the note is required or permitted to be repaid. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10% per annum, calculated on the basis of a 365-day year.

 

The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $0.075 (as adjusted for stock splits, stock combinations and similar events); provided, however that in the event, the Company’s Common Stock trades below $0.08 per share for more than three (3) consecutive trading days, the Holder of this Note is entitled, at its option, to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock equal to 65% of the lowest trading price of the Common Stock for the twenty prior trading days including the day upon which a Notice of Conversion is received. The conversion discount, look back period and other terms of the Note will be adjusted on a ratchet basis if the Company offers a more favorable conversion discount, prepayment rate, interest rate, (whether through a straight discount or in combination with an original issue discount), look back period or other more favorable term to another party for any financings while this Note is in effect

 

 

The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

 

The Company incurred approximately $9,300 in debt issuance costs.

 

The company also issued 47,547 shares of common stock as a commission fee to the investment banker. The fair value of the common stock which was approximately $5,040 was recorded as debt issuance expense.

 

Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $102,823 with $87,039 charged to derivative expense and $15,784 recorded as a debt discount.

 

Total discounts recorded were $66,500. The Company recorded an original issue discount of $3,500, a discount of $9,300 for issuance costs, a discount related to the warrants of approximately $37,916 and a discount related to the derivative of $15,784 based on the relative fair value of the instruments. The warrant fair value on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.48%, volatility of 302.11%, and an expected term of 0.60 years in calculating the fair value of the warrants.

 

On August 11, 2021, the exercise price of the warrants was adjusted to $0.075 and the Company issued an additional 213,333 warrants to the note holder. The Company recorded approximately $25,000 as a deemed dividend upon the repricing based upon the change in fair value of the warrants using a binomial valuation model. The Company used a risk-free rate of 0.81, volatility of 209%, and expected term of 0.57 years in calculating the fair value of the warrants.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $13,000 and $18,000 to the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $4,000 in interest expense. No interest expense or debt discount was recognized for the same period of 2020.

 

At September 30, 2021, the Company has recorded $66,500 of outstanding principal and approximately $4,000 of accrued interest and $49,000 of unamortized discount and issuance expenses.

 

Convertible Promissory Note – August 11, 2021

 

On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $220,500 and warrants to purchase 800,000 shares of the common stock of the Company for which the Company received consideration of $210,000 net of an original issued discount of $10,500. In addition, the Company entered into a Registration Rights Agreement with the investor and issued the investor 100,000 common shares as a commitment fee.

 

The note matures one year from issuance and provides for an interest rate of 10% per annum, payable at maturity, and is convertible into common stock of the Company at a price of $0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date.

 

In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.

 

 

The Warrants are initially exercisable for a period of three years at a price of $0.095 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant.

 

The Company incurred approximately $30,000 in debt issuance costs.

 

The Company also issued 140,000 shares of common stock to the investment banker as a commission on the note.

 

Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $340,893 with $234,388 charged to derivative expense and $106,505 recorded as a debt discount.

 

The Company recorded a total debt discount of $220,500 including an original issue discount of $10,500, a discount related to the warrants of approximately $56,454 a discount related to issuance costs of $30,000 and a discount related to the issuance of common stock of approximately $17,041, and a $106,505 discount related to the initial derivative value of the embedded conversion feature on the note all based on the relative fair value of the instruments,

 

The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81%, volatility of 253%, and an expected term of one year in calculating the fair value of the warrants. The discounts are being amortized over the term of the convertible note.

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $30,810 for the amortization of the debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $3,000 in interest expense.

 

At September 30, 2021, the Company has remaining $220,500 of outstanding principal and approximately $3,000 of accrued interest and $190,000 of unamortized discount.

 

Convertible Promissory Note – August 17, 2021

 

On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the Buyer its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $220,500 and warrants to purchase 800,000 shares of the common stock of the Company for which the Company received consideration of $210,000 net of original discount of $10,500. In addition, the Company entered into a Registration Rights Agreement with the Buyer and issued the Buyer 100,000 common shares as a commitment fee.

 

The note matures one year from issuance and provides for an interest rate of 10% per annum, payable at maturity, and is convertible into common stock of the Company at a price of $0.075 per share, subject to anti-dilution adjustments in the event of certain corporate events as set forth in the Note, provided that if the average closing price of the Company’s common stock during any three consecutive trading days is below $0.08, the conversion price shall be reduced to 65% of the lowest trading price during the 20 consecutive trading days immediately preceding the conversion date. The embedded conversion option will be treated as a bifurcated derivative liability.

 

In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold.

 

 

The Warrants are initially exercisable for a period of three years at a price of $0.095 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant

 

The Company incurred approximately $30,000 in debt issuance costs. The Company also issued 112,601 shares of common stock to the investment banker as a commission on the note.

 

Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $398,404 with $297,833 charged to derivative expense and $100,571 recorded as a debt discount.

 

The Company recorded a total debt discount of $220,500 including an original issue discount of $10,500, a discount related to the warrants of approximately $62,220 a discount related to issuance costs of $30,000 a discount related to the issuance of common stock of approximately $17,209, and a $100,571 discount related to the initial derivative value of the embedded conversion feature on the Note all based on the relative fair value of the instruments.

 

The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77%, volatility of 254%, and an expected term of one year in calculating the fair value of the warrants. The discounts are being amortized over the life of the convertible note.

 

At September 30, 2021, the Company has recorded $220,500 of outstanding principal and approximately $3,000 of accrued interest and $193,000 of unamortized discount and issuance expenses.

 

Derivative Liabilities Pursuant to Convertible Notes and Warrants

 

In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion option to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. In accordance with ASC 815-40 –Derivatives and Hedging – Contracts in an Entity’s Own Stock, the embedded conversion option contained in the Notes and Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion options was determined using the Binomial Lattice valuation model. At the end of each period and on note conversion date or repayment, the Company revalues the derivative liabilities resulting from the embedded option.

 

During the nine months ended September 30, 2021, in connection with the issuance of the Notes and Warrants, on the initial measurement dates, the fair values of the embedded conversion options of $842,120 was recorded as derivative liabilities of which $222,860 was allocated as a debt discount and $619,260 as derivative expense.

 

At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with these revaluations, the Company recorded a loss from the change in the derivative liabilities fair value of approximately $3.1 million for the nine months ended September 30, 2021.

 

During the nine months ended September 30, 2021, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2021, using the Binomial Lattice valuation model with the following assumptions:

 

Dividend rate   —%
Term (in years)   0.01 to 1 year 
Volatility   247% to 412%
Risk-free interest rate   0.07% to 0.87%

 

For the three and nine-month period ended September 30, 2021, the Company recognized approximately $27,000 for the amortization of debt discount. For both the three and nine-month periods ended September 30, 2021, the Company recognized approximately $3,000 in interest expense.

 
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Licensing Agreements
 9 Months Ended
Sep. 30, 2021
Licensing Agreements  
Licensing Agreements

Note 3 - Licensing Agreements

 

Les Laboratories Servier

 

As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia® in the U.S. (and its territories and possessions).

 

On January 4, 2021, the licensor terminated the licensing agreement with the Company for the commercialization of Prestalia®.

 

No royalties were paid for the three or nine-month periods ended September 30, 2020, or 2021.

 

Novosom Agreements

 

In 2010, the Company entered into an asset purchase agreement with Novosom Verwaltungs GmbH (“Novosom”), pursuant to which the Company acquired intellectual property for Novosom’s SMARTICLES-based liposomal delivery system. In May 2018, the Company issued to Novosom 51,988 shares of our common stock, with a fair value of $75,000, as additional consideration pursuant to the Asset Purchase Agreement. Such shares were due to Novosom as a result of the receipt by our company of a license fee under the License Agreement that we entered into with Lipomedics Inc. in February 2017. On December 23, 2019, Novosom repurchased the acquired intellectual property for $45,000 of which $20,000 was payable upon execution of the agreement and $25,000 was to be paid upon the Company’s achievement of certain performance obligations by September 30, 2020.

 

The Company recognized $5,000 and $45,000 as other income from the agreement for the three and nine-month periods ended September 30, 2020, respectively.

 

 

License of DiLA2 Assets

 

On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $200,000 and future additional consideration for sales and development milestones. The upfront fee was contingent upon the Company obtaining a third-party consent to the agreement within ninety days of execution. As of September 30, 2021, and December 31, 2020, the Company had not obtained consent for the sublicense and has classified the upfront payment it had previously recorded as an accrued liability on its balance sheet.

 
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
 9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 4 - Related Party Transactions

 

Due to Related Party

 

The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.

 

The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018.

 

An unpaid balance for previous years services performed under the agreement of approximately $4,000 is included in due to related party in the accompanying consolidated balance sheets at September 30, 2021, and December 31, 2020.

 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 5 - Stockholders’ Equity

 

Preferred Stock

 

Adhera has authorized 100,000 shares of preferred stock for issuance and has designated 1,000 shares as Series B Preferred Stock (“Series B Preferred”) and 90,000 shares as Series A Junior Participating Preferred Stock (“Series A Preferred”). No shares of Series A Preferred or Series B Preferred are outstanding. In March 2014, Adhera designated 1,200 shares as Series C Convertible Preferred Stock (“Series C Preferred”). In August 2015, Adhera designated 220 shares as Series D Convertible Preferred Stock (“Series D Preferred”). In April 2018, Adhera designated 3,500 shares of Series E Convertible Preferred Stock (“Series E Preferred”). In July 2018, Adhera designated 2,200 shares of Series F Convertible Preferred Stock (“Series F Preferred”). In December 2019, Adhera designated 6,000 shares of Series G Convertible Preferred Stock (“Series G Preferred”). The Company plans to file a certificate of elimination with respect to the Series B stock and a certificate of decrease with respect to each of its Series C, D and F Preferred stock.

 

Series C Preferred

 

Each share of Series C Preferred has a stated value of $5,000 per share, has a $5,100 liquidation preference per share, has voting rights of 666.67 votes per share, and is convertible into shares of common stock at a conversion price of $7.50 per share.

 

As of September 30, 2021, and December 31, 2020, 100 shares of Series C Preferred stock were outstanding.

 

Series D Preferred

 

Each share of Series D Preferred has a stated value of $5,000 per share, has a liquidation preference of $300 per share, has voting rights of 1,250 votes per share and is convertible into shares of common stock at a conversion price of $4.00 per share. The Series D Preferred has a 5% stated dividend rate when, and if declared by the Board of Directors, is not redeemable and has voting rights on an as-converted basis.

 

 

As of September 30, 2021, and December 31, 2020, 40 shares of Series D Preferred were outstanding.

 

Series E Convertible Preferred Stock and Warrants

 

The Series E Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series E Preferred stock is convertible into shares of common stock at $0.50. Anti-dilution price protection on Series E Preferred stock expired on February 10, 2020. Warrants issued with Series E Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.

 

On March 19, 2021, the exercise price of the Series E warrants was adjusted from $0.50 to $0.05 per share upon the conversion of $25,900 debt for 518,000 shares common stock. The Company recorded approximately $390,000 as a deemed dividend based upon the change in fair value of the Series E Preferred stock warrants using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and expected term of .41 to .43 years in calculating the fair value of the warrants.

 

As of May 17, 2021, the three-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders.

 

On June 8, 2021, an investor converted 8 shares of Series E Preferred and accrued dividends of approximately $10,000 into 101,010 shares of common stock. In addition, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants.

 

On July 30, 2021, and investor converted 50 shares of Series E Preferred stock with a state value of $250,000 into 500,000 shares of common stock.

 

As of September 30, 2021, the Company had a total of 30,405,600 warrants issued with Series E Preferred stock outstanding. The warrants expire in 2023.

 

The Company had accrued dividends on the Series E Preferred stock of approximately $4,756,000 and $3.7 million, as of September 30, 2021, and December 31, 2020, respectively.

 

At September 30, 2021 and December 31, 2020, there were 3,400 and 3,458 Series E shares outstanding, respectively.

 

Series F Convertible Preferred Shares and Warrants

 

The Series F Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series F Preferred stock is convertible into shares of common stock at $0.50. Anti-dilution price protection on Series F Preferred stock expired on February 10, 2020. The Series F Preferred stock includes a mandatory conversion feature on November 9, 2021, which is the three-year anniversary of the closing of the issuance. Warrants issued with Series F Convertible Preferred Stock have anti-dilution price protection, are exercisable for a period of five years, and contain customary exercise limitations.

 

On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $100,000 by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.

 

On March 19, 2021, the exercise price of the Series F warrants was adjusted from $0.50 to $0.05 upon the conversion of $25,900 of debt for 518,000 shares of common stock. The Company recorded approximately $31,000 as a deemed dividend based upon the change in fair value of the Series F Preferred stock using a binomial valuation model. The Company used a risk-free rate of 0.16%, volatility of 262.27%, and an expected term of .46 to .53 years in calculating the fair value of the warrants.

 

As of September 30, 2021, the Company had a total of 3,088,500 Series F Preferred stock warrants outstanding. The warrants expire in 2023.

 

The Company had accrued dividends on the Series F Preferred stock of approximately $455,000 and $347,000, as of September 30, 2021, and December 31, 2020, respectively.

 

At September 30, 2021 and December 31, 2020, there were 361 Series F Preferred shares outstanding.

 

 

Series G Convertible Preferred Shares

 

The Series G Preferred Stock has a stated value of $5,000 per share and accrues 8% dividends per annum that are payable in cash or stock at the Company’s discretion. The Series G Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights. Series G Preferred stock is convertible into shares of common stock at $0.50.

 

As of September 30, 2021, no Series G Preferred Stock has been issued by the Company.

 

Common Stock

 

On March 19, 2021, the Company issued 518,000 unregistered shares of common stock to the holder of the January 2020 convertible note for conversion of $25,900 in accrued interest.

 

On June 8, 2021, an investor converted 8 shares of Series E Preferred and accrued dividends of approximately $10,000 into 101,010 shares of common stock. In addition, the Company issued 53,571 shares of common stock to the investor for a cashless exercise of 75,000 warrants.

 

On July 30, 2021, and investor converted 50 shares of Series E Preferred stock with a stated value of $250,000 into 500,000 shares of common stock.

 

On August 11, 2021, the Company issued 100,000 shares of common stock to a convertible note investor as a commitment fee which was valued at it relative fair value of $56,464.

 

On August 18, 2021, the Company issued 100,000 shares of common stock to a convertible note investor as a commitment fee which was valued at its relative fair value of $62,220.

 

On September 22, 2021, the Company issued 300,148 shares of common stock to an investment banker for commissions due under a banking agreement. The shares were recorded at their relative fair value of approximately $39,290.

 

During the three-month period ending September 30, 2021 the company issued 1.7 million common shares upon the conversion of $50,855 principal and $34,155 accrued interest on the February 2020 convertible note.

 

The common shares issued upon conversions of convertible notes for the nine months ended September 30,2021 were valued at fair value based on the quoted trading prices on the conversion dates aggregating $379,422 resulting in a loss on debt extinguishment of $268,522.

 

Warrants

 

As of September 30, 2021, there were 61,306,350 warrants outstanding, with a weighted average exercise price of $0.07 per share, and annual expirations as follows:

 

Warrant Summary:                    
   Shares   2023   2024   2025   2026 
Series E Preferred    30,405,600    30,405,600                
Series F Preferred   3,088,500    3,088,500                
Convertible Notes   27,463,517         1,013,333    22,905,731    3,544,453 
Other   348,733    10,080    335,452    3,201      
Total Warrants   61,306,350    33,504,180    1,348,785    22,908,932    3,544,453 

 

The above includes 60,957,617 price adjustable warrants.

 

A total of 343,750 warrants expired during the period. There were 75,000 Series E warrants exercised as of September 30, 2021 on a cashless basis.

 
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Incentive Plans
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock Incentive Plans

Note 6 - Stock Incentive Plans

 

Stock Options

 

The following table summarizes stock option activity for the Nine months ended September 30, 2021.

 

   Options Outstanding 
   Shares  

Weighted

Average

Exercise Price

 
Outstanding, December 31, 2020   391,350   $0.58 
Options granted   —    — 
Options expired / forfeited   (3,800)   2.60 
Outstanding, September 30, 2021   387,550    0.99 
Exercisable, September 30, 2021   387,550   $0.99 

 

 

The following table summarizes additional information on stock options outstanding as of September 30, 2021.

 

      Options Outstanding    Options Exercisable 
 Range of Exercise Prices     Number Outstanding    Weighted- Average Remaining Contractual Life (Years)    Weighted Average Exercise Price    Number Exercisable    Weighted Average Exercise Price 
$0.98 - $1.00      383,500    1.57   $0.98    383,500   $0.98 
$1.70    4,050    .27   $1.70    4,050   $1.70 
                           
 Totals    387,550    1.56   $0.99    387,550   $0.99 

 

During the nine months ended September 30, 2021, the Company granted no stock options.

 

Total expense related to stock options was approximately $8,000 for the nine months ended September 30, 2020, respectively. No stock-based compensation expense was recognized for the nine-month period ended September 30, 2021.

 

As of September 30, 2021, the Company had no unrecognized compensation expense related to unvested stock options.

 

As of September 30, 2021, the intrinsic value of stock options outstanding was zero.

 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 7 - Commitments and Contingencies

 

Litigation

 

Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors.

 

Leases

 

The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs.

 

Share Repurchase Agreement

 

On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants held by such officer for $100,000 by not later than March 1, 2020. As of September 30, 2021, the Company had not repurchased the remaining shares.

 

Licensing Agreement– MLR 1019

 

On July 28, 2021, the Company and Melior Pharmaceuticals II, LLC (“MP”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $21,750,000 upon meeting certain performance milestones, as well as a royalty of 5% of gross sales.

 

The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to get its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using MP’s data shall terminate. Additionally, if the Company has completed the necessary steps to affect an Uplisting Event, the Company will have the option to purchase the all rights held by MP on the MLR-1019 licensed products in consideration for 10% of the outstanding shares of the Company’s common stock (immediately post Uplisting Event) and 2.5% royalty of future gross product sales.

 

As of September 30, 2021, no performance milestones had been met.

 

Licensing Agreement – MLR 1023

 

On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. for the development, commercialization and exclusive license of Melior’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes.

 

Under the Agreement, the Company was granted an exclusive license to use the MP Patents and know-how to develop products in consideration for cash payments up to $21,750,000 upon meeting certain performance milestones, as well as a tiered royalty of 8-12% of gross sales.

 

If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.

 
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 8 - Subsequent Events

 

Except for the events discussed below, there were no subsequent events that required recognition or disclosure.

 

Issuance of Common Stock

 

On October 4, 2021, the Company issued 525,000 shares of common stock upon the conversion of $26,250 of principal and interest on the January 2020 convertible note.

 

Secured Note Default

 

On July 30, 2021, the Company defaulted under the Secured Convertible Promissory Note from January 2021 and the interest rate on the note reset to 18%.

 

 

Issuance of Common Stock

 

On October 4, 2021, the Company issued 255,540 shares of common stock upon the conversion of 20 shares Series E Preferred stock and accrued dividends.

 

Issuance of Common Stock

 

On October 15, 2021, the Company issued 37,043 shares of common stock upon the conversion of 3 shares of Series F Preferred stock and accrued dividends.

 

Issuance of a Convertible Note

 

On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received consideration of $110,000. In addition, the Company issued 59,523 shares of common stock as a commitment fee to the Buyer.

 

The Note is due October 5, 2022. The Note provides for guaranteed interest at the rate of 10% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $0.075 per share, subject to certain adjustments.

 

The Warrants are exercisable for three-years from October 5, 2021, at an exercise price of $0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $45,238.05. The company will record a debt discount related to the relative fair value of the warrants.

 

Issuance of a Convertible Note

 

On October 13, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $131,250 and a three-year warrant to purchase 476,190 shares of common stock of the Company for which the Company received consideration of $110,000. In addition, the Company issued 59,523 shares of common stock as a commitment fee to the Buyer.

 

The Note is due October 7, 2022. The Note provides for guaranteed interest at the rate of 10% per annum, payable at maturity. The Note is convertible into shares of common stock at any time following the date of cash payment at the Buyer’s option at a conversion price of $0.075 per share, subject to certain adjustments.

 

The Warrants are exercisable for three-years from October 7, 2021, at an exercise price of $0.095 per share, subject to certain adjustments, which exercise price may be paid on a cashless basis. The aggregate exercise price is $45,238.05. The company will record a debt discount related to the relative fair value of the warrants.

 

Extension of Notes Maturity Date

 

On October 27, 2021, the Company and the institutional investor who holds two convertible promissory notes agreed to extend the maturity date of each of the Notes by six months. The $220,500 Note issued in August 2021 had its maturity date extended to February 17, 2023, and the $66,500 Note issued in June 2021 had its maturity date extended to December 25, 2022.

 

Issuance of Common Stock

 

On November 4, 2021, the Company issued 153,227 shares of common stock upon a cashless exercise of 250,000 warrants issued with the April 2021 Convertible Note.

 

Licensing Agreement MLR-1023 Amendment

 

On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Reclassification

Reclassification

 

Certain reclassifications have been made to prior periods consolidated statements of operations including adjustments related to the adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to conform to current period presentation. These reclassifications had no material effect on prior periods consolidated net loss or stockholders’ deficit.

 
Use of Estimates

Use of Estimates

 

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.

 

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

 

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
   
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
   
Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

 

As of September 30, 2021, the Company measured conversion features on outstanding convertible notes as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $3.5 million. The value of the derivative liability as of September 30, 2021 was determined by using the binomial lattice model using the following inputs: 0.09% risk free rate, volatility of 404% and time to maturity of 0 - .18 years. There were no liabilities or assets measured at fair value on a non-recurring basis as of September 30, 2021, and there were no liabilities or assets measured at fair value on a reoccurring or non-recurring basis as of December 31, 2020.

 

(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at September 30, 2021 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liability  $-   $-   $3,475   $3,475 
Total  $-   $-   $3,475   $3,475 

 

A roll forward of the level 3 valuation financial instruments is as follows:

 

                
  

Nine months Ended

September 30, 2021		 
(In thousands)  Warrants   Notes   Total 
Balance at December 31, 2020  $—   $—   $— 
Initial valuation of derivative liabilities included in debt discount   —    223    223 
Initial valuation of derivative liabilities included in derivative expense   —    619    619 
Reclassification of derivative liabilities to gain on debt extinguishment   —    (92)   (92)
Reclass from Additional paid-in capital   46    244   290
Change in fair value included in derivative expense   361    2,074    2,435 
Balance at September 30, 2021  $407   $3,068   $3,475 

 

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments.

 
Convertible Debt and Warrant Accounting

Convertible Debt and Warrant Accounting

 

Debt with warrants

 

In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”),the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

Convertible debt – derivative treatment

 

When the Company issues debt with a conversion feature, it first assess whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet that requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position.

 

 

Convertible debt – beneficial conversion feature

 

Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) on January 1, 2021, if the conversion feature was not treated as a derivative, the Company assessed whether it is a beneficial conversion feature (“BCF”). A BCF exists if the effective conversion price of the convertible debt instrument is less than the stock price on the commitment date. This typically occurs when the conversion price is less than the fair value of the stock on the date the instrument was issued. The value of a BCF is equal to the intrinsic value of the feature, the difference between the conversion price and the common stock into which it is convertible and is recorded as additional paid in capital and as a debt discount in the consolidated balance sheets. The Company amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations.

 

If the conversion feature does not qualify for either the derivative treatment or as a BCF, the convertible debt is treated as traditional debt.

 
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

Recently Adopted

 

In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements.

 

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements.

 

Not Yet Adopted

 

In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic:

 

1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument.
   
2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows:
       
  a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider:
       
    i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments.
       
    ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50.
       
  b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged.
       
3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows:
       
  a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs.
     
  b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest.
       
  c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation.

 

An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction.

 

The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is evaluating the impact of the revised guidance and believes that it will not have a significant impact on its financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 
Net Loss per Common Share

Net Loss per Common Share

 

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.

 

 

The following table presents the computation of net loss per share (in thousands, except share and per share data):

 

   2021   2020   2021   2020 
  

Three Months Ended

September 30,

   Nine Months Ended

September 30,

 
   2021   2020   2021   2020 
Numerator                
Net loss  $(3,739)  $(539)  $(4,682)  $(3,283)
Dividends   (406)   (388)   (1,679)   (1,153)
Net Loss allocable to common stockholders  $(4,145)  $(927)  $(6,361)  $(4,436)
Denominator                    
Weighted average common shares outstanding used to compute net loss per share, basic and diluted   12,986,391    10,869,530    11,742,315    10,869,530 
Net loss per share of common stock, basic and diluted                    
Net loss per share  $(0.32)  $(0.09)  $(0.54)  $(0.41)

 

Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:

 

   2021   2020 
Convertible Notes   24,332,784    23,690,018 
Stock options outstanding   387,550    1,216,350 
Warrants   61,306,350    69,047,000 
Series C Preferred Stock   66,667    66,667 
Series D Preferred Stock   50,000    50,000 
Series E Preferred Stock   43,514,922    41,597,256 
Series F Preferred Stock   4,519,872    4,230,973 
Total   134,178,046    139,898,264 

 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of Fair Value Measurements

 

(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
   Fair Value Measurements at September 30, 2021 
   Quoted Prices in Active Markets for Identical Assets   Other Observable Inputs   Significant Unobservable Inputs     
(in thousands)  (Level 1)   (Level 2)   (Level 3)   Total 
Derivative liability  $-   $-   $3,475   $3,475 
Total  $-   $-   $3,475   $3,475 
Schedule of Roll Forward of Level 3 Financial Instruments

A roll forward of the level 3 valuation financial instruments is as follows:

 

                
  

Nine months Ended

September 30, 2021		 
(In thousands)  Warrants   Notes   Total 
Balance at December 31, 2020  $—   $—   $— 
Initial valuation of derivative liabilities included in debt discount   —    223    223 
Initial valuation of derivative liabilities included in derivative expense   —    619    619 
Reclassification of derivative liabilities to gain on debt extinguishment   —    (92)   (92)
Reclass from Additional paid-in capital   46    244   290
Change in fair value included in derivative expense   361    2,074    2,435 
Balance at September 30, 2021  $407   $3,068   $3,475 
Schedule of Earnings Per Share, Basic and Diluted

The following table presents the computation of net loss per share (in thousands, except share and per share data):

 

   2021   2020   2021   2020 
  

Three Months Ended

September 30,

   Nine Months Ended

September 30,

 
   2021   2020   2021   2020 
Numerator                
Net loss  $(3,739)  $(539)  $(4,682)  $(3,283)
Dividends   (406)   (388)   (1,679)   (1,153)
Net Loss allocable to common stockholders  $(4,145)  $(927)  $(6,361)  $(4,436)
Denominator                    
Weighted average common shares outstanding used to compute net loss per share, basic and diluted   12,986,391    10,869,530    11,742,315    10,869,530 
Net loss per share of common stock, basic and diluted                    
Net loss per share  $(0.32)  $(0.09)  $(0.54)  $(0.41)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:

 

   2021   2020 
Convertible Notes   24,332,784    23,690,018 
Stock options outstanding   387,550    1,216,350 
Warrants   61,306,350    69,047,000 
Series C Preferred Stock   66,667    66,667 
Series D Preferred Stock   50,000    50,000 
Series E Preferred Stock   43,514,922    41,597,256 
Series F Preferred Stock   4,519,872    4,230,973 
Total   134,178,046    139,898,264 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable (Tables)
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Convertible Promissory Notes

The following table summarizes the Company’s outstanding convertible notes as of September 30, 2021, and December 31, 2020:

 

(in thousands)  September 30, 2021   December 31, 2020 
Convertible Notes  $1,296   $720 
Unamortized discounts   (434)   (79)
Convertible Notes Payable  $862   $641 
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode

During the nine months ended September 30, 2021, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2021, using the Binomial Lattice valuation model with the following assumptions:

 

Dividend rate   —%
Term (in years)   0.01 to 1 year 
Volatility   247% to 412%
Risk-free interest rate   0.07% to 0.87%
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights

 

Warrant Summary:                    
   Shares   2023   2024   2025   2026 
Series E Preferred    30,405,600    30,405,600                
Series F Preferred   3,088,500    3,088,500                
Convertible Notes   27,463,517         1,013,333    22,905,731    3,544,453 
Other   348,733    10,080    335,452    3,201      
Total Warrants   61,306,350    33,504,180    1,348,785    22,908,932    3,544,453 
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Incentive Plans (Tables)
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Arrangement, Option, Activity

The following table summarizes stock option activity for the Nine months ended September 30, 2021.

 

   Options Outstanding 
   Shares  

Weighted

Average

Exercise Price

 
Outstanding, December 31, 2020   391,350   $0.58 
Options granted   —    — 
Options expired / forfeited   (3,800)   2.60 
Outstanding, September 30, 2021   387,550    0.99 
Exercisable, September 30, 2021   387,550   $0.99 
Schedule of Share-based Payment Arrangement, Option, Exercise Price Range

The following table summarizes additional information on stock options outstanding as of September 30, 2021.

 

      Options Outstanding    Options Exercisable 
 Range of Exercise Prices     Number Outstanding    Weighted- Average Remaining Contractual Life (Years)    Weighted Average Exercise Price    Number Exercisable    Weighted Average Exercise Price 
$0.98 - $1.00      383,500    1.57   $0.98    383,500   $0.98 
$1.70    4,050    .27   $1.70    4,050   $1.70 
                           
 Totals    387,550    1.56   $0.99    387,550   $0.99 
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Fair Value Measurements (Details)
$ in Thousands
Sep. 30, 2021
USD ($)
Defined Benefit Plan Disclosure [Line Items]  
Derivative liability $ 3,475
Total 3,475
Fair Value, Inputs, Level 1 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]  
Defined Benefit Plan Disclosure [Line Items]  
Derivative liability 3,475
Total $ 3,475
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Roll Forward of Level 3 Financial Instruments (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
USD ($)
Short-term Debt [Line Items]  
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount 223
Initial valuation of derivative liabilities included in derivative expense 619
Reclassification of derivative liabilities to gain on debt extinguishment (92)
Reclass from Additional paid-in capital 290
Change in fair value included in derivative expense 2,435
Balance at September 30, 2021 3,475
Warrants [Member]  
Short-term Debt [Line Items]  
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount
Initial valuation of derivative liabilities included in derivative expense
Reclassification of derivative liabilities to gain on debt extinguishment
Reclass from Additional paid-in capital 46
Change in fair value included in derivative expense 361
Balance at September 30, 2021 407
Convertible Notes [Member]  
Short-term Debt [Line Items]  
Balance at December 31, 2020
Initial valuation of derivative liabilities included in debt discount 223
Initial valuation of derivative liabilities included in derivative expense 619
Reclassification of derivative liabilities to gain on debt extinguishment (92)
Reclass from Additional paid-in capital 244
Change in fair value included in derivative expense 2,074
Balance at September 30, 2021 $ 3,068
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Accounting Policies [Abstract]                
Net loss $ (3,739) $ (514) $ (428) $ (539) $ (906) $ (1,838) $ (4,682) $ (3,283)
Dividends (406)     (388)     (1,679) (1,153)
Net Loss allocable to common stockholders $ (4,145)     $ (927)     $ (6,361) $ (4,436)
Weighted average common shares outstanding used to compute net loss per share, basic and diluted 12,986,391     10,869,530     11,742,315 10,869,530
Net loss per share $ (0.32)     $ (0.09)     $ (0.54) $ (0.41)
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 134,178,046 139,898,264
Convertible Notes Payable [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 24,332,784 23,690,018
Stock Options Outstanding [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 387,550 1,216,350
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 61,306,350 69,047,000
Series C Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 66,667 66,667
Series D Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 50,000 50,000
Series E Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 43,514,922 41,597,256
Series F Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 4,519,872 4,230,973
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)
 9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Cash and Cash Equivalents, at Carrying Value $ 151,000  
Working capital 20,200,000  
Net loss 4,700,000  
Accumulated deficit $ 51,000,000.0  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0.09%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 404.00%  
Fair Value, Net Asset (Liability) $ 0 $ 0
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 0 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term 18 years  
Fair Value, Inputs, Level 3 [Member]    
Property, Plant and Equipment [Line Items]    
Long-term Debt, Fair Value $ 3,500,000  
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Convertible Promissory Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Debt Disclosure [Abstract]    
Convertible Notes $ 1,296 $ 720
Unamortized discounts (434) (79)
Convertible Notes Payable $ 862 $ 641
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details)
Sep. 30, 2021
Measurement Input, Expected Dividend Rate [Member]  
Debt Instrument [Line Items]  
Derivative Liability, Measurement Input 0
Measurement Input, Expected Term [Member] | Minimum [Member]  
Debt Instrument [Line Items]  
Long-term Debt, Term 3 days
Measurement Input, Expected Term [Member] | Maximum [Member]  
Debt Instrument [Line Items]  
Long-term Debt, Term 1 year
Measurement Input, Price Volatility [Member] | Minimum [Member]  
Debt Instrument [Line Items]  
Derivative Liability, Measurement Input 247,000
Measurement Input, Price Volatility [Member] | Maximum [Member]  
Debt Instrument [Line Items]  
Derivative Liability, Measurement Input 4.12
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]  
Debt Instrument [Line Items]  
Derivative Liability, Measurement Input 0.07
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]  
Debt Instrument [Line Items]  
Derivative Liability, Measurement Input 0.0087
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable (Details Narrative)
 3 Months Ended 9 Months Ended
Oct. 12, 2021
Sep. 13, 2021
USD ($)
shares
Aug. 17, 2021
USD ($)
$ / shares
shares
Aug. 16, 2021
USD ($)
shares
Aug. 11, 2021
USD ($)
$ / shares
shares
Jul. 31, 2021
Jul. 29, 2021
USD ($)
shares
Jun. 25, 2021
USD ($)
$ / shares
shares
Apr. 12, 2021
USD ($)
$ / shares
shares
Mar. 19, 2021
USD ($)
Integer
$ / shares
shares
Jan. 31, 2021
USD ($)
$ / shares
shares
Oct. 30, 2020
USD ($)
$ / shares
shares
Sep. 24, 2020
$ / shares
Aug. 05, 2020
Jun. 26, 2020
USD ($)
Jun. 15, 2020
May 05, 2020
$ / shares
Feb. 05, 2020
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
Apr. 30, 2021
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 28, 2019
Short-term Debt [Line Items]                                                      
Convertible notes payable, current                                     $ 862,000     $ 862,000     $ 641,000    
Debt discount to be amortized                                     434,000     434,000     $ 79,000    
Amortization of debt discount                                           230,000 $ 765,000        
Loss on extinguishment of debt                                     $ 177,000   $ 177,000        
Conversion of convertible debt                                       $ 26,000              
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger                       70.00%                              
Class of warrant or right, exercise price of warrants or rights | $ / shares                                     $ 0.07     $ 0.07          
Derivative expense                                     $ 2,968,000   $ 3,055,000        
[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount]                                           223,000          
[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense]                                           619,000          
Senior Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                       $ 111,111             $ 111,111     $ 111,111          
Debt instrument, interest rate                       10.00%             125.00%     125.00%          
Debt instrument, effective percentage                       10.00%                       18.00%      
Interest expense                                     $ 5,000     $ 15,600          
Amortization of debt issuance costs                                     0     2,600          
Accured interest                                     13,000     13,000          
Convertible notes payable, current                       $ 100,000                 13,000   13,000        
Debt instrument, convertible, conversion price | $ / shares                   $ 0.05   $ 0.07                              
Warrant term                   11 months 1 day                                  
Amortization of debt discount                                     $ 0     $ 79,000          
Debt instrument, convertible, beneficial conversion feature                       $ 45,000                              
Convertible note, premimum description                                           The 25% premium will be recorded once a demand occurs          
Intrinsic value of the beneficial conversion feature                       69,000                              
Unamortized debt issuance expense                       $ 9,000                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares                   634,919   1,587,301                              
Class of warrant or right, exercise price of warrants or rights | $ / shares                       $ 0.08                              
Deemed dividend                   $ 57,000                                  
Senior Secured Convertible Promissory Note One [Member] | Valuation Technique, Option Pricing Model [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized                       $ 6,000                              
Unamortized debt issuance expense                       5,000                              
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs | Integer                   0.16                                  
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs | Integer                   262.27                                  
Conversion Feature [Member]                                                      
Short-term Debt [Line Items]                                                      
Derivative liability                                           $ 76,000          
Senior Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                     $ 52,778                                
Debt issuance costs, net                     $ 2,000                                
Debt instrument, effective percentage                     10.00%               125.00%     125.00%          
Interest expense                                     $ 2,900     $ 5,700          
Amortization of debt issuance costs                                     100     700          
Accured interest                                     5,000     5,000          
Convertible notes payable, current                     $ 47,500                                
Debt instrument, convertible, conversion price | $ / shares                   $ 0.05 $ 0.07                                
Warrant term                   11 months 19 days                                  
Debt discount to be amortized                     $ 2,000                                
Amortization of debt discount                                     5,600     $ 34,000          
Debt default interest rate           18.00%                                          
Convertible note, premimum description                                           The 25% premium will be recorded once a demand occurs          
Class of warrant or right, exercise price of warrants or rights | $ / shares                     $ 0.08                                
Deemed dividend                   $ 27,000                                  
Debt Instrument, Convertible, Conversion Ratio                     0.70                                
Warrants issued | shares                   301,592 753,968                                
Amotized interest expense                     $ 1,000                                
Debt Instrument, Unamortized Discount, Current                     35,000                                
Notes payable                                     52,778     $ 52,778          
Senior Secured Convertible Promissory Note Two [Member] | Investor and lender [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized                     5,278                                
Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs                   0.16                                  
Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs                   262.27                                  
Senior Secured Convertible Promissory Note Three [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                 $ 66,667                   66,667     66,667          
Debt instrument, interest rate 125.00%               10.00%                                    
Debt maturity date                 Oct. 12, 2021                                    
Debt instrument, effective percentage                 10.00%                                    
Interest expense                                     1,700     3,200          
Accured interest                                     3,200     3,200          
Convertible notes payable, current                 $ 60,000                                    
Debt instrument, convertible, conversion price | $ / shares                 $ 0.075                                    
Debt conversion rate                 70.00%                                    
Amortization of debt discount                 $ 3,000                   19,000     35,000          
Debt default interest rate 18.00%                                                    
Convertible note, premimum description The 25% premium will be recorded once a demand occurs                                                    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares                 800,000                                    
Class of warrant or right, exercise price of warrants or rights | $ / shares                 $ 0.095                                    
Debt Instrument, Unamortized Discount, Current                 $ 6,667                   2,400     2,400          
Class of Warrant or Right, Expense or Revenue Recognized                 five                                    
Senior Secured Convertible Promissory Note Four [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount               $ 66,500                     66,500     66,500          
Debt instrument, interest rate               10.00%                                      
Debt maturity date               Jun. 25, 2022                                      
Debt instrument, effective percentage               5.00%                                      
Interest expense                                     4,000     4,000          
Accured interest                                     4,000     4,000          
Debt instrument, convertible, conversion price | $ / shares               $ 0.075                                      
Debt conversion rate               65.00%                                      
Debt discount to be amortized               $ 5,040                     49,000     49,000          
Amortization of debt discount               15,784                     13,000     18,000          
Unamortized debt issuance expense               $ 9,300                                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares               800,000                                      
Class of warrant or right, exercise price of warrants or rights | $ / shares               $ 0.095                                      
Debt Instrument, Unamortized Discount, Current               $ 3,500                                      
Class of Warrant or Right, Expense or Revenue Recognized               three                                      
Secured Debt               $ 63,000                                      
Warrants and Rights Outstanding               $ 76,000                                      
Stock Issued During Period, Shares, New Issues | shares               47,547                                      
Derivative liabilities               $ 102,823                                      
Derivative expense               87,039                                      
Debt discount               $ 66,500                                      
Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount         $ 220,500                           220,500     220,500          
Debt issuance costs, net         $ 30,000                                            
Debt instrument, interest rate         10.00%                                            
Interest expense                                           3,000          
Accured interest                                     3,000     3,000          
Debt instrument, convertible, conversion price | $ / shares         $ 0.075                                            
Debt conversion rate         65.00%                                            
Debt discount to be amortized         $ 220,500                           190,000     190,000          
Amortization of debt discount         $ 106,505                                 30,810          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares         800,000                                            
Debt Instrument, Unamortized Discount, Current         $ 10,500                                            
Warrants and Rights Outstanding         $ 210,000                                            
Stock Issued During Period, Shares, New Issues | shares         140,000                                            
Derivative liabilities         $ 340,893                                            
Derivative expense         $ 234,388                                            
Debt term         1 year                                            
Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount     $ 220,500                               220,500     220,500          
Debt issuance costs, net     $ 30,000                                                
Debt instrument, interest rate     10.00%                                                
Interest expense                                           3,000          
Accured interest                                     3,000     3,000          
Debt instrument, convertible, conversion price | $ / shares     $ 0.075                                                
Debt conversion rate     65.00%                                                
Debt discount to be amortized     $ 220,500                               193,000     193,000          
Amortization of debt discount     $ 100,571                                     27,000          
Debt Conversion, Converted Instrument, Shares Issued | shares     112,601                                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares     800,000                                                
Debt Instrument, Unamortized Discount, Current     $ 10,500                                                
Warrants and Rights Outstanding     210,000                                                
Derivative liabilities     398,404                                                
Derivative expense     $ 297,833                                                
Debt term     1 year                                                
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized                       66,000                              
Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt issuance costs, net                     $ 1,000                                
Warrant term                     1 year                                
Debt discount to be amortized                     $ 32,000                                
Amortization of debt discount                     $ 3,000                                
Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs                     0.45                                
Warrant [Member] | Senior Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs                     240.83                                
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt instrument, convertible, conversion price | $ / shares               $ 0.075                                      
Warrant term               11 months 15 days                                      
Debt discount to be amortized                 $ 34,000                                    
Amortization of debt discount                 $ 3,700                                    
Deemed dividend               $ 11,000                                      
Warrants issued | shares               88,893                                      
Class of Warrant or Right, Expense or Revenue Recognized                 one year                                    
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs               0.92 0.89                                    
Warrant [Member] | Senior Secured Convertible Promissory Note Three [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs               247.52 240.64                                    
Warrant [Member] | Senior Secured Convertible Promissory Note Four [Member]                                                      
Short-term Debt [Line Items]                                                      
Warrant term         6 months 25 days     7 months 6 days                                      
Debt discount to be amortized               $ 37,916                                      
Amortization of debt discount               $ 15,784                                      
Class of warrant or right, exercise price of warrants or rights | $ / shares         $ 0.075                                            
Deemed dividend         $ 25,000                                            
Warrants issued | shares         213,333                                            
Warrant [Member] | Senior Secured Convertible Promissory Note Four [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs         0.81     0.48                                      
Warrant [Member] | Senior Secured Convertible Promissory Note Four [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs         209     302.11                                      
Warrant [Member] | Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Warrant term         1 year                                            
Debt discount to be amortized         $ 56,454                                            
Unamortized debt issuance expense         $ 30,000                                            
Class of warrant or right, exercise price of warrants or rights | $ / shares         $ 0.095                                            
Warrant [Member] | Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs         0.81                                            
Warrant [Member] | Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs         253                                            
Warrant [Member] | Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Warrant term     1 year                                                
Debt discount to be amortized     $ 62,220                                                
Derivative liability                                           3,100,000          
Unamortized debt issuance expense     $ 30,000                                                
Class of warrant or right, exercise price of warrants or rights | $ / shares     $ 0.095                                                
Derivative liabilities                                     842,120     842,120          
[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount]                                           222,860          
[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense]                                           619,260          
Warrant [Member] | Secured Convertible Promissory Note Two [Member] | Measurement Input, Risk Free Interest Rate [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs     0.77                                                
Warrant [Member] | Secured Convertible Promissory Note Two [Member] | Measurement Input, Price Volatility [Member]                                                      
Short-term Debt [Line Items]                                                      
Fair value of warrants measurement inputs     254                                                
Common Stock [Member]                                                      
Short-term Debt [Line Items]                                                      
Conversion of convertible debt                                       $ 3,000              
Common Stock [Member] | Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized         $ 17,041                                            
Common Stock [Member] | Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized     $ 17,209                                                
Four Convertible Notes [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                                     788,000     788,000          
Convertible Debt [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt conversion amount                                           $ 379,422          
Debt Conversion, Converted Instrument, Shares Issued | shares                                           2,218,000          
Debt principal and interest                                           $ 110,900          
Loss on extinguishment of debt                                           268,522          
Derivative liability                                           91,890          
Gain on extinguishment of debt                                           91,890          
Net loss on extinguishment                                           176,632          
Conversion of convertible debt                                           2,218,000          
Debt instrument, convertible, beneficial conversion feature                                           2,000,000.0          
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member]                                                      
Short-term Debt [Line Items]                                                      
Interest expense                                     3,000   9,000 8,000 10,000        
Amortization of debt issuance costs                                         7,000   8,000        
Debt instrument, convertible, conversion price | $ / shares                         $ 0.02                            
Debt conversion rate                         65.00%                            
Amortization of debt discount                                         28,000   30,000        
Debt default interest rate                           18.00%                          
Debt instrument, convertible, beneficial conversion feature                             $ 50,000                        
Intrinsic value of the beneficial conversion feature                             203,000                        
Convertible Debt [Member] | Secured Convertible Promissory Note [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                                     $ 58,055     $ 58,055          
Debt instrument, interest rate                                     140.00%     140.00%          
Convertible note, premimum description                                           The 40% premium will be recorded once a demand occurs.          
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt issuance costs, net                       4,000                              
Amortization of debt discount                       $ 5,000                              
Convertible Debt [Member] | Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized         $ 106,505                                            
Convertible Debt [Member] | Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt discount to be amortized     $ 100,571                                                
Convertible Note [Member] | Senior Secured Convertible Promissory Note [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                             58,055                        
Debt issuance costs, net                             $ 14,000                        
Debt instrument, interest rate                             10.00%                        
Debt instrument, effective percentage                             10.00%                        
Debt discount to be amortized                             $ 52,500                        
Registration Rights Agreement [Member] | Secured Convertible Promissory Note One [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt Conversion, Converted Instrument, Shares Issued | shares         100,000                                            
Registration Rights Agreement [Member] | Secured Convertible Promissory Note Two [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt Conversion, Converted Instrument, Shares Issued | shares     100,000                                                
Accredited Investors [Member] | Term Loan Subscription Agreements [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                             $ 5,700,000                     $ 5,700,000  
Debt issuance costs, net                                                   $ 707,000  
Debt instrument, interest rate                                                   12.00%  
Debt maturity date                                           Jun. 28, 2020          
Debt instrument, effective percentage                                                     15.00%
Interest expense                                     $ 215,000   215,000 $ 637,000 986,000        
Amortization of debt issuance costs                                         0   347,000        
Accured interest                                     1,800,000     1,800,000          
Repayments of Debt                                           5,700,000          
Accredited Investors [Member] | Securities Purchase Agreement [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                                   $ 550,500                  
Debt instrument, interest rate                                   10.00%                  
Debt instrument, effective percentage                                   10.00%                  
Convertible notes payable, current                                   $ 499,950                  
Debt instrument, convertible, conversion price | $ / shares                                 $ 0.50                    
Weighted average price of common stock                                 70.00%                    
Debt conversion rate                                 60.00%                    
Conversion price adjusted for stock splits, stock combinations and similar events (in dollars per share) | $ / shares                                 $ 0.05                    
Debt discount to be amortized                                   $ 380,593                  
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Warrant [Member]                                                      
Short-term Debt [Line Items]                                                      
Warrant term                                   5 years                  
Debt discount to be amortized                                   $ 322,000                  
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member]                                                      
Short-term Debt [Line Items]                                                      
Interest expense                                     25,000   31,000 75,000 86,000        
Amortization of debt issuance costs                                   38,000     7,000   38,000        
Amortization of debt discount                                   21,000     $ 67,000   $ 343,000        
Debt default interest rate                               18.00%                      
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Debt [Member] | Warrant [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt issuance costs, net                                   53,000                  
Amortization of debt discount                                   $ 30,000                  
Accredited Investors [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]                                                      
Short-term Debt [Line Items]                                                      
Principal amount                                     499,615     499,615          
Accured interest                                     $ 90,000     $ 90,000          
Debt conversion amount   $ 32,500   $ 25,000     $ 27,500     $ 25,900                                  
Debt Conversion, Converted Instrument, Shares Issued | shares   650,000   500,000     550,000     518,000                                  
Convertible note, premimum description                                           The 40% premium will be recorded once a demand occurs          
Holders [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]                                                      
Short-term Debt [Line Items]                                                      
Debt instrument, interest rate                                     140.00%     140.00%          
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Licensing Agreements (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 23, 2019
Mar. 16, 2018
May 31, 2018
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Other income       $ 5,000 $ 45,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member]              
Common stock issued     51,988        
Fair value of common stock issued     $ 75,000        
Proceeds form sale of intangible asset $ 45,000            
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Upon Execution of Agreement [Member]              
Payables on intellectual property         20,000   20,000
Novosom Verwaltungs GmbH [Member] | Intellectual Property [Member] | Achievement of Performance Obligation [Member]              
Payables on intellectual property         25,000   25,000
Les Laboratories Servier License Agreement [Member]              
Payments for royalties       $ 0 0 $ 0 0
Novosom Agreement [Member]              
Other income         $ 5,000   $ 45,000
License Of DiLA Assets [Member] | Accrued Liabilities [Member]              
Upfront payment agreement for license agreement   $ 200,000          
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions (Details Narrative)
Dec. 31, 2020
USD ($)
Related Party Transactions [Abstract]  
Due to Related Parties $ 4,000
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Stockholders' Equity Note, Warrants or Rights (Details)
Sep. 30, 2021
shares
Class of Stock [Line Items]  
Warrant shares 61,306,350
Warrant [Member]  
Class of Stock [Line Items]  
Warrant shares 61,306,350
Expiring in 2023 33,504,180
Expiring in 2024 1,348,785
Expiring in 2025 22,908,932
Expiring in 2026 3,544,453
Convertible Notes [Member]  
Class of Stock [Line Items]  
Warrant shares 27,463,517
Expiring in 2024 1,013,333
Expiring in 2025 22,905,731
Expiring in 2026 3,544,453
Other [Member]  
Class of Stock [Line Items]  
Warrant shares 348,733
Expiring in 2023 10,080
Expiring in 2024 335,452
Expiring in 2025 3,201
Series E Preferred Stock [Member]  
Class of Stock [Line Items]  
Warrant shares 30,405,600
Expiring in 2023 30,405,600
Series F Preferred Stock [Member]  
Class of Stock [Line Items]  
Warrant shares 3,088,500
Expiring in 2023 3,088,500
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders’ Equity (Details Narrative)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 22, 2021
USD ($)
shares
Aug. 18, 2021
USD ($)
shares
Aug. 11, 2021
USD ($)
shares
Jul. 30, 2021
USD ($)
shares
Jun. 08, 2021
USD ($)
shares
Mar. 19, 2021
USD ($)
$ / shares
shares
Oct. 30, 2019
USD ($)
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Mar. 31, 2021
shares
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
shares
Jul. 31, 2018
shares
Apr. 30, 2018
shares
Aug. 31, 2015
shares
Mar. 31, 2014
shares
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               100,000     100,000   100,000          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Warrant exercise price per share | $ / shares               $ 0.07     $ 0.07              
Warrants outstanding               61,306,350     61,306,350              
Dividends, Preferred Stock | $               $ 406,000   $ 388,000 $ 1,679,000 $ 1,153,000            
[custom:LossOnExtinguishmentOfDebt] | $               177,000   177,000            
February 2020 Convertible Note [Member]                                    
Class of Stock [Line Items]                                    
Interest payable | $               $ 34,155     34,155              
Stock Issued During Period, Shares, Conversion of Convertible Securities               1,700,000                    
Principal amount | $               $ 50,855     50,855              
Banking Agreement [Member]                                    
Class of Stock [Line Items]                                    
Number of shares issued 300,148                                  
Fair value | $ $ 39,290                                  
Convertible Note Investor [Member]                                    
Class of Stock [Line Items]                                    
Number of shares issued   100,000 100,000                              
Fair value | $   $ 62,220 $ 56,464                              
2020 Term Loan [Member]                                    
Class of Stock [Line Items]                                    
Number of shares issued           518,000                        
Interest payable | $           $ 25,900                        
Convertible Debt [Member]                                    
Class of Stock [Line Items]                                    
Value of converted shares | $                     $ 379,422              
Number of shares issued upon conversion                     2,218,000              
[custom:LossOnExtinguishmentOfDebt] | $                     $ 268,522              
Series F Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Warrants outstanding               3,088,500     3,088,500              
Series E Warrants [Member]                                    
Class of Stock [Line Items]                                    
Number of shares converted, value | $           $ 25,900                        
Number of shares converted           518,000                        
Warrants outstanding               30,405,600     30,405,600              
Series E Warrants [Member] | Maximum [Member]                                    
Class of Stock [Line Items]                                    
Warrant exercise price per share | $ / shares           $ 0.50                        
Series E Warrants [Member] | Minimum [Member]                                    
Class of Stock [Line Items]                                    
Warrant exercise price per share | $ / shares           $ 0.05                        
Series E Preferred [Member]                                    
Class of Stock [Line Items]                                    
Number of shares converted, value | $       $ 250,000                            
Number of shares converted       50 8                          
Accrued dividends | $         $ 10,000                          
Number of shares in accrued dividends         101,010                          
Number of shares issued         53,571                          
Warrant [Member]                                    
Class of Stock [Line Items]                                    
Common stock for a cashless exercise         75,000                          
Warrants outstanding               61,306,350     61,306,350              
Adjustable warrants, shares               60,957,617     60,957,617              
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations                     343,750              
[custom:NumberOfWarrantsExercised]                     75,000              
Common Stock [Member]                                    
Class of Stock [Line Items]                                    
Number of shares converted       500,000                            
Stock Issued During Period, Shares, Conversion of Convertible Securities                 518,000                  
Series F Warrants [Member]                                    
Class of Stock [Line Items]                                    
Value of converted shares | $           $ 25,900                        
Number of shares issued upon conversion           518,000                        
Series F Warrants [Member] | Maximum [Member]                                    
Class of Stock [Line Items]                                    
Warrant exercise price per share | $ / shares           $ 0.50                        
Series F Warrants [Member] | Minimum [Member]                                    
Class of Stock [Line Items]                                    
Warrant exercise price per share | $ / shares           $ 0.05                        
Series B Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred stock designated, shares               1,000     1,000              
Series A Junior Participating Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred stock designated, shares               90,000     90,000              
Series A Preferred Stock and Series B Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred stock, shares outstanding               0     0              
Series C Convertible Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               1,200     1,200   1,200          
Preferred stock designated, shares                                   1,200
Preferred stock, shares outstanding               100     100   100          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Series D Convertible Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               220     220   220          
Preferred stock designated, shares                                 220  
Preferred stock, shares outstanding               40     40   40          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Series E Convertible Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               3,500     3,500   3,500          
Preferred stock designated, shares                               3,500    
Preferred stock, shares outstanding               3,400     3,400   3,458          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Series F Convertible Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               2,200     2,200   2,200          
Preferred stock designated, shares                             2,200      
Preferred stock, shares outstanding               361     361   361          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Number of shares repurchased             20                      
Warrants to purchase shares of common stock             150,000                      
Stock repurchase | $             $ 100,000                      
Value of warrants held | $             $ 100,000                      
Accrued dividends | $                     $ 455,000   $ 347,000          
Series G Convertible Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred Stock, Shares Authorized               6,000     6,000   6,000          
Preferred stock designated, shares                           6,000        
Preferred stock, shares outstanding               0     0   0          
Stated value per share | $ / shares               $ 0.01     $ 0.01   $ 0.01          
Series C Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred stock, shares outstanding               100     100   100          
Stated value per share | $ / shares               $ 5,000     $ 5,000              
Preferred stock liquidation preference per share | $ / shares               5,100     $ 5,100              
Preferred Stock, Voting Rights                     voting rights of 666.67 votes per share              
Common stock at a conversion price, per share | $ / shares               $ 7.50     $ 7.50              
Series D Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Preferred stock, shares outstanding               40     40   40          
Stated value per share | $ / shares               $ 5,000     $ 5,000              
Preferred stock liquidation preference per share | $ / shares               300     $ 300              
Preferred Stock, Voting Rights                     voting rights of 1,250 votes per share              
Common stock at a conversion price, per share | $ / shares               4.00     $ 4.00              
Preferred stock stated dividend rate                     5.00%              
Series E Convertible Preferred Stock and Warrants [Member]                                    
Class of Stock [Line Items]                                    
Stated value per share | $ / shares               5,000     $ 5,000              
Common stock at a conversion price, per share | $ / shares               $ 0.50     $ 0.50              
Preferred stock stated dividend rate                     8.00%              
Anti-dilution price protection, expiration date                     Feb. 10, 2020              
Series E Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Deemed dividend | $           $ 390,000                        
Warrants outstanding               30,405,600     30,405,600              
Dividends, Preferred Stock | $                     $ 4,756,000,000,000   $ 3,700,000          
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]                                    
Class of Stock [Line Items]                                    
Fair value of warrants measurement inputs           0.16                        
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member]                                    
Class of Stock [Line Items]                                    
Fair value of warrants measurement inputs           262.27                        
Series E Preferred Stock [Member] | Maximum [Member]                                    
Class of Stock [Line Items]                                    
Warrant term           5 months 4 days                        
Series E Preferred Stock [Member] | Minimum [Member]                                    
Class of Stock [Line Items]                                    
Warrant term           4 months 28 days                        
Series F Convertible Preferred Stock and Warrants [Member]                                    
Class of Stock [Line Items]                                    
Stated value per share | $ / shares               $ 5,000     $ 5,000              
Common stock at a conversion price, per share | $ / shares               $ 0.50     $ 0.50              
Preferred stock stated dividend rate                     8.00%              
Anti-dilution price protection, expiration date                     Feb. 10, 2020              
Warrants term description                     three-year              
Series F Preferred Stock [Member]                                    
Class of Stock [Line Items]                                    
Deemed dividend | $           $ 31,000                        
Warrants outstanding               3,088,500     3,088,500              
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]                                    
Class of Stock [Line Items]                                    
Fair value of warrants measurement inputs           0.16                        
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member]                                    
Class of Stock [Line Items]                                    
Fair value of warrants measurement inputs           262.27                        
Series F Preferred Stock [Member] | Maximum [Member]                                    
Class of Stock [Line Items]                                    
Warrant term           6 months 10 days                        
Series F Preferred Stock [Member] | Minimum [Member]                                    
Class of Stock [Line Items]                                    
Warrant term           5 months 15 days                        
Series G Convertible Preferred Shares [Member]                                    
Class of Stock [Line Items]                                    
Stated value per share | $ / shares               $ 5,000     $ 5,000              
Common stock at a conversion price, per share | $ / shares               $ 0.50     $ 0.50              
Preferred stock stated dividend rate                     8.00%              
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Share-based Payment Arrangement, Option, Activity (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2021
$ / shares
shares
Share-based Payment Arrangement [Abstract]  
Options Outstanding Beginning | shares 391,350
Options outstanding, weighted average exercise price, beginning | $ / shares $ 0.58
Options granted | shares
Options granted, weighted average exercise price | $ / shares $ 0
Options expired / forfeited | shares (3,800)
Options expired/forfeited, weighted average exercise price | $ / shares $ 2.60
Options Outstanding Ending | shares 387,550
Options outstanding, weighted average exercise price, ending | $ / shares $ 0.99
Options Exercisable | shares 387,550
Exercisable, weighted average exercise price | $ / shares $ 0.99
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details)
shares in Thousands
 9 Months Ended
Sep. 30, 2021
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Numbers outstanding | shares 387,550
Weighted- Average Remaining Contractual Life (Years) 1 year 6 months 21 days
Weighted average exercise price $ 0.99
Number exercisable | shares 387,550
Weighted average exercise price $ 0.99
Range One [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Range of exercise prices, lower 0.98
Range of exercise prices, upper $ 1.00
Numbers outstanding | shares 383,500
Weighted- Average Remaining Contractual Life (Years) 3 months 7 days
Weighted average exercise price $ 0.98
Number exercisable | shares 383,500
Weighted average exercise price $ 0.98
Range Two [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Range of exercise prices, upper $ 1.70
Numbers outstanding | shares 4,050
Weighted- Average Remaining Contractual Life (Years) 1 year 6 months 25 days
Weighted average exercise price $ 1.70
Number exercisable | shares 4,050
Weighted average exercise price $ 1.70
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Stock Incentive Plans (Details Narrative)
 9 Months Ended
Sep. 30, 2020
USD ($)
Share-based Payment Arrangement, Option [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Share-based Payment Arrangement, Expense $ 8,000
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details Narrative) - USD ($)
Aug. 24, 2021
Jul. 28, 2021
Oct. 30, 2019
Licensing Agreement M L R 1019 [Member]      
Loss Contingencies [Line Items]      
Debt instrument cash payment   $ 21,750,000  
Gross sales percentage   5.00%  
Licensing Agreement M L R 1019 [Member] | Minimum [Member]      
Loss Contingencies [Line Items]      
Gross sales percentage   8.00%  
Licensing Agreement M L R 1019 [Member] | Maximum [Member]      
Loss Contingencies [Line Items]      
Gross sales percentage   12.00%  
Licensing Agreement M L R 1023 [Member]      
Loss Contingencies [Line Items]      
Debt instrument cash payment $ 21,750,000    
License agreement commitments description If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.    
Series F Convertible Preferred Stock [Member]      
Loss Contingencies [Line Items]      
Number of shares repurchased     20
Warrants to purchase shares of common stock     150,000
Stock repurchase     $ 100,000
Value of warrants held     $ 100,000
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details Narrative) - USD ($)
 3 Months Ended
Nov. 17, 2021
Nov. 04, 2021
Oct. 27, 2021
Oct. 15, 2021
Oct. 13, 2021
Oct. 07, 2021
Oct. 05, 2021
Oct. 04, 2021
Aug. 24, 2021
Mar. 31, 2021
Sep. 30, 2021
Jul. 30, 2021
Subsequent Event [Line Items]                        
Class of Warrant or Right, Outstanding                     61,306,350  
Class of Warrant or Right, Exercise Price of Warrants or Rights                     $ 0.07  
Number of stock issued conversion                   $ 26,000    
Common Stock [Member]                        
Subsequent Event [Line Items]                        
Number of stock issued conversion                   $ 3,000    
Warrant [Member]                        
Subsequent Event [Line Items]                        
Class of Warrant or Right, Outstanding                     61,306,350  
Licensing Agreement M L R 1023 [Member]                        
Subsequent Event [Line Items]                        
License agreement commitments description                 If the Company fails to raise $4.0 million dollars within 120 days of the Effective Date then the License shall immediately terminate unless, by 120 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.      
Series E Preferred Stock [Member]                        
Subsequent Event [Line Items]                        
Class of Warrant or Right, Outstanding                     30,405,600  
Series F Preferred Stock [Member]                        
Subsequent Event [Line Items]                        
Class of Warrant or Right, Outstanding                     3,088,500  
Secured Promissory Note [Member]                        
Subsequent Event [Line Items]                        
Debt instrument effective percentage                       18.00%
Subsequent Event [Member]                        
Subsequent Event [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued       37,043       255,540        
Debt conversion converted instrument amount     $ 66,500                  
Maturity date     Feb. 17, 2023                  
Maturity date description     On October 27, 2021, the Company and the institutional investor who holds two convertible promissory notes agreed to extend the maturity date of each of the Notes by six months. The $220,500 Note issued in August 2021 had its maturity date extended to February 17, 2023, and the $66,500 Note issued in June 2021 had its maturity date extended to December 25, 2022.                  
Number of stock issued conversion     $ 220,500                  
Subsequent Event [Member] | Common Stock [Member]                        
Subsequent Event [Line Items]                        
Number of share issued   153,227                    
Subsequent Event [Member] | Warrant [Member]                        
Subsequent Event [Line Items]                        
Number of warrant issued   250,000                    
Subsequent Event [Member] | Buyer [Member]                        
Subsequent Event [Line Items]                        
Number of share issued         59,523 59,523            
Subsequent Event [Member] | Licensing Agreement M L R 1023 [Member]                        
Subsequent Event [Line Items]                        
License agreement commitments description On November 17, 2021, Melior Pharmaceuticals I, Inc. extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising.                      
Subsequent Event [Member] | Institutional Investor [Member] | Securities Purchase Agreement [Member]                        
Subsequent Event [Line Items]                        
Debt Instrument, Face Amount           $ 131,250            
Subsequent Event [Member] | Series E Preferred Stock [Member]                        
Subsequent Event [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued               20        
Subsequent Event [Member] | Series F Preferred Stock [Member]                        
Subsequent Event [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued       3                
Subsequent Event [Member] | January Convertible Note [Member]                        
Subsequent Event [Line Items]                        
Debt Conversion, Converted Instrument, Shares Issued               525,000        
Debt conversion converted instrument amount               $ 26,250        
Subsequent Event [Member] | Convertible Redeemable Note [Member] | Securities Purchase Agreement [Member]                        
Subsequent Event [Line Items]                        
Debt instrument effective percentage           10.00%            
Warrants and Rights Outstanding, Term           3 years 3 years          
Maturity date         Oct. 07, 2022 Oct. 05, 2022            
Debt Instrument, Convertible, Conversion Price         $ 0.075 $ 0.075            
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 0.095 $ 0.095          
Aggregate exercise price of warrants           $ 45,238 $ 45,238          
Debt Instrument, Interest Rate, Stated Percentage         10.00%              
Subsequent Event [Member] | Convertible Redeemable Note [Member] | Institutional Investor [Member] | Securities Purchase Agreement [Member]                        
Subsequent Event [Line Items]                        
Debt instrument effective percentage         10.00% 10.00%            
Debt Instrument, Face Amount         $ 131,250              
Warrants and Rights Outstanding, Term         3 years 3 years            
Class of Warrant or Right, Outstanding         476,190 476,190            
Proceeds from Convertible Debt         $ 110,000 $ 110,000            
EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 394 319 1 false 91 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://adherathera.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://adherathera.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://adherathera.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://adherathera.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) Sheet http://adherathera.com/role/StatementOfStockholdersEquityDeficit Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://adherathera.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies Sheet http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies Nature of Operations, Basis of Presentation and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Notes Payable Notes http://adherathera.com/role/NotesPayable Notes Payable Notes 8 false false R9.htm 00000009 - Disclosure - Licensing Agreements Sheet http://adherathera.com/role/LicensingAgreements Licensing Agreements Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Transactions Sheet http://adherathera.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - Stockholders??? Equity Sheet http://adherathera.com/role/StockholdersEquity Stockholders??? Equity Notes 11 false false R12.htm 00000012 - Disclosure - Stock Incentive Plans Sheet http://adherathera.com/role/StockIncentivePlans Stock Incentive Plans Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://adherathera.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Subsequent Events Sheet http://adherathera.com/role/SubsequentEvents Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies) Policies http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables) Tables http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Notes Payable (Tables) Notes http://adherathera.com/role/NotesPayableTables Notes Payable (Tables) Tables http://adherathera.com/role/NotesPayable 17 false false R18.htm 00000018 - Disclosure - Stockholders??? Equity (Tables) Sheet http://adherathera.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://adherathera.com/role/StockholdersEquity 18 false false R19.htm 00000019 - Disclosure - Stock Incentive Plans (Tables) Sheet http://adherathera.com/role/StockIncentivePlansTables Stock Incentive Plans (Tables) Tables http://adherathera.com/role/StockIncentivePlans 19 false false R20.htm 00000020 - Disclosure - Schedule of Fair Value Measurements (Details) Sheet http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails Schedule of Fair Value Measurements (Details) Details 20 false false R21.htm 00000021 - Disclosure - Schedule of Roll Forward of Level 3 Financial Instruments (Details) Sheet http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails Schedule of Roll Forward of Level 3 Financial Instruments (Details) Details 21 false false R22.htm 00000022 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails Schedule of Earnings Per Share, Basic and Diluted (Details) Details 22 false false R23.htm 00000023 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 23 false false R24.htm 00000024 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) Sheet http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative) Details http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - Schedule of Convertible Promissory Notes (Details) Notes http://adherathera.com/role/ScheduleOfConvertiblePromissoryNotesDetails Schedule of Convertible Promissory Notes (Details) Details 25 false false R26.htm 00000026 - Disclosure - Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details) Sheet http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details) Details 26 false false R27.htm 00000027 - Disclosure - Notes Payable (Details Narrative) Notes http://adherathera.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://adherathera.com/role/NotesPayableTables 27 false false R28.htm 00000028 - Disclosure - Licensing Agreements (Details Narrative) Sheet http://adherathera.com/role/LicensingAgreementsDetailsNarrative Licensing Agreements (Details Narrative) Details http://adherathera.com/role/LicensingAgreements 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://adherathera.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://adherathera.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Sheet http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails Schedule of Stockholders' Equity Note, Warrants or Rights (Details) Details 30 false false R31.htm 00000031 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://adherathera.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://adherathera.com/role/StockholdersEquityTables 31 false false R32.htm 00000032 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Activity (Details) Sheet http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails Schedule of Share-based Payment Arrangement, Option, Activity (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details) Sheet http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stock Incentive Plans (Details Narrative) Sheet http://adherathera.com/role/StockIncentivePlansDetailsNarrative Stock Incentive Plans (Details Narrative) Details http://adherathera.com/role/StockIncentivePlansTables 34 false false R35.htm 00000035 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://adherathera.com/role/CommitmentsAndContingencies 35 false false R36.htm 00000036 - Disclosure - Subsequent Events (Details Narrative) Sheet http://adherathera.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://adherathera.com/role/SubsequentEvents 36 false false All Reports Book All Reports form10-q.htm atrx-20210930.xsd atrx-20210930_cal.xml atrx-20210930_def.xml atrx-20210930_lab.xml atrx-20210930_pre.xml ex31-1.htm ex32-1.htm http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 394, "dts": { "calculationLink": { "local": [ "atrx-20210930_cal.xml" ] }, "definitionLink": { "local": [ "atrx-20210930_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "atrx-20210930_lab.xml" ] }, "presentationLink": { "local": [ "atrx-20210930_pre.xml" ] }, "schema": { "local": [ "atrx-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 453, "entityCount": 1, "hidden": { "http://adherathera.com/20210930": 57, "http://fasb.org/us-gaap/2021-01-31": 162, "http://xbrl.sec.gov/dei/2021": 4, "total": 223 }, "keyCustom": 55, "keyStandard": 264, "memberCustom": 58, "memberStandard": 26, "nsprefix": "atrx", "nsuri": "http://adherathera.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adherathera.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Related Party Transactions", "role": "http://adherathera.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Stockholders\u2019 Equity", "role": "http://adherathera.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Stock Incentive Plans", "role": "http://adherathera.com/role/StockIncentivePlans", "shortName": "Stock Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Commitments and Contingencies", "role": "http://adherathera.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Subsequent Events", "role": "http://adherathera.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Nature of Operations, Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)", "role": "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "Nature of Operations, Basis of Presentation and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Notes Payable (Tables)", "role": "http://adherathera.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://adherathera.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Stock Incentive Plans (Tables)", "role": "http://adherathera.com/role/StockIncentivePlansTables", "shortName": "Stock Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://adherathera.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Schedule of Fair Value Measurements (Details)", "role": "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails", "shortName": "Schedule of Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "atrx:ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "atrx:InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Schedule of Roll Forward of Level 3 Financial Instruments (Details)", "role": "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails", "shortName": "Schedule of Roll Forward of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "atrx:ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "lang": null, "name": "atrx:ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Schedule of Earnings Per Share, Basic and Diluted (Details)", "role": "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "shortName": "Schedule of Earnings Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative)", "role": "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "shortName": "Nature of Operations, Basis of Presentation and Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Convertible Promissory Notes (Details)", "role": "http://adherathera.com/role/ScheduleOfConvertiblePromissoryNotesDetails", "shortName": "Schedule of Convertible Promissory Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_MeasurementInputExpectedDividendRateMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details)", "role": "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "shortName": "Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_MeasurementInputExpectedDividendRateMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Notes Payable (Details Narrative)", "role": "http://adherathera.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-10-292020-10-30", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherIncome", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Licensing Agreements (Details Narrative)", "role": "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "shortName": "Licensing Agreements (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "atrx:LicensingAgreementTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2018-05-012018-05-31_custom_NovosomVerwaltungsGmbHMember_us-gaap_IntellectualPropertyMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://adherathera.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://adherathera.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights (Details)", "role": "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "shortName": "Schedule of Stockholders' Equity Note, Warrants or Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "atrx:ClassOfWarrantOrRightExpiringInYearTwo", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-09-30_custom_FebruaryTwoThousandTwentyConvertibleNoteMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Activity (Details)", "role": "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails", "shortName": "Schedule of Share-based Payment Arrangement, Option, Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details)", "role": "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails", "shortName": "Schedule of Share-based Payment Arrangement, Option, Exercise Price Range (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Stock Incentive Plans (Details Narrative)", "role": "http://adherathera.com/role/StockIncentivePlansDetailsNarrative", "shortName": "Stock Incentive Plans (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-272021-07-28_custom_LicensingAgreementMLR1019Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-272021-07-28_custom_LicensingAgreementMLR1019Member", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://adherathera.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-30_custom_SecuredPromissoryNoteMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://adherathera.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-07-012020-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingAndMarketingExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)", "role": "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-03-31_us-gaap_RetainedEarningsMember", "decimals": "-3", "lang": null, "name": "us-gaap:Dividends", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://adherathera.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-01-012020-09-30", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Nature of Operations, Basis of Presentation and Significant Accounting Policies", "role": "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Nature of Operations, Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Notes Payable", "role": "http://adherathera.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "atrx:LicensingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Licensing Agreements", "role": "http://adherathera.com/role/LicensingAgreements", "shortName": "Licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-01to2021-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "atrx:LicensingAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 91, "tag": { "atrx_AccreditedInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accredited Investors [Member]", "label": "Accredited Investors [Member]" } } }, "localname": "AccreditedInvestorsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_AccruedAndDeemedDividends": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued and deemed dividends.", "label": "Dividends" } } }, "localname": "AccruedAndDeemedDividends", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_AccruedInterest": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued interest" } } }, "localname": "AccruedInterest", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_AchievementOfPerformanceObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Achievement of Performance Obligation [Member]", "label": "Achievement of Performance Obligation [Member]" } } }, "localname": "AchievementOfPerformanceObligationMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_AdjustableWarrantsShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustable warrants, shares.", "label": "Adjustable warrants, shares" } } }, "localname": "AdjustableWarrantsShare", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "atrx_AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivative": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of derivative.", "label": "Reclassification of derivative" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfDerivative", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_AggregateExercisePriceOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate exercise price of warrants.", "label": "Aggregate exercise price of warrants" } } }, "localname": "AggregateExercisePriceOfWarrants", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_AmortizedInterestExpenseRelatedToFairValueMethod": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amotized interest expense.", "label": "Amotized interest expense" } } }, "localname": "AmortizedInterestExpenseRelatedToFairValueMethod", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_AntidilutionPriceProtectionExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antidilution price protection expiration date.", "label": "Anti-dilution price protection, expiration date" } } }, "localname": "AntidilutionPriceProtectionExpirationDate", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "atrx_BankingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Banking Agreement [Member]", "label": "Banking Agreement [Member]" } } }, "localname": "BankingAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_BeneficialConversionFeatureOnNotesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature on notes payable.", "label": "BeneficialConversionFeatureOnNotesPayable", "negatedLabel": "Beneficial conversion feature on issuance notes payable" } } }, "localname": "BeneficialConversionFeatureOnNotesPayable", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_BuyerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyer [Member]", "label": "Buyer [Member]" } } }, "localname": "BuyerMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_CashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of warrants.", "label": "CashlessExerciseOfWarrants", "negatedLabel": "Cashlesss exercise of Series E warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_ChangeInFairValueIncludedInDerivativeExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value included in derivative expense.", "label": "Change in fair value included in derivative expense" } } }, "localname": "ChangeInFairValueIncludedInDerivativeExpense", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_ClassOfWarrantOrRightExpiringInYearFive": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or Right expiring in five year.", "label": "Expiring in 2026" } } }, "localname": "ClassOfWarrantOrRightExpiringInYearFive", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "sharesItemType" }, "atrx_ClassOfWarrantOrRightExpiringInYearFour": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or Right expiring in four year.", "label": "Expiring in 2025" } } }, "localname": "ClassOfWarrantOrRightExpiringInYearFour", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "sharesItemType" }, "atrx_ClassOfWarrantOrRightExpiringInYearThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or Right expiring in three year.", "label": "Expiring in 2024" } } }, "localname": "ClassOfWarrantOrRightExpiringInYearThree", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "sharesItemType" }, "atrx_ClassOfWarrantOrRightExpiringInYearTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents class of warrant or right expiring in year two.", "label": "Expiring in 2023" } } }, "localname": "ClassOfWarrantOrRightExpiringInYearTwo", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "sharesItemType" }, "atrx_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period.", "label": "Warrants issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "atrx_ClassOfWarrantOrRightTermDescriptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants term description.", "label": "Warrants term description" } } }, "localname": "ClassOfWarrantOrRightTermDescriptions", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "atrx_CommonStockAtConversionPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock at a conversion price, per share.", "label": "Common stock at a conversion price, per share" } } }, "localname": "CommonStockAtConversionPrice", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "atrx_CommonStockForCashlessExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock for cashless exercise, shares.", "label": "Common stock for a cashless exercise" } } }, "localname": "CommonStockForCashlessExercise", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "atrx_ConversionFeatureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Conversion Feature [Member]" } } }, "localname": "ConversionFeatureMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_ConversionOfSeriesEToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Conversion of stock.", "label": "ConversionOfSeriesEToCommonStock", "negatedLabel": "Conversion of Series E to common stock" } } }, "localname": "ConversionOfSeriesEToCommonStock", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_ConversionPriceAdjustedForStockSplitsStockCombinationsAndSimilarEventsPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion price adjusted for stock splits, stock combinations and similar events.", "label": "Conversion price adjusted for stock splits, stock combinations and similar events (in dollars per share)" } } }, "localname": "ConversionPriceAdjustedForStockSplitsStockCombinationsAndSimilarEventsPricePerShare", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "atrx_ConvertibleNoteInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note Investor [Member]", "label": "Convertible Note Investor [Member]" } } }, "localname": "ConvertibleNoteInvestorMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note [Member]", "label": "Convertible Note [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_ConvertibleNotePremimumDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible note, premimum description" } } }, "localname": "ConvertibleNotePremimumDescription", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "atrx_ConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes [Member]", "label": "Convertible Notes [Member]" } } }, "localname": "ConvertibleNotesMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "domainItemType" }, "atrx_ConvertibleRedeemableNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Redeemable Note [Member]", "label": "Convertible Redeemable Note [Member]" } } }, "localname": "ConvertibleRedeemableNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_DebtDefaultInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt default interest rate.", "label": "Debt default interest rate" } } }, "localname": "DebtDefaultInterestRate", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "atrx_DebtDiscountsForIssuanceCostsWarrantsAndDerivatives": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DebtDiscountsForIssuanceCostsWarrantsAndDerivatives", "negatedLabel": "Debt discounts for issuance costs, warrants and derivatives" } } }, "localname": "DebtDiscountsForIssuanceCostsWarrantsAndDerivatives", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "atrx_DebtInstrumentConvertibleIntrinsicValueOfBeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of the beneficial conversion feature.", "label": "Intrinsic value of the beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleIntrinsicValueOfBeneficialConversionFeature", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_DeemedDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend.", "label": "Deemed dividend" } } }, "localname": "DeemedDividend", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_DerivativeExpense": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative expense.", "label": "DerivativeExpense", "negatedLabel": "Derivative expense", "verboseLabel": "Derivative expense" } } }, "localname": "DerivativeExpense", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "atrx_DisclosureLicensingAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreements" } } }, "localname": "DisclosureLicensingAgreementsAbstract", "nsuri": "http://adherathera.com/20210930", "xbrltype": "stringItemType" }, "atrx_FairValueOfDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of derivative liability.", "label": "Total" } } }, "localname": "FairValueOfDerivativeLiability", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_FebruaryTwoThousandTwentyConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 2020 Convertible Note [Member]", "label": "February 2020 Convertible Note [Member]" } } }, "localname": "FebruaryTwoThousandTwentyConvertibleNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_FourConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Four Convertible Notes [Member]", "label": "Four Convertible Notes [Member]" } } }, "localname": "FourConvertibleNotesMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_GainOnExtinguishmentOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of debt.", "label": "Gain on extinguishment of debt" } } }, "localname": "GainOnExtinguishmentOfDebt", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_GrossSalesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross sales percentage" } } }, "localname": "GrossSalesPercentage", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "atrx_HoldersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Holders [Member]", "label": "Holders [Member]" } } }, "localname": "HoldersMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial valuation of derivative liabilities included in debt discount.", "label": "Initial valuation of derivative liabilities included in debt discount", "verboseLabel": "[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount]" } } }, "localname": "InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial valuation of derivative liabilities included in derivative expense.", "label": "Initial valuation of derivative liabilities included in derivative expense", "verboseLabel": "[custom:InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense]" } } }, "localname": "InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_InstitutionalInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Institutional Investor [Member]", "label": "Institutional Investor [Member]" } } }, "localname": "InstitutionalInvestorMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_InvestorAndLenderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investor and lender [Member]", "label": "Investor and lender [Member]" } } }, "localname": "InvestorAndLenderMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_IssuanceOfCommonStockForCashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for cashless exercise of warrants.", "label": "Issuance of common stock for cashless exercise of warrants" } } }, "localname": "IssuanceOfCommonStockForCashlessExerciseOfWarrants", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_IssuanceOfCommonStockForCashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for cashless exercise of warrants, shares" } } }, "localname": "IssuanceOfCommonStockForCashlessExerciseOfWarrantsShares", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "atrx_IssuanceOfCommonStockForSeriesEConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for series E conversion.", "label": "Issuance of common stock for Series E conversion" } } }, "localname": "IssuanceOfCommonStockForSeriesEConversion", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_IssuanceOfCommonStockForSeriesEConversionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for Series E conversion, shares" } } }, "localname": "IssuanceOfCommonStockForSeriesEConversionShares", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "atrx_JanuaryConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "January Convertible Note [Member]", "label": "January Convertible Note [Member]" } } }, "localname": "JanuaryConvertibleNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_LesLaboratoriesServierLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Les Laboratories Servier License Agreement [Member]", "label": "Les Laboratories Servier License Agreement [Member]" } } }, "localname": "LesLaboratoriesServierLicenseAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_LicenseAgreementCommitmentsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License agreement commitments description" } } }, "localname": "LicenseAgreementCommitmentsDescription", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "atrx_LicenseOfDiLAAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Of DiLA Assets [Member]", "label": "License Of DiLA Assets [Member]" } } }, "localname": "LicenseOfDiLAAssetsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_LicensingAgreementMLR1019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreement M L R 1019 [Member]" } } }, "localname": "LicensingAgreementMLR1019Member", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_LicensingAgreementMLR1023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreement M L R 1023 [Member]" } } }, "localname": "LicensingAgreementMLR1023Member", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_LicensingAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing Agreement [Text Block]", "label": "LicensingAgreementTextBlock", "verboseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementTextBlock", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreements" ], "xbrltype": "textBlockItemType" }, "atrx_LossOnExtinguishmentOfDebt": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://adherathera.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on extinguishment of debt.", "label": "Loss on debt extinguishment", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "[custom:LossOnExtinguishmentOfDebt]", "verboseLabel": "Loss on extinguishment of debt" } } }, "localname": "LossOnExtinguishmentOfDebt", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StatementsOfCashFlows", "http://adherathera.com/role/StatementsOfOperations", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_NovosomAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novosom Agreement [Member]", "label": "Novosom Agreement [Member]" } } }, "localname": "NovosomAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_NovosomVerwaltungsGmbHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novosom Verwaltungs GmbH [Member]", "label": "Novosom Verwaltungs GmbH [Member]" } } }, "localname": "NovosomVerwaltungsGmbHMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_NumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "[custom:NumberOfWarrantsExercised]" } } }, "localname": "NumberOfWarrantsExercised", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "atrx_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other [Member]", "label": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails" ], "xbrltype": "domainItemType" }, "atrx_PayablesOnIntellectualProperty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payables on intellectual property.", "label": "Payables on intellectual property" } } }, "localname": "PayablesOnIntellectualProperty", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_PreferredStockDesignatedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Designated, Shares.", "label": "Preferred stock designated, shares" } } }, "localname": "PreferredStockDesignatedShares", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "atrx_PreferredStockLiquidationPreferencePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock liquidation preference per share.", "label": "Preferred stock liquidation preference per share" } } }, "localname": "PreferredStockLiquidationPreferencePerShare", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "atrx_RangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range One [Member]", "label": "Range One [Member]" } } }, "localname": "RangeOneMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "atrx_RangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range Two [Member]", "label": "Range Two [Member]" } } }, "localname": "RangeTwoMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "atrx_ReclassificationOfAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reclass from APIC.", "label": "Reclass from Additional paid-in capital" } } }, "localname": "ReclassificationOfAdditionalPaidInCapital", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of derivative liabilities to gain on debt extinguishment.", "label": "Reclassification of derivative liabilities to gain on debt extinguishment" } } }, "localname": "ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "atrx_RegistrationRightsAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Registration Rights Agreement [Member]", "label": "Registration Rights Agreement [Member]" } } }, "localname": "RegistrationRightsAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_RetainedEarningsAccumulatedDeficits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Retained earnings accumulated deficit.", "label": "Retained earnings accumulated deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficits", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Roll Forward of Level 3 Financial Instruments [Table Text Block]", "label": "Schedule of Roll Forward of Level 3 Financial Instruments" } } }, "localname": "ScheduleOfRollForwardOfLevelsFinancialInstrumentsTableTextBlock", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "atrx_SecuredConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible Promissory Note [Member]", "label": "Secured Convertible Promissory Note [Member]" } } }, "localname": "SecuredConvertiblePromissoryNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SecuredConvertiblePromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible Promissory Note One [Member]", "label": "Secured Convertible Promissory Note One [Member]" } } }, "localname": "SecuredConvertiblePromissoryNoteOneMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SecuredConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible Promissory Note Two [Member]", "label": "Secured Convertible Promissory Note Two [Member]" } } }, "localname": "SecuredConvertiblePromissoryNoteTwoMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Promissory Note [Member]", "label": "Secured Promissory Note [Member]" } } }, "localname": "SecuredPromissoryNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement [Member]", "label": "Securities Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeniorSecuredConvertiblePromissoryNoteFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Convertible Promissory Note Four [Member]", "label": "Senior Secured Convertible Promissory Note Four [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteFourMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeniorSecuredConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Convertible Promissory Note [Member]", "label": "Senior Secured Convertible Promissory Note [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeniorSecuredConvertiblePromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Convertible Promissory Note One [Member]", "label": "Senior Secured Convertible Promissory Note One [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteOneMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeniorSecuredConvertiblePromissoryNoteThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Convertible Promissory Note Three [Member]", "label": "Senior Secured Convertible Promissory Note Three [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteThreeMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeniorSecuredConvertiblePromissoryNoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Convertible Promissory Note Two [Member]", "label": "Senior Secured Convertible Promissory Note Two [Member]" } } }, "localname": "SeniorSecuredConvertiblePromissoryNoteTwoMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesAJuniorParticipatingPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Junior Participating Preferred Stock [Member]", "label": "Series A Junior Participating Preferred Stock [Member]" } } }, "localname": "SeriesAJuniorParticipatingPreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesAPreferredStockAndSeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Preferred Stock and Series B Preferred Stock [Member]", "label": "Series A Preferred Stock and Series B Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockAndSeriesBPreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesCConvertiablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member] [Default Label]", "verboseLabel": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiablePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "atrx_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesDConvertiablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock [Member]", "label": "Series D Convertible Preferred Stock [Member] [Default Label]", "verboseLabel": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiablePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "atrx_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Preferred Stock [Member]", "label": "Series D Convertible Preferred Stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesEConvertiablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock [Member]", "label": "Series E Convertible Preferred Stock [Member] [Default Label]", "verboseLabel": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiablePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "atrx_SeriesEConvertiblePreferredStockAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock and Warrants [Member]", "label": "Series E Convertible Preferred Stock and Warrants [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockAndWarrantsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Convertible Preferred Stock [Member]", "label": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesEPreferredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Preferred [Member]", "label": "Series E Preferred [Member]" } } }, "localname": "SeriesEPreferredMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesEWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E Warrants [Member]", "label": "Series E Warrants [Member]" } } }, "localname": "SeriesEWarrantsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesFConvertiablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Convertible Preferred Stock [Member]", "label": "Series F Convertible Preferred Stock [Member] [Default Label]", "verboseLabel": "Series F Convertible Preferred Stock [Member]" } } }, "localname": "SeriesFConvertiablePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "atrx_SeriesFConvertiblePreferredStockAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Convertible Preferred Stock and Warrants [Member]", "label": "Series F Convertible Preferred Stock and Warrants [Member]" } } }, "localname": "SeriesFConvertiblePreferredStockAndWarrantsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesFConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Convertible Preferred Stock [Member]", "label": "Series F Convertible Preferred Stock [Member]" } } }, "localname": "SeriesFConvertiblePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesFWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Warrants [Member]", "label": "Series F Warrants [Member]" } } }, "localname": "SeriesFWarrantsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesGConvertiablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series G Convertible Preferred Stock [Member]", "label": "Series G Convertible Preferred Stock [Member] [Default Label]", "verboseLabel": "Series G Convertible Preferred Stock [Member]" } } }, "localname": "SeriesGConvertiablePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "domainItemType" }, "atrx_SeriesGConvertiblePreferredSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series G Convertible Preferred Shares [Member]", "label": "Series G Convertible Preferred Shares [Member]" } } }, "localname": "SeriesGConvertiblePreferredSharesMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_SeriesGConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series G Convertible Preferred Stock [Member]", "label": "Series G Convertible Preferred Stock [Member]" } } }, "localname": "SeriesGConvertiblePreferredStockMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for convertible note and interest conversions, shares.", "label": "Issuance of common stock for convertible note and interest conversions, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesOne", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "atrx_StockIssuedDuringPeriodSharesWarrantsAndCommonStockConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of warrants and common stock with convertible notes, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsAndCommonStockConversionOfConvertibleNotes", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "atrx_StockIssuedDuringPeriodValueAccruedDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value accrued dividend.", "label": "Accrued and deemed dividend" } } }, "localname": "StockIssuedDuringPeriodValueAccruedDividend", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for convertible note and interest conversions.", "label": "Issuance of common stock for convertible note and interest conversions" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_StockIssuedDuringPeriodValueWarrantsAndCommonStockConversionOfConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of warrants with convertible notes.", "label": "Issuance of warrants and common stock with convertible notes -" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsAndCommonStockConversionOfConvertibleNotes", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "atrx_StockOptionsOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Outstanding [Member]" } } }, "localname": "StockOptionsOutstandingMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "atrx_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Term Loan [Member]", "label": "2020 Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_TermLoanSubscriptionAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Subscription Agreements [Member]", "label": "Term Loan Subscription Agreements [Member]" } } }, "localname": "TermLoanSubscriptionAgreementsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_UpfrontPaymentAgreementForLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment agreement for license agreement.", "label": "Upfront payment agreement for license agreement" } } }, "localname": "UpfrontPaymentAgreementForLicenseAgreement", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_UponExecutionOfAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Upon Execution of Agreement [Member]", "label": "Upon Execution of Agreement [Member]" } } }, "localname": "UponExecutionOfAgreementMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "atrx_ValueOfWarrantsHeld": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of warrants held.", "label": "Value of warrants held" } } }, "localname": "ValueOfWarrantsHeld", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "atrx_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "atrx_WeightedAveragePriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price of common stock.", "label": "Weighted average price of common stock" } } }, "localname": "WeightedAveragePriceOfCommonStock", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "atrx_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working capital" } } }, "localname": "WorkingCapital", "nsuri": "http://adherathera.com/20210930", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r407", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Series [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://adherathera.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r163", "r203", "r242", "r244", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r385", "r386", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r163", "r203", "r242", "r244", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r385", "r386", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r163", "r203", "r228", "r242", "r244", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r385", "r386", "r396", "r397" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r163", "r203", "r228", "r242", "r244", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r385", "r386", "r396", "r397" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r84", "r88", "r243" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r84", "r88", "r136", "r243", "r332" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r122", "r323" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInvestmentIncomeReceivable": { "auth_ref": [ "r14", "r360", "r379" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.", "label": "Accrued Investment Income Receivable", "verboseLabel": "Accrued dividends" } } }, "localname": "AccruedInvestmentIncomeReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r269", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r76", "r77", "r78", "r266", "r267", "r268", "r295" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r217", "r225", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Benefical conversion feature - convertible notes" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Issuance of warrants with notes payable" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r245", "r247", "r272", "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r247", "r264", "r271" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r51", "r61", "r183", "r313" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r48", "r61", "r183", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r61", "r183", "r193", "r194", "r315" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "negatedLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r72", "r114", "r116", "r120", "r124", "r146", "r147", "r148", "r150", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r281", "r285", "r304", "r327", "r329", "r361", "r374" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r36", "r72", "r124", "r146", "r147", "r148", "r150", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r281", "r285", "r304", "r327", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r248", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r291", "r294" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r20", "r329", "r392", "r393" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r20", "r63" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r57", "r63", "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash - End of Period", "periodStartLabel": "Cash \u2013 Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r57", "r305" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash Investing and Financing Activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r69", "r72", "r92", "r93", "r94", "r97", "r99", "r103", "r104", "r105", "r124", "r146", "r151", "r152", "r153", "r157", "r158", "r201", "r202", "r206", "r210", "r304", "r413" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r226", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of warrant or right, exercise price of warrants or rights", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrant exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightExpenseOrRevenueRecognized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of expense or revenue offset related to the warrants or rights.", "label": "Class of Warrant or Right, Expense or Revenue Recognized" } } }, "localname": "ClassOfWarrantOrRightExpenseOrRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Number of warrant issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants to purchase shares of common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrant shares", "terseLabel": "Class of Warrant or Right, Outstanding", "verboseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r135", "r367", "r380" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r142", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Number of shares in accrued dividends" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r76", "r77", "r295" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r217" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.006 par value; 180,000,000 shares authorized, 14,485,438 and 11,112,709 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r64", "r65", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Number of shares converted, value" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r64", "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Number of shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r159", "r160", "r161", "r163", "r173", "r174", "r175", "r179", "r180", "r181", "r182", "r183", "r191", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Schedule of Convertible Promissory Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r10", "r363", "r375", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes payable, net", "terseLabel": "Convertible notes payable, current", "verboseLabel": "Convertible Notes Payable" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r8", "r362", "r373", "r394" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r64", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion amount", "terseLabel": "Debt conversion converted instrument amount", "verboseLabel": "Value of converted shares" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentRate": { "auth_ref": [ "r64", "r66" ], "lang": { "en-us": { "role": { "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.", "label": "Debt conversion rate" } } }, "localname": "DebtConversionConvertedInstrumentRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r64", "r66" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Number of shares issued upon conversion" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r68", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r177", "r184", "r185", "r187", "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r8", "r9", "r10", "r71", "r74", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r191", "r192", "r193", "r194", "r317", "r362", "r363", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r224" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt instrument, convertible, beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r162", "r188" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt instrument, convertible, conversion price", "verboseLabel": "Debt Instrument, Convertible, Conversion Price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r30", "r162", "r218", "r221", "r223" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r160", "r191", "r192", "r314", "r317", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount", "verboseLabel": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r189", "r314", "r317" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt instrument, effective percentage", "verboseLabel": "Debt instrument effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28", "r161" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate", "verboseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r29", "r163", "r300" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt maturity date", "verboseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Maturity date description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r31", "r71", "r74", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r191", "r192", "r193", "r194", "r317" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r31", "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt principal and interest", "verboseLabel": "Debt instrument cash payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r71", "r74", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r186", "r191", "r192", "r193", "r194", "r218", "r222", "r223", "r224", "r313", "r314", "r317", "r318", "r372" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r173", "r313", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt discount to be amortized", "negatedLabel": "Unamortized discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfConvertiblePromissoryNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r313", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r173", "r313", "r314", "r315", "r316", "r318" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Convertible Debt and Warrant Accounting" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r22", "r173", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "periodEndLabel": "Balance at September 30, 2021", "periodStartLabel": "Balance at December 31, 2020" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r37", "r40", "r41", "r293", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "verboseLabel": "Derivative liability" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r38", "r39", "r40", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stock Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r225", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends [Default Label]", "negatedLabel": "Accrued dividend" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r6", "r26" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued dividends" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r225", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Dividends" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockCash": { "auth_ref": [ "r225", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.", "label": "Dividends, Preferred Stock, Cash", "verboseLabel": "Accrued dividends" } } }, "localname": "DividendsPreferredStockCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r225", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "verboseLabel": "Deemed dividend" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r23", "r73", "r149", "r151", "r152", "r156", "r157", "r158", "r322" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r73", "r149", "r151", "r152", "r156", "r157", "r158", "r322", "r365", "r382" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per share \u2013 Common Stockholders - basic and diluted", "verboseLabel": "Net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r76", "r77", "r78", "r80", "r85", "r87", "r102", "r125", "r217", "r225", "r266", "r267", "r268", "r276", "r277", "r295", "r306", "r307", "r308", "r309", "r310", "r311", "r387", "r388", "r389", "r418" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r175", "r191", "r192", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r298", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r175", "r229", "r230", "r235", "r241", "r298", "r334" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r175", "r191", "r192", "r229", "r230", "r235", "r241", "r298", "r335" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r175", "r191", "r192", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r298", "r336" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r175", "r191", "r192", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r334", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r126", "r127", "r129", "r130", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r126", "r128" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r61", "r195", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Net loss on extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r60" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r60" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Derivative expense" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r60" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r51", "r181", "r190", "r193", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r6", "r7", "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accured interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r366", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r72", "r117", "r124", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r282", "r285", "r286", "r304", "r327", "r328" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r72", "r124", "r304", "r329", "r364", "r378" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27", "r72", "r124", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r282", "r285", "r286", "r304", "r327", "r328", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Term loan" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTerm": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Long-term Debt, Term" } } }, "localname": "LongTermDebtTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfFairValueOfDerivativeLiabilitiesEstimatedIssuanceAndValuationModeDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows Provided By Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r57", "r59", "r62" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows Used in Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r42", "r43", "r46", "r47", "r62", "r72", "r79", "r81", "r82", "r83", "r84", "r86", "r87", "r95", "r114", "r115", "r118", "r119", "r121", "r124", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r296", "r304", "r368", "r383" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://adherathera.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StatementsOfCashFlows", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r81", "r82", "r83", "r84", "r90", "r91", "r96", "r99", "r114", "r115", "r118", "r119", "r121" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Loss allocable to common stockholders", "totalLabel": "Net Loss Applicable to Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r50" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r10", "r363", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r114", "r115", "r118", "r119", "r121" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r75", "r89", "r113", "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Nature of Operations, Basis of Presentation and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r384" ], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "verboseLabel": "Other income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r55" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Notes payable issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred stock stated dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Dividends" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreferenceValue": { "auth_ref": [ "r69", "r206" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.", "label": "Preferred stock, liquidation preference value" } } }, "localname": "PreferredStockLiquidationPreferenceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r12", "r201" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized", "verboseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r12", "r201" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r12", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r12", "r218" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r53" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable, net or original issue discounts" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds form sale of intangible asset" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r42", "r43", "r46", "r56", "r72", "r79", "r86", "r87", "r114", "r115", "r118", "r119", "r121", "r124", "r146", "r147", "r148", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r280", "r283", "r284", "r287", "r288", "r296", "r304", "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r236", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r236", "r321", "r324", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r319", "r320", "r322", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r225", "r269", "r329", "r377", "r390", "r391" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r76", "r77", "r78", "r80", "r85", "r87", "r125", "r266", "r267", "r268", "r276", "r277", "r295", "r387", "r389" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value Measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r21", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r248", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Payment Arrangement, Option, Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r250", "r256", "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Payment Arrangement, Option, Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r33", "r69", "r103", "r104", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r206", "r210", "r215", "r218", "r219", "r220", "r222", "r223", "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r226", "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r10", "r363", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://adherathera.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesFPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series F Preferred Stock [Member]" } } }, "localname": "SeriesFPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r60" ], "calculation": { "http://adherathera.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Options expired / forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r252", "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding Ending", "periodStartLabel": "Options Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, weighted average exercise price, ending", "periodStartLabel": "Options outstanding, weighted average exercise price, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r246", "r249" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockIncentivePlansDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Options expired/forfeited, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options granted, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, lower" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Numbers outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Range of exercise prices, upper" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r260", "r270" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted- Average Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfShare-basedPaymentArrangementOptionExercisePriceRangeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfRollForwardOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r69", "r72", "r92", "r93", "r94", "r97", "r99", "r103", "r104", "r105", "r124", "r146", "r151", "r152", "r153", "r157", "r158", "r201", "r202", "r206", "r210", "r217", "r304", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r35", "r44", "r45", "r46", "r76", "r77", "r78", "r80", "r85", "r87", "r102", "r125", "r217", "r225", "r266", "r267", "r268", "r276", "r277", "r295", "r306", "r307", "r308", "r309", "r310", "r311", "r387", "r388", "r389", "r418" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r76", "r77", "r78", "r102", "r345" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/BalanceSheetsParenthetical", "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r64", "r65", "r66" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of common stock for conversion of convertible debt" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r34", "r178", "r217", "r218", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Issuance of common stock for convertible note conversion, shares", "verboseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r12", "r13", "r217", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of share issued", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r35", "r217", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Issuance of common stock for convertible note conversion", "terseLabel": "Number of stock issued conversion", "verboseLabel": "Conversion of convertible debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r12", "r13", "r217", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Fair value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Fair value of common stock issued" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r12", "r13", "r217", "r225" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Number of shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r12", "r13", "r217", "r225" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock repurchase" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r17", "r18", "r72", "r123", "r124", "r304", "r329" ], "calculation": { "http://adherathera.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets", "http://adherathera.com/role/StatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r202", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r216", "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r312", "r331" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r312", "r331" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r312", "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r312", "r331" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r330", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplementary Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://adherathera.com/role/LicensingAgreementsDetailsNarrative", "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized debt issuance expense" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r111", "r112" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NatureOfOperationsBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique." } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating price of option.", "label": "Valuation Technique, Option Pricing Model [Member]" } } }, "localname": "ValuationTechniqueOptionPricingModelMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/ScheduleOfStockholdersEquityNoteWarrantsOrRightsDetails", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Fair value of warrants measurement inputs" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrant term", "verboseLabel": "Warrants and Rights Outstanding, Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/NotesPayableDetailsNarrative", "http://adherathera.com/role/StockholdersEquityDetailsNarrative", "http://adherathera.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted average shares outstanding - basic and diluted", "verboseLabel": "Weighted average common shares outstanding used to compute net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://adherathera.com/role/ScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://adherathera.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r403": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r404": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r405": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r406": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r407": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r408": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r409": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r410": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r411": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r412": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r414": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r415": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r416": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r417": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 53 0001493152-21-029537-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-029537-xbrl.zip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end

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